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Physiological glucose levels are maintained by the complex integration of 
neuroendocrine, hormonal and nutritional signals controlled by multiple tissues in 
the body. A dysregulation in these mechanisms leads to increasingly prevalent 
conditions characterised by an inability to regulate blood glucose levels, such as 
diabetes. Maintaining glycaemia within a target range remains a daily challenge 
for individuals with both Type 1 and Type 2 diabetes and a better understanding 
of the pathophysiology of impaired glucose homeostasis in these conditions is 
still required to identify more effective and targeted therapeutic approaches.  
Work in this thesis focused on elucidating the mechanisms by which lipid 
overflow, be it from increasingly sedentary behaviour or overfeeding, leads to the 
development of insulin and anabolic resistance in skeletal muscle. Loss of insulin-
stimulated glucose clearance by skeletal muscle is a main driver for impaired 
glucose disposal in Type 2 diabetes and a role for excessive lipid availability in 
this pathology is well established. Here, muscle cells were treated with high 
concentrations of a saturated fatty acid and data demonstrated that lipid overflow 
led to impaired anabolic sensitivity, inflammatory cytokine release and 
mitochondrial dysfunction. Furthermore, these experiments elucidated a novel 
role for adenosine tri-phosphate, acting as a signalling molecule, in the regulation 
of muscle glucose metabolism, identifying insulin and exercise mimetic roles of 
the nucleotide that could be therapeutically targetable.  
This work was translated into humans, where the effect of lipid overflow by high-
fat overfeeding was assessed in an experimental model of inactivity-induced 
insulin and anabolic resistance. Data suggested that two days of disuse (by 
forearm immobilisation) were sufficient to cause substantial muscle insulin 
resistance. After 7 days, muscle strength was significantly reduced and anabolic 
resistance was evident due to decreased forearm balance of potent anabolic 
amino acids such as leucine. Contrary to the hypothesis, high-fat overfeeding did 
not accelerate or exacerbate these impairments, suggesting that removal of 
contraction represents a potent stimulus for loss of substrate demand by muscle, 




Insulin replacement therapy has been the cornerstone of treatment for Type 1 
and advanced Type 2 diabetes for over 8 decades. A serious and inadvertent 
consequence of prolonged insulin therapy is the increased risk of hypoglycaemia. 
Hypoglycaemia can lead to impaired physiological defences against a decrease 
in blood glucose and loss of awareness of these changes. AMP-activated protein 
kinase activators, which are widely used (to target peripheral tissues) as anti-
hyperglycaemic agents in Type 2 diabetes have demonstrated central effects that 
amplify the first defence against hypoglycaemia, or counterregulatory response. 
Data presented here demonstrated that peripheral administration of a brain 
permeable AMP-activated protein kinase activator amplified the 
counterregulatory response to hypoglycaemia by enhancing glucagon levels in 
healthy rats, without altering fasting blood glucose. This demonstrates important 
clinical implications for the pharmaceutical use of AMP-activated protein kinase 
activators as the central roles that regulate blood glucose may supersede the 
peripheral effects of these compounds, during hypoglycaemia.  
Work presented here highlights the complexity of the regulation of glycaemia and 
discusses the contribution of extracellular and intracellular nucleotides/nucleotide 
sensors to glucose homeostasis. It can be concluded from this work that 
strategies to manage or treat diabetes in future should consider the importance 
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1.1 Diabetes Mellitus 
Diabetes is the term given to a collective of metabolic disorders primarily 
characterised by increased blood glucose, or hyperglycaemia, arising from 
impaired glucose homeostasis and insulin action. The most recent figures show 
that 425 million individuals worldwide between the ages of 20 and 79 live with 
diabetes, with an additional 352 million believed to be at risk of developing the 
condition (International Diabetes Foundation, 2017). The prevalence is expected 
to increase further to 9.9 % by the year 2045 raising the number of affected 
individuals to a staggering 629 million people in the next 25 years (International 
Diabetes Foundation, 2017). Diabetes places a great physical and emotional 
burden on individuals and remains a lifelong condition. In addition, it places 
considerable socioeconomic pressures on individuals and overwhelming costs 
on global health economies, costing the USA 727 billion USD (in 2017), and the 
National Health System (UK) £10 billion each year (Diabetes UK, 2014).  
Diabetes is primarily classified into Type 2 diabetes (T2D), Type 1 diabetes (T1D) 
and gestational diabetes mellitus (GDM), referred to as the polygenic disorders, 
given the role of environmental factors in their aetiology. Other specific types 
include monogenic diabetes syndrome, including neonatal diabetes and maturity-
onset diabetes of the young (MODY), and more recently characterised diseases 
of the endocrine pancreas (cystic fibrosis and pancreatitis) and drug or chemical-
induced diabetes such as that arising from glucocorticoid use in the treatment of 
HIV/AIDS or after organ transplantation (American Diabetes Association, 2019a). 
Diagnostically, hyperglycaemia is assessed by fasting plasma glucose (FPG) 
levels, glucose tolerance tests in response to 75 g oral anhydrous glucose bolus 
(OGTT) and glycated haemoglobin A1C (HbA1c) levels. The thresholds for 
hyperglycaemia are ≥ 7 mmol/L fasting, ≥ 11.1 mmol/L during 2 hour OGTT and 
HbA1C score ≥48 mmol/moL (Alberti and Zimmet, 1998; American Diabetes 
Association, 2019a). Hyperglycaemia also causes the symptoms commonly 
associated with diabetes, such as polyuria, fatigue, nausea, increased thirst and 
visual impairments (Alberti and Zimmet, 1998).  
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1.1.1 Type 2 diabetes mellitus  
T2D is primarily characterised by relative insulin insufficiency and peripheral 
insulin resistance (IR), leading to hyperglycaemia. Glycaemic status determines 
disease stage from normal to impaired to diabetic, with gradual increases in blood 
glucose often occurring several years before diagnosis.  
Between 1980 and 2014 the numbers of adults with diabetes increased 4 fold 
from 180 million to 422 million, an increase partly driven by a rise in the incidence 
of obesity caused by increasingly sedentary lifestyles and ageing population 
(International Diabetes Foundation, 2017). T2D accounts for 90-95 % of these 
cases. Importantly, over 50 % of all cases of T2D could be prevented or delayed 
by lifestyle interventions, a critical factor to consider as the numbers of people at 
risk of developing the condition are expected to rise to over 5 million by 2025 in 
the UK alone (Diabetes UK, 2019). 
The aetiology of T2D is not completely understood but well-characterised risk 
factors for disease development include excess body weight, obesity, physical 
inactivity, age, and increased consumption of high fat and sugar diets (Chatterjee 
et al., 2017). Higher frequency is also seen in women with prior GDM and 
hypertensive and dyslipidaemic individuals. Genetic factors also contribute, as 
first-degree relatives have increased risk of developing T2D (Zheng et al., 2018). 
T2D places individuals at a higher risk of developing co-morbidities, particularly 
cardiovascular complications, which cause 80 % of deaths in T2D. Individuals 
with T2D are nearly 2.5 times more likely to develop heart attacks, over 2.5 times 
more likely to experience heart failure and twice as likely to have a stroke, 
compared to those without diabetes (Diabetes UK, 2019).  
1.1.2 Type 1 diabetes mellitus 
T1D, previously referred to as juvenile-onset or insulin-dependent diabetes, 
accounts for 8-10 % of all diabetes cases, affecting 400,000 people in the UK, 
29,000 of which are children (JDRF, 2018). A doubling of cases in children under 
5 and 70 % increase in those younger than 15 years was predicted between 
2005-2020 (Patterson et al., 2009) and the incidence is still increasing, especially 
in the developed world, with the age at onset shifting to a younger age (Van Belle 
et al., 2011). 
Introduction  Chapter 1 
4 
 
Although also characterised by hyperglycaemia, this arises as a consequence of 
autoimmune pancreatic β-cell dysfunction, resulting in insulin insufficiency and 
consequent loss of inhibition of glucose production and glucose uptake into 
tissues. Although the aetiology is not fully elucidated, the condition most likely 
results from a combination of higher genetic susceptibility and environmental 
triggers (Van Belle et al., 2011).  
Autoreactive T-cells are the primary drivers of β-cell destruction (Pugliese, 2017) 
resulting in production of autoimmune markers such as glutamic acid 
decarboxylase (GAD), islet antigen 2 (IA-2), insulin, and zinc transporter 8 protein 
(ZnT8) (Atkinson and Eisenbarth, 2001), which are used as diagnostic markers 
of disease. The origin of the autoimmune response remains unclear. Genome-
wide association studies identified a genetic risk of T1D (Mehers and Gillespie, 
2008; Jerram et al., 2017), supporting the hereditary theory introduced by Harley 
in 1866 (Harley, 1866). However, as ~50 % of monogenic twins are discordant 
for T1D, non-genetically determined factors also play an important role in disease 
aetiology, including enteroviral infection (Filippi and von Herrath, 2008; 
Richardson et al., 2009) and changes to the microbiome (Zheng et al., 2018).  
1.2 Glucose homeostasis 
Physiological plasma glucose concentration ranges between 4.4-6.1 mmol/L. 
This is maintained by a balance of glucose clearing processes such as insulin-
stimulated glucose uptake into tissues and glucose appearance. Circulating 
glucose arises from postprandial intestinal absorption (regulated by gastric 
emptying), from the breakdown of glycogen (polymerised storage form of 
glucose) during glycogenolysis, and from de novo synthesis via gluconeogenesis 
(Aronoff et al., 2004). The body relies on well-tuned neuroendocrine mechanisms 
to combat changes to glucose availability such as during hyperglycaemia and 
hypoglycaemia, to maintain energy balance (Pocai et al., 2005). The 
pathophysiology underlying impairments in glucose homeostasis, as seen in 
diabetes, involves a complex interplay between cellular and systemic factors. 
These are mediated by tissues such as the pancreas, liver, adipose tissue (AT), 
skeletal muscle (SM) and brain that can sense glucose and act to maintain 
homeostasis.  
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1.2.1 Glucose metabolism 
Glucose homeostasis is maintained by a balance of glucose production, 
breakdown and interconversion. The processes involved are primarily glucose 
transport, glycogenolysis, glycogenesis, gluconeogenesis and glycolysis 
(progressing into oxidative phosphorylation). This thesis primarily touched on the 
transport and metabolism of glucose in gluconeogenesis and glycolysis so these 
are described in more detail below. Glycogen handling is outside the scope of 
this thesis and the reader is referred to a current review for the understanding of 
glycogen metabolism (Adeva-Andany et al., 2016). 
1.2.2 Glucose transport 
Glucose is sensed and transported via glucose transporters (GLUT), of which 
there are multiple isoforms with different tissue distributions. For example, GLUT4 
translocation to the plasma membrane is regulated by insulin signalling in AT and 
SM, and the transporter has high affinity for glucose (Km ~ 5 mM), making it a 
key regulator of postprandial insulin-stimulated glucose uptake and storage 
(Cushman and Wardzala, 1980). GLUT2 also acts as a glucose sensor and is 
primarily expressed in pancreatic β-cells and hepatocytes, and it has a low affinity 
for glucose (Km ~17 mM) ensuring that GLUT2-mediated glucose import occurs 
during hyperglycaemia (Thorens, 1992). During fasting, when intrahepatic 
concentrations are high, glucose is exported via GLUT2 to maintain blood 
glycaemia. GLUT1 has higher affinity for glucose (Km ~ 1-3 mM) and, although 
ubiquitously expressed, is particularly important in facilitating glucose transport 
across the blood-brain barrier (BBB), neuronal membranes and erythrocytes 
(Gorovits and Charron, 2003; Augustin, 2010; Mueckler and Thorens, 2013). 
GLUT3 is primarily expressed in the brain (also placenta and testes) and has the 
highest affinity for glucose (Km ~1.5 mM) (Kayano et al., 1988; Simpson et al., 
2008).  
1.2.3 Glycolysis, Krebs cycle & gluconeogenesis 
Glycolysis is the cytoplasmic enzymatically controlled process by which glucose 
is metabolised to pyruvate or lactate following glucose entry into cells. A 
diagrammatical representation of the molecules and enzymes involved in this 
process is shown in Figure 1.1.  
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Glycolytic rate is determined at the level of glucose uptake, glucose 
phosphorylation by hexokinase (HK) II or IV (glucokinase, GK, in liver and β-
cells); and generation of fructose-1,2-biphosphate, catalysed by phosphofructo-
1-kinase (PFK1) (Lenzen, 2014). The latter is activated by fructose-2-6-
biphosphate whose production is regulated by 6-phosphofructo-2-
kinase/fructose-2, 6-biphosphatase, which is differentially regulated by nutritional 
status (Massa et al., 2004). Pyruvate kinase (PK) catalyses the final step to 
convert phosphoenolpyruvate (PEP) into pyruvate. Pyruvate is then transported 
into the mitochondria and oxidised to generate acyl groups (oxidative 
decarboxylation by pyruvate dehydrogenase, PDH) which reacts with Coenzyme 
A to form acetyl-Coenzyme A (acetyl-CoA). Acetyl-CoA is then used in the Krebs 
cycle (or citric acid cycle) to generate adenosine triphosphate (ATP), reduced 
nicotinamide adenine dinucleotide (NADH), reduced flavin adenine dinucleotide 
(FADH2) and carbon dioxide (CO2). This process (schematic representation in 
Figure 1.2) harvests high-energy electrons that are re-oxidised in oxidative 
phosphorylation to maximise ATP. In the absence of oxygen, pyruvate is reduced 
by lactate dehydrogenase (LDH) into lactate. Conversion of glucose to lactate 
releases protons and acidifies the extracellular space (Mookerjee et al., 2017). 
The rate of extracellular acidification is commonly used as a proxy for direct and 
quantitative assessment of glycolytic rate in vitro (Nicholls et al., 2010; 
Nadanaciva et al., 2012). 
Glycolysis is an important regulator of glucose production and insulin secretion 
(Terrettaz et al., 1986; Rossetti and Giaccari, 1990), stimulates lipogenesis in AT 
via production of glycerol phosphate (Huo et al., 2010), contributes to 
hypothalamic control of food intake (Dunn-Meynell et al., 2002; Kang et al., 2006) 
and plays a role in inflammatory responses (Huo et al., 2010). As such, 
impairments in the glycolytic pathway are implicated in diabetes pathophysiology, 
as seen by a hyperglycaemic phenotype in liver-specific knockouts of GK (Postic 
et al., 1999) and impaired ability of insulin to increase in vivo GK activity in 
obesity-associated IR (Lam et al., 2003). 
 
 




Figure 1.1 Enzymes and metabolites regulating glycolysis and 
gluconeogenesis 
Major enzymes and metabolites involved in glycolysis (blue) and gluconeogenesis (orange) 
including glucogenic amino acids and stimulatory processes (green) and inhibitory 
processes (red). Enzymes in glycolysis: HK, hexokinase; GK, glucokinase; PFK1, 
phosphofructokinase-1; PFK2, phosphofructokinase-2; PK, pyruvate kinase. Enzymes in 
gluconeogenesis: G6Pase, glucose-6-phosphatase; PC, pyruvate carboxylase; PEPCK, 
phosphoenolpyruvate carboxykinase; FBPase, fructose 1,6-bisphosphatase; FBPase-2, 
fructose-1,2-bisphosphatase. Glycerol, derived from triglyceride (TG) breakdown is 
converted to dihydroxyacetone phosphate (DHAP) and subsequently to glyceraldehyde-3-
phosphate or fructose-1,6-bisphosphate to enter the gluconeogenic pathway. Glucogenic 
amino acids such as glutamate/glutamine or asparagine/aspartate are converted into 
alanine or Krebs cycle intermediates, acting as substrates for gluconeogenesis. AST, 
aspartate aminotransaminase; ALT, alanine aminotransaminase; LHD, lactate 
dehydrogenase. Glucagon binds the hepatic glucagon receptor, activating adenylate 
cyclase (AC) and generates cAMP, which in turn, stimulates cAMP-dependent protein 
kinase (PKA) which phosphorylates the cAMP-response element binding protein (CREB). 
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Gluconeogenesis is the process by which glucose is produced from non-
carbohydrate sources such as amino acids (AAs), lactate and glycerol. However, 
the HK/GK, PFK-1 and PK steps of glycolysis are irreversible and overcome in 
the gluconeogenic pathway by four enzymes unique to this process, glucose-6-
phosphatase (G6P), fructose-1,6-bisphosphatase (FBPase), cytosolic PEP 
carboxykinase (PEPCK) and pyruvate carboxylase (PC) (Ekberg et al., 1999), as 
indicated in Figure 1.1. Substrates such as lactate (Cori and Cori, 1929) and 
alanine (Felig et al., 1970) are first converted into pyruvate, which enters the 
mitochondria and is carboxylated by PC into oxaloacetate (OAA). OAA is reduced 
to malate and shuttled to the cytoplasm and converted back to OAA, where it is 
converted to PEP by PEPCK. There are other glucogenic AAs such as aspartate 
and glutamate that are first converted into alanine or intermediates of the Krebs 
cycle for gluconeogenesis (Mallet, Exton and Park, 1969). Glycerol from AT in 
converted in the liver to dihydroxyacetone phosphate (DHAP) and subsequently 
into glyceraldehyde-3-phosphate or fructose-1,6,-bisphosphate to enter the 
pathway (Song et al., 2001). Dysregulation or deficiency in the key regulatory 







Figure 1.2. Krebs cycle (TCA/Citric acid cycle) 
Process by which acetyl-CoA derived from carbohydrates, fats or proteins is oxidised to 
generate ATP and CO2 in the mitochondrial matrix. IDH, Isocitrate dehydrogenase; ACO2, 
acotinase; OGDH, α-ketoglutarate dehydrogenase; SDH, succinate dehydrogenase; FH, 
fumarate hydratase; MDH, malate dehydrogenase; CS, citrate synthase. 
Introduction  Chapter 1 
9 
 
1.2.4 Oxidative phosphorylation (OXPHOS) 
In OXPHOS, the final stage of cellular respiration in eukaryotic cells, the electrons 
released by re-oxidation of by-products of the Krebs cycle create an electron-
motive force that is converted into a proton-motive force as electrons flow through 
the electron transport chain (ETC) across the inner mitochondrial membrane. 
Electrons (e-) originate from NADH entering complex I (NADH ubiquinone 
reductase), succinate conversion to fumarate at complex II (succinate 
dehydrogenase) and oxidation of FADH2 (Slack, 2013). Electron flow is then 
directed by reduced ubiquinone which is processed through complex III, and e- 
passed to cytochrome c and directed to complex IV (cytochrome c oxidase) 
(Jastroch et al., 2010). These complexes generate protons to create a proton 
gradient across the mitochondrial membrane which is used to drive ATP 
synthesis from adenosine diphosphate (ADP) and inorganic phosphate (Pi) at 
complex V (ATP synthase, F0F1-ATPase). ATP synthesis is coupled (partly 
mediated by uncoupling proteins, UCPs) to this proton gradient and offset by 
proton leak (flow of protons in the opposite direction) (Jastroch et al., 2010). The 
ETC also generates significant ROS, such as superoxide, so that mitochondrial 
oxygen consumption is associated with oxidative damage by oxygen radicals 
(Balaban et al., 2005). A schematic representation of the complexes involved in 
this pathway is represented in Figure 1.3.  
Mitochondrial dysfunction contributes to the pathophysiology of IR and is seen in 
both T1D and T2D as mitochondrial biogenesis, number, morphology and 
fission/fusion dynamics become dysfunctional (Sivitz and Yorek, 2010). The 
mechanisms by which mitochondrial dysfunction contributes to IR are described 










Pancreatic endocrine cells cluster in islets of Langerhans which account for 1-2% 
of pancreatic mass (Chandra and Liddle, 2009). These cells produce and secrete 
insulin, amylin and C-peptide (β-cell); glucagon (α-cell); somatostatin (δ-cell); 
ghrelin (ε-cell) and pancreatic polypeptide (PP cells) (Jouvet and Estall, 2017). 
In response to elevated plasma glucose, AAs and fatty acids (FAs) following a 
meal, the β-cells synthesise and secrete insulin, a process referred to as glucose-
stimulated insulin secretion (GSIS) (Ashcroft et al., 1994). Insulin acts in target 
tissues to promote glucose disposal, glycogenesis (Miller and Larner, 1973; 
Sibrowski and Seitz, 1984), lipogenesis (Walton and Etherton, 1986; McTernan 
et al., 2002) and protein synthesis (Biolo et al., 1995), representing one of the 
most important anabolic stimuli in the body. Elevated blood glucose causes 
glucose to enter the β-cell via facilitated diffusion through GLUT2 on the cell 
surface and glucose is metabolised intracellularly through glycolysis and 
OXPHOS, resulting in the generation of ATP and increased ATP/ ADP ratio. This 
causes closure of the ATP sensitive potassium (K) channel (KATP) and 
subsequent decrease in the outward-directed K+ current, causing membrane 
Figure 1.3. Electron transport chain and oxidative phosphorylation 
Complexes involved in ETC and OXPHOS across the inner mitochondrial 
membrane. Cyt c, cytochrome C; Complex I, NADH dehydrogenase; Complex II, 
SDH, succinate dehydrogenase; Complex III, ubiquinol-cytochrome C reductase; 
Complex IV, cytochrome-c oxidase; Complex V, H+-transporting ATPase. 
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depolarisation and influx of calcium ions (Ca2+) through L-type voltage-gated 
calcium channels (VGCC). The increase in intracellular calcium concentration 
([Ca2+]i) results in the translocation and fusion of insulin-containing large dense-
core vesicles to the plasma membrane and insulin secretion (IS) into the 
circulation (Komatsu et al., 2013). Insulin granules contain an equimolar amount 
of insulin and C-peptide, and as C-peptide has a slower metabolic clearance than 
insulin, it is often used as a marker of endogenous insulin secretion (Jones and 
Hattersley, 2013). Although genetically and functionally similar (identical catalytic 
GK activity) (De Vos et al., 1995; Ferrer et al., 1995; McCulloch et al., 2011), 
rodent and human islets differentially express GLUT2 and GLUT1 and GLUT3, 
respectively, which results in differing glucose-sensing properties. The higher 
affinity of GLUT1 and GLUT3 transporters leads to insulin secretion at lower 
glucose concentrations in humans compared to mice (Henquin et al., 2006) and 
coincides with the differences in basal glucose concentrations between species 
(4-7 mM in man (Aronoff et al., 2004) compared to 7-14 mM in mice (Togashi et 
al., 2016).  
GSIS is bi-phasic, occurring via an initial transient “first-phase response” followed 
by a gradually developing secondary secretion (Curry et al., 1968). First phase 
GSIS occurs from vesicles already present at the plasma membrane in response 
to increased nutrient availability (MacDonald, Joseph and Rorsman, 2005). 
Diabetes is associated with the selective loss of first phase IS (White, Shaw and 
Taylor, 2016). Second phase IS requires metabolisable secretagogues (glucose 
or lipids), de novo vesicle biosynthesis and sustained maintenance of vesicular 
transport to the plasma membrane (Gembal et al., 1992; Henquin, 2000). 
Vesicular transport and membrane fusion are partly regulated by the superfamily 
of the soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) 
receptor proteins (SNAREs) (Jewell et al., 2010).  
Importantly, in a pre-diabetic state, β-cells expand to compensate for higher 
insulin requirements (Chen et al., 2017). Over time, however, β-cell 
compensation progressively fails to meet insulin requirements. This occurs in 
conjunction with enhanced mitochondrial ROS production (Newsholme et al., 
2016) driven by higher circulating glucose and lipid levels, leading to 
glucolipotoxicity, inflammation, and ultimately β-cell fatigue and death (Cnop et 
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al., 2005; Hotamisligil and Erbay, 2008). In contrast, blood glucose decreases 
during fasting. Low blood glucose, or hypoglycaemia, leads to suppression of IS 
(from healthy β-cells) and subsequent stimulation of glucagon from pancreatic α-
cells (discussed further under counterregulation). This increases hepatic and 
renal gluconeogenesis to increase blood glucose levels (Orci et al., 1975; Gerich 
et al., 1979). Glucagon secretion is also stimulated by sympathetic and 
parasympathetic nerves of the autonomic nervous system (ANS) activated by 
hypoglycaemia-sensing neurones in the hepatoportal vein (Hevener, Bergman 
and Donovan, 1997; Burcelin, Dolci and Thorens, 2000) and central nervous 
system (CNS) (Marty et al., 2007; Lamy et al., 2014). Conversely, during 
hyperglycaemia, insulin (Ostenson, 1979) and somatostatin (Starke et al., 1987) 
suppress glucagon secretion. A state of hyperglucagonaemia is characteristically 
seen in diabetes, where hyperglycaemia occurs in response to lack of 
postprandial inhibition of glucagon secretion (Baron et al., 1987), and this is not 
suppressed by exogenous insulin administration in T1D (Dinneen et al., 1995). 
1.2.6 Liver  
Hepatic glucose production (HGP) accounts for approximately 90 % of 
endogenous glucose production (Ekberg et al., 1999), and is maintained by 
glucose-raising (gluconeogenesis, glycogenolysis) and glucose-lowering 
(glycogen synthesis, glycolysis) processes (Rui, 2014). The liver is also a main 
site for lipid biosynthesis, maintaining lipid fluxes between meals (Nguyen et al., 
2008). Systemic regulation of glucose homeostasis by the liver primarily arises 
from an initial increase in glycogenolysis and subsequent onset of 
gluconeogenesis, as glycogen stores become depleted (during prolonged 
fasting) (Röder et al., 2016). Obligate glucose-consuming tissues such as the 
brain rely on HGP during fasting whereas, postprandially, the liver suppresses 
glycogenolysis and gluconeogenesis and promotes glucose uptake (Moore et al., 
2012).  
HGP is hormonally regulated by insulin, which directly enhances glycogen 
synthesis (maximal during hyperglycaemia and hyperinsulinaemia) (Al-Khalili et 
al., 2005) and acutely suppresses adipose lipolysis, reducing supply of FAs and 
glycerol for gluconeogenesis (Chakrabarti et al., 2013). Glucagon suppresses 
hepatic glycolysis by inhibiting PFK-1 (Pilkis et al., 1982) while promoting 
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gluconeogenesis in a cyclic-adenosine monophosphate (cAMP)-protein kinase A 
(PKA) and cAMP-response element binding protein (CREB)-mediated manner, 
enhancing activation of PEPCK and G6P (Gonzalez and Montminy, 1989). 
In T2D, impaired hepatic glucose metabolism is primarily a consequence of lipid-
induced IR, enhanced glucagon levels and excessive lipolysis. The mechanisms 
by which these factors regulate gluconeogenesis are beyond the scope of this 
thesis but, for reference, were comprehensively reviewed by Peterson and 
colleagues (Petersen et al., 2017). 
1.2.7 Adipose tissue 
AT, namely white adipose tissue (WAT) plays an important metabolic role in its 
ability to store excess fat in the form of triglycerides (TG) through lipogenesis 
(Trayhurn, 2007). In instances of negative energy balance, energy expenditure 
requirements or when storage exceeds adipocyte capacity, these TG are broken 
down into free FAs (FFAs) and glycerol via lipolysis (Lafontan and Langin, 2009). 
These are then released into the circulation and utilised by muscle, liver and other 
organs to maintain energy balance.  
Postprandial glucose uptake into AT accounts for ~10-15 % of total body glucose 
disposal. However, alterations in adiposity play a critical role in impaired glucose 
homeostasis. Anti-hyperglycaemic mediators released by AT are endocrine in 
nature, such as adipokines leptin and adiponectin (Lago et al., 2009). Leptin is 
particularly important in repressing orexigenic pathways in the hypothalamus to 
suppress food intake. Leptin also enhances muscle and liver insulin sensitivity 
(Amitani et al., 2013), and reduces intramyocellular lipid (IMCL) accumulation by 
activation of AMP-activated protein kinase (AMPK) (Minokoshi et al., 2012). AT 
also responds to insulin by decreasing lipolysis while enhancing FA and TG 
synthesis from lipids and glucose (Dimitriadis et al., 2011). 
Paradoxically, AT releases blood glucose-raising mediators such as resistin, 
cytokines tumour necrosis factor α (TNF-α) (Hotamisligil, 1999) and interleukin 6 
(IL-6) (Rotter et al., 2003) and excessive non-esterified FAs (NEFAs) (Roden et 
al., 1996). The involvement of these markers in the pathogenesis of IR is explored 
below.  




Lipogenesis is the process by which FFAs and subsequently TGs (esterified), are 
synthesised from acetyl-CoA subunits produced during glycolysis and occurs 
primarily in AT and liver (Coleman and Lee, 2004) (and at a smaller scale in SM 
(Hollands and Cawthorne, 1981). The flow of carbons from glucose to fatty acids 
occurs via a coordinated series of enzymatic reactions summarised in Figure 1.4. 
Glucose, via glycolysis and the Krebs cycle, is converted to citrate, which is 
transported to the cytoplasm and is acted on by ATP-citrate lyase (ACLY) to 
release acetyl-CoA (Watson et al., 1969). The resulting acetyl-CoA is irreversibly 
converted to malonyl-CoA under the regulated catalytic activity of acetyl-CoA 
carboxylase 1 (ACC1), marking the first step in fatty acid synthesis (Bianchi et 
al., 1990). Synthesis of saturated long-chain fatty acids from acetyl-CoA, malonyl-
CoA and NADPH is then catalysed by fatty acid synthase (FASN) (Wakil, 1989). 
Repeated condensation, reduction, dehydration and reduction of acetyl-CoA and 
malonyl-CoA bound to the acyl-carrier protein domain of FASN generates 
(initially) a 16 carbon-chain fatty acid, referred to as palmitic acid (or palmitate). 
Palmitate is subsequently elongated and desaturated to generate different 
carbon-chained complex fatty acids such as palmitoleic acid, stearic acid and 
oleic acid.  
Lipogenesis is regulated by allosteric regulation of ACC and at the transcriptional 
level by activation of the sterol regulatory element binding protein 1c (SREBP1c) 
and carbohydrate response element binding protein (ChREBP) (Sanders and 
Griffin, 2016). In the fed period, insulin stimulates lipogenesis by PI3K-PKB-
mediated activation of SRBP1c, which, once converted to a mature form, 
translocates to the nucleus to promote the transcription of lipogenic genes such 
as FASN and ACC (Peterson et al., 2011; Ricoult and Manning, 2013). This 
results in increased TG storage in adipocytes and low-density lipoprotein (LDL) 
in hepatocytes (Kersten, 2001). At high glucose (postprandially and during 
hyperglycaemia) lipogenesis is also stimulated via activation of ChREBP by 
metabolites of glycolysis (in an insulin-independent manner) (Uyeda and Repa, 
2006; Dentin et al., 2012). Lipogenesis is suppressed in the postabsorptive 
period, primarily due to inhibition of ACC by activated AMPK and enhanced 
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cAMP-PKA signalling (Kawaguchi et al., 2001; Munday, 2002; Lu and Shyy, 
2006).  
Dysregulated de novo lipogenesis can result in metabolic disease, with the most 
prevalent condition associated with enhanced lipogenesis being non-alcoholic 
fatty liver disease (NAFLD) (Kawano and Cohen, 2013). NAFLD is associated 
with hepatic insulin resistance and increased risk of T2D (Tilg et al., 2017). 
1.2.8 Skeletal muscle  
SM is not only vital for physical movement and posture but also has critical 
metabolic and endocrine roles contributing to glucose disposal, lipid oxidation 
and protein metabolism. Muscle mass is maintained by a balance between 
muscle protein synthesis (MPS) and muscle protein breakdown (MPB) and 
dysregulation of this balance leads to muscle atrophy seen in ageing (sarcopenia) 
(Rennie et al., 2010), which is aggravated in disuse and T2D (Park et al., 2006). 
The ability to maintain MPS in response to anabolic stimuli such as protein and 
AA ingestion is lost in these states, a phenomenon referred to as anabolic 
resistance (Hodson et al., 2019) and this is associated with lipid overflow and IR 
(Stephens et al., 2015). As muscle accounts for 80 % of whole-body insulin-
stimulated glucose disposal, and is highly metabolically flexible, as proposed by 
Randle’s glucose-FA cycle hypothesis (Randle, 1998), it is an important mediator 
of IR in T2D.  
In the postprandial period, glucose metabolism is favoured over fat metabolism 
as insulin stimulates GLUT4-mediated glucose uptake. Glucose is metabolised 
in glycolysis, glycogen synthesis and pyruvate oxidation, while FA oxidation 
(FAO) is suppressed (Randle, 1998). During fasting, cellular energy depletion 
activates AMPK, which releases the inhibition on FAO while stimulating glucose 
uptake (Hardie and Pan, 2002). AMPK is also activated by an increase in the 
AMP/ATP ratio during exercise which increases the transcription, translation and 
activity of the transcriptional coactivator PPAR gamma coactivator 1-alpha 
(PGC1-α), which in turn co-activates several factors promoting mitochondrial 
biogenesis and OXPHOS (Herzig and Shaw, 2018). Increased mitochondrial 
biogenesis, OXPHOS and FAO improve insulin sensitivity (Pagel-Langenickel et 
al., 2010).  
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In addition to insulin-mediated glucose uptake, SM partly regulates glucose 
homeostasis by acting as a reservoir for AAs, released during fasting to promote 
gluconeogenesis and sustain glycaemia. As an endocrine tissue, it releases 
myokines such as myostatin (Han et al., 2013) and irisin (Vaughan et al., 2015) 
as well as IL-6 (Steensberg et al., 2000; Pedersen and Febbraio, 2008) and 
macrophage migration inhibitory factor (MIF) (Reimann et al., 2010) which act in 
an autocrine and paracrine manner to regulate energy homeostasis. 
Skeletal muscle metabolism is a major focus of this thesis so the pathways that 
are critical for its role in the pathophysiology of diabetes and energy homeostasis 
are introduced in more detail below, including insulin signalling, FAO and AA 
sensing and signalling. 
1.2.8.1 Fatty acid oxidation 
Mitochondrial FAO (β-oxidation) in liver and SM provides energy from FAs when 
circulating levels of glucose and lipids are lower (during fasting). Figure 1.4 
summarises the main steps in FA transport across plasma and mitochondrial 
membranes for β-oxidation. FFAs or TGs (first hydrolysed by lipoprotein lipase) 
are first taken up by cells, primarily by FA transporter proteins (FATP) (Bonen et 
al., 1999). SM expresses FATP1 and FATP4, which enhance uptake of long-
chain and very-long chain FAs across the membrane (Black et al., 2009). Uptake 
is also regulated by plasma membrane FA binding proteins (FATBPpm) and FA 
translocase (CD36) (Cameron-Smith et al., 2003) and these, along with 
cytoplasmic FABPs regulate the rate of FAO (Binas et al., 2003). FATPs and a 
second family of membrane proteins, the long-chain acyl-CoA synthetases 
(ACSL) ensure that FAs are rapidly converted to acyl-CoAs in preparation for 
mitochondrial import (Soupene and Kuypers, 2008).  
As mitochondrial membranes are impermeable to acyl-CoAs, these are 
converted to acyl-carnitines by carnitine palmitoyltransferase 1 A and B (CPT1) 
at the outer mitochondrial membrane. Acyl-carnitines are transported across the 
mitochondrial membrane by carnitine acyl-carnitine translocase (CACT) and, 
once inside, are converted back into acyl-CoAs by carnitine palmitoyltransferase 
2 (CPT2) in the inner mitochondrial membrane, to enter the β-oxidation pathway 
(Van der Leij et al., 2000; Ramsay et al., 2001; Bonnefont et al., 2004).  
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This pathway is a series of four enzymatic reactions in which acyl-CoAs of 
different lengths are oxidised to generate a two-carbon shortened acyl-CoA and 
acetyl-CoA as well as FADH2 and NADH after each cycle. The resulting acyl-CoA 
enters another cycle and acetyl-CoA is used in the Krebs cycle, ultimately 
generating more electron carriers, which along with NADH and FADH2 from this 
process, enhance OXPHOS.  
CPT1 catalyses one of the rate-limiting steps of FAO (Bonnefont et al., 2004) and 
CPT1 activity is directly regulated by inhibition from malonyl-CoA. One of the 
triggers for enhanced FAO during energy depletion is the activation of AMPK, 
which phosphorylates acetyl-CoA carboxylase (ACC), inhibiting its effect on the 
generation of malonyl-CoA from acetyl-CoA, and therefore suppressing inhibition 
at the level of CPT1. Another important regulator of FAO is PDH. Its upstream 
regulators such as pyruvate dehydrogenase kinase (PDK) are allosterically 
inhibited by elevated acetyl-CoA and NADH generated during FAO, which leads 
to phosphorylation and inactivation of PDH. This spares pyruvate for 
gluconeogenesis to prevent hypoglycaemia. Increased FA availability also 
enhances citrate levels, which inhibit PFK1 and PFK2, phosphoinositide-
dependent kinase 1 (PDK1) and GLUT, suppressing glucose uptake (Garland et 
al., 1963; Williams and O’Neill, 2018).  
Appropriate lipid handling and mitochondrial function are important regulators of 
metabolic flexibility and both impaired FAO and mitochondrial dysfunction are 
important aetiological factors in the development of IR (introduced below). 









Figure 1.4. Fatty acid transport across plasma membrane and mitochondria for 
β-oxidation 
Fatty acids must be taken up into tissues for utilisation. This occurs via diffusion or 
protein-regulated facilitated transport across membranes. Facilitator proteins include 
CD36 (whose extracellular site interacts with transporter protein FABPpm), which 
accept fatty acids and facilitates membrane translocation. In the cytosol, cytosolic 
binding proteins (FABPc) assist in binding and transport to utilisation sites.  Before 
entering the mitochondria, plasma-derived or intramyocellular triglyceride-derived 
fatty acids are converted to acyl-CoAs by acyl-CoA synthetases (ACSL). To enter 
the mitochondria, a carnitine group is added to each species by carnitine 
palmitoyltransferase 1 (CPT1) and the resulting fatty acyl-carnitines are shuttled to 
the mitochondrial matrix via carnitine-acyl carnitine translocase (CACT). In the 
matrix, CPT2 converts carnitinized species back to fatty acyl-CoAs, which are 
oxidised in β-oxidation and generate acetyl-CoA. MPC, mitochondrial pyruvate 
carrier; PDH, pyruvate dehydrogenase complex. 
 




The brain accounts for ~ 2 % of total body mass but consumes ~20 % of its daily 
energy (Rolfe and Brown, 1997), preferentially metabolising glucose (Allaman 
and Magistretti, 2013). The high glucose threshold of GLUT1 and GLUT3 ensures 
insulin-independent uptake into the brain via the blood brain barrier (BBB) and 
subsequent uptake into neurones (GLUT3, 4) and astrocytes (GLUT1) (Shah et 
al., 2012). The primary regions contributing to central control of glucose 
homeostasis are the hypothalamus, particularly four of the eleven nuclei, the 
ventromedial (VMH), arcuate (ARC) paraventricular (PVN) and lateral (LHN) 
hypothalamic nuclei; and brainstem, namely the nucleus of the tractus solaris 
(NTS) (Williams et al., 2001). These regions integrate stimuli of neuronal (e.g. 
vagal nerve), nutritional, including glucose (Routh et al., 2014), FA (Lam et al., 
2005) and AA (Su et al., 2012) levels; and hormonal (insulin, leptin, ghrelin) 
(Baskin et al., 1999; Bellinger and Bernardis, 2002) origin to regulate energy 
expenditure, appetite, fat deposition and the counterregulatory response to 
hypoglycaemia (Morton et al., 2006). 
The ability to sense glucose is attributed to populations of “glucose-excited” (GE) 
and “glucose-inhibited” (GI) neurones, identified in the 1960s, whose electrical 
activity is augmented in response to increases and decreases in glucose, 
respectively (Anand et al., 1964). GE neuronal activation by glucose is akin that 
of the β-cells, involving ATP-dependent closure of KATP channels, causing 
depolarisation and increased [Ca2+]i and initiation of action potential firing (Beall 
et al., 2012). Conversely, GI neurones are depolarised in low glucose and both 
populations rely on AMPK, the intracellular “fuel-gauge” (McCrimmon et al., 
2008), to instigate these responses (Beall et al., 2012). 
These glucose-sensing brain regions also contribute to the regulation of appetite. 
Orexigenic (ghrelin, adiponectin) stimuli promote food intake whereas 
anorexigenic (leptin, insulin) hormones suppress it (Nakazato et al., 2001; Sahu, 
2003). These hormonal, along with neuronal, signals are sensed by two 
populations of functionally opposing neurones, the pro-opiomelanocortin (POMC) 
and neuropeptide Y (NPY) and agouti-related peptide (AgRP)-containing 
neurones (in the ARC and NTS) which suppress and promote food intake, 
respectively (Betley et al., 2013).  
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1.3 Therapeutic approaches to combat hyperglycaemia 
Currently available therapeutic strategies primarily aim at combating 
hyperglycaemia in diabetes (anti-hyperglycaemic agents in T2D), with insulin 
replacement therapy remaining the cornerstone treatment for T1D and advanced 
T2D. Although drug development has improved exponentially over the past few 
decades, it is important to remember that lifestyle interventions, particularly 
dietary manipulation and exercise, play a critical role in the prevention and 
therapy of diabetes (primarily T2D).  
1.3.1 Exercise 
Increased physical activity and regular exercise improve physical and mental 
well-being and help prevent and treat T2D. Aerobic exercise augments 
mitochondrial density, insulin sensitivity, compliance, lung function, immune 
function and cardiovascular output, improving glycaemic control in T2D (Garber 
et al., 2011).  
This is partly mediated by enhanced insulin-stimulated glucose uptake and 
increased expression of GLUT4 and insulin receptors (Zanuso et al., 2010; Mann 
et al., 2014). Insulin-independent mechanisms also increase muscle glucose 
uptake after acute bouts of aerobic exercise (Magkos et al., 2008; Roberts et al., 
2013). In T1D aerobic training promotes cardiovascular fitness, muscle strength, 
insulin sensitivity and improves lipid levels and endothelial function (Colberg et 
al., 2016). High-intensity interval training shows added benefit to muscle oxidative 
capacity, insulin sensitivity and glycaemic control in T2D (Fiocco et al., 2013) and 
does not deteriorate glycaemic control in T1D. Fear of severe hypoglycaemia and 
lack of knowledge of strategies to avoid hypoglycaemia remain the overriding 
barriers to maintaining or enhancing physical activity in T1D (Brazeau et al., 2008; 
Gomez et al., 2015). Resistance training promotes muscle hypertrophy and 
improves glycaemic control, insulin sensitivity, fat mass and strength in T2D 
(Gordon et al., 2009) and can minimise the risk of post-exercise hypoglycaemia 
in T1D (Yardley et al., 2013). Regular exercise also increases muscle capillary 
density, an important feature given the reduced capillary density and blood flow 
seen in T1D (Rivard et al., 1999) and impaired micro and macrovascular function 
associated with loss of muscle mass in T2D (Groen et al., 2014). 
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A better understanding of the insulin-dependent and independent mechanisms 
by which exercise regulates whole-body glucose homeostasis and muscle mass 
and strength is still required to elucidate therapeutically targetable exercise-
mimetics.  
1.3.2 AMPK activators 
AMPK emerged as an important therapeutic target given its role in the regulation 
of glucose/lipid homoeostasis (Hardie, 2004; Kahn et al., 2005), food intake (Xue 
and Kahn, 2006), insulin signalling (Towler and Hardie, 2007) and mitochondrial 
function in response to metabolic stress (Fogarty and Hardie, 2010). 
AMPK is a serine/threonine protein kinase that is structurally comprised of a 
catalytic α-subunit and two regulatory β and γ subunits. There are two isoforms 
of the alpha subunit α1 and α2, two β isoforms, β1 and β2 and three γ isoforms 
γ1,γ2,γ3 allowing for 12 combinations of heterotrimeric complexes (Carling et al., 
1994; Davies et al., 1994). AMPKα1β1γ1 heterotrimers are ubiquitously 
expressed in many tissues so initial pharmacological AMPK activators were 
developed to target this complex.  
This has proved somewhat limiting given the specific tissues distribution of 
distinct complexes, strengthened by evidence showing that inactivating mutations 
and genetic deletion of specific isoforms generates tissue-specific effects (Salt et 
al., 1998). AMPK is endogenously activated by stimuli that deplete intracellular 
energy levels, such as nutritional status (decreased glucose) and toxins that 
inhibit respiration and exercise (Shaw et al., 2004; Hawley et al., 2005). Elevated 
AMP (and ADP) levels relative to ATP in energy-deficient cells allosterically 
activates AMPK (Carling et al., 1989), and pharmacological AMP mimetics form 
part of the class of indirect AMPK activators. Table 1.1 summarises the 
mechanisms of action and complex specificity of AMPK activators.  
Metformin remains the first line of treatment in T2D. A complex picture has 
developed over the past decade elucidating multiple AMPK-dependent and 
independent mechanisms of action of metformin (Rena et al., 2017). Some 
evidence suggests that metformin accumulates in mitochondria and inhibits 
mitochondrial complex I of the ETC, which indirectly activates AMPK by 
increasing AMP levels (Bridges et al., 2014). AMPK-dependent actions of 
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metformin, however, have been questioned by hepatic AMPK knockout 
experiments in mice (Foretz et al., 2010). More recently discovered, and now 
most well-accepted mechanism of action of the drug, was the ability of metformin 
to suppress hepatic gluconeogenesis via inhibition of fructose-1-6-
bisphosphatase (Hunter et al., 2018). The group, concomitantly with other’s 
observations (Shaw et al., 2005; Madiraju et al., 2014; Patel et al., 2014), 
concluded that AMPK activation is neither sufficient nor necessary to acutely 
suppress HGP but plays an important role in the chronic and indirect attenuation 
of hepatic insulin resistance (Cool et al., 2006; Fullerton et al., 2013).  
Other indirect AMPK activators include thiazolidinediones, which inhibit 
mitochondrial complex I and activate AMPK in liver and muscle to promote 
glucose uptake and FAO (Fryer et al., 2002; Brunmair et al., 2004); polyphenols, 
such as resveratrol which inhibit ATP synthase (Zheng and Ramirez, 2000; 
Gledhill et al., 2007); ginsenosides that decrease hepatic TG and cholesterol 
levels and suppress HGP and lipogenesis (Jeong et al., 2014); and α-lipoic acid 
which suppresses AMPK activity in the hypothalamus to reduce food intake (Kim 
et al., 2004). 
Direct AMPK activators were first explored with 5-aminoimisazole-4-carboxamide 
riboside (AICAR) which acts as an AMP mimetic (ZMP) and directly binds AMPKγ 
subunits (Sullivan et al., 1994; Corton et al., 1995). Others include A-769662 
which directly binds the catalytic subunit to inhibit AMPK dephosphorylation 
(Moreno et al., 2008; Scott et al., 2014) and aspirin. Compound 911, more 
recently developed, specifically targets β1 (but not β2)-expressing complexes 
with 5-10 fold higher potency compared to A-769662 (Xiao et al., 2013). Small 
molecule activators are also being developed and characterised. PT-1 directly 
activates AMPK (γ1 complexes in SM) and downstream substrate ACC 
independently of changes to AMP/ATP ratio (Pang et al., 2008; Jensen et al., 
2015) and indirectly by mitochondrial respiratory chain inhibition (Jensen et al., 
2015). Small molecule activator MK-8722 (Van Heek et al., 2017) is highly 
selective for β1-containing complexes and, like PF-793 (Cokorinos et al., 2017), 
promotes SM glucose uptake ex-vivo in an insulin-independent manner. More 
recently developed small molecule PAN-AMPK activator O304 showed anti-
hyperglycaemic and hyperinsulinaemic effects and attenuated IR in diet-induced 
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obese (DIO) mice; reduced FGC and markers of IR in humans with T2D treated 
for 28 days (Steneberg et al., 2018).  
Data suggest that AMPK activation in distinct brain regions may be glucose-
raising (McCrimmon et al., 2004), directly contrasting its peripheral glucose-
lowering effects (summarised in Figure 1.5). Further work is necessary to assess 
the utility of central and peripheral AMPK activation in the control of whole-body 
glucose homeostasis. This is explored further in Chapter 5. 
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Figure 1.5. Roles of AMPK activation in the control of whole-body glucose 
and lipid homeostasis. 
Activation of AMPK in peripheral tissues primarily acts to suppress anabolic 
processes such as protein synthesis, gluconeogenesis and fatty acid (FA) 
synthesis; and promote catabolic processes such as glucose uptake, glycolysis and 
fatty acid oxidation (FAO). These function to decrease blood glucose. Conversely, 
as depicted in the yellow shaded box, under conditions of hypoglycaemia, AMPK 
activation in energy sensing brain regions (such as the hypothalamus) has glucose 
raising effects. Activation of hypothalamic AMPK enhanced the counterregulatory 
response (CRR) to hypoglycaemia, partly via enhanced glucagon and adrenaline 
release and stimulates food intake and hepatic glucose production (HGP).  
 
 
Introduction  Chapter 1 
26 
 
1.3.3 Other pharmacological agents 
Insulin secretagogues such as sulphonylureas and meglitinides or glinides 
stimulate insulin release by blocking pancreatic KATP channels (Madison et al., 
1959; Ashcroft, 1996) and their differential pharmacokinetic profiles lead to 
decreased FPG in the case of sulphonylureas and decreased postprandial 
glucose by meglitinides (Del Prato and Pulizzi, 2006). Meglitinides are associated 
with less hypoglycaemic side-effects and weight gain compared to 
sulphonylureas (Madsbad et al., 2001; Plosker and Figgitt, 2004) and although 
the latter remain the most cost-effective option (Holman et al., 2008) loss of 
effectiveness over time is seen in some cases (Takahashi et al., 2007). 
More recently developed compounds include dipeptidyl peptidase-4 inhibitors 
(DPP4). These compounds suppress the inhibition of glucagon-like peptide 
(GLP-1) and gastric inhibitory peptide (GIP) secretion by DPP4, ultimately 
improving islet function and glycaemic control in T2D (Deacon, 2011).  
Sodium glucose co-transporter-2 inhibitors (iSGLT2) have a unique mechanism 
of action by inhibiting renal reabsorption of glucose and reducing hyperglycaemia 
by consequential increased excretion of glucose in urine (Abdul-Ghani et al., 
2011; Defronzo et al., 2013). The independence from insulin posts a lower risk of 
hypoglycaemia and no risk of overstimulation or fatigue of islets (Nauck, 2014). 
Injectable agents have also been developed, namely GLP-1 receptor agonists 
(RA-GLP1), which unlike GLP-1 that is rapidly broken down by DPP4, have 
extended duration. RA-GLP1 treatment effectively lowers HbA1c, FGC, body 
weight and blood pressure with low risk of causing hypoglycaemia (Willms et al., 
1996; Inzucchi et al., 2015).  
1.3.4 Insulin replacement therapy 
Insulin replacement therapy has been the cornerstone of treatment for T1D and 
advanced T2D for over 8 decades (Owens et al., 2014). In that time, more and 
better insulin analogues have been developed, including short-acting pre-meal 
compounds as well as longer-acting once-daily options (Horvath et al., 2007), 
which can be combined in basal bolus therapy. The inherent pharmacokinetic 
properties of these agents however, hinder the maintenance of glycaemia in 
range, partly due to individual variability in absorption (Morello, 2011). 
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Insulin injection or intranasal administration before a meal can still lead to an 
elevated postprandial glucose excursion with delayed hypoglycaemia, but these 
responses are ameliorated by the use of subcutaneously administered insulin via 
pumps.   
The unfortunate consequence of the use of insulin or insulin secretagogues is the 
increased risk of hypoglycaemia (iatrogenic hypoglycaemia). Hypoglycaemia in 
T1D and insulin-treated T2D negatively influences quality of life (Alvarez-
Guisasola et al., 2010) and promotes fear of future episodes of hypoglycaemia 
(Anderbro et al., 2010), being associated with less self-care and poorer glycaemic 
control as well as reluctance towards intensifying therapy (Barnard et al., 2010; 
Haugstvedt et al., 2010).  
The development of strategies to prevent, detect and minimise hypoglycaemic 
risk is of utmost importance to reduce the social and emotional impact of this 
phenomenon and help individuals safely achieve glycaemic targets.   
1.4 Hypoglycaemia 
Hypoglycaemia is defined clinically by low plasma glucose levels (< 4.0 mmol/L 
for insulin-treated individuals), symptomatic response to administration of 
carbohydrates (or raised plasma glucose) and the development of autonomic or 
neuroglucopenic symptoms (American Diabetes Association, 2019c). The degree 
of severity of hypoglycaemia is determined by clinical manifestations from mild to 
moderate and severe, with severe episodes being characterised by the 
requirement of assistance from another person, potential loss of consciousness 
and plasma glucose level < 2.8 mmol/L (Yale, Paty and Senior, 2018), Symptoms 
can occur after a single hypoglycaemic episode and include autonomic 
responses such as sweating, anxiety, hunger and nausea; as well as 
neuroglucopenic symptoms such as confusion, dizziness, difficulty speaking and 
vision changes (Yale et al., 2018). The frequency of mild hypoglycaemic events 
is approximately twice-weekly (Ovalle et al., 1998), while severe episodes occur 
1-3 times per year (Heller et al., 2007), and the latter are associated with 
increased morbidity and mortality in T1D (Skyler et al., 2009) and increased risk 
of cardiovascular complications in T2D (Hayward et al., 2015).  
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Repeated exposure to hypoglycaemia leads to a reduction in the body’s first line 
of defence against hypoglycaemia, termed the counterregulatory response 
(CRR) (Ma et al., 2018), as well as reduced psychological and behavioural 
responses, referred to as impaired awareness of hypoglycaemia (IAH) (Geddes 
et al., 2008). Some of the strategies available to manage hypoglycaemia include 
better education and psycho-behavioural programs to improve detection (Kinsley 
et al., 1999), continuous subcutaneous insulin infusion (CSII) and continuous 
glucose monitoring (CGM), or both (sensor-augmented pump) to reduce risk of 
hypoglycaemia (Ly et al., 2013; Little et al., 2014); and islet cell transplantation, 
which has been shown to restore counterregulation (Rickels, 2012) and reduce 
hypoglycaemia in T1D (Hering et al., 2016).  
1.4.1 Counterregulatory response  
The CRR to hypoglycaemia refers to the myriad of physiological and behavioural 
responses (neural-endocrine axis) that converge to raise blood glucose following 
a progressive decline in plasma glucose concentration (Schwartz et al., 1987).  
As plasma glucose falls within the physiological range (4.4-4.7 mmol/L), the body 
first responds by suppressing insulin secretion to reduce glucose utilisation 
(Fanelli et al., 1994). If levels continue to fall below 3.6-3.9 mmol/L the release of 
counterregulatory hormones glucagon, adrenaline and noradrenaline is triggered, 
with the latter two being released from the adrenal medulla. Adrenaline acts on 
the liver via β-2 adrenergic receptors to increase glycogenolysis and enhances 
lipolysis, mobilising gluconeogenic precursors from peripheral tissues to 
stimulate HGP (Exton, 1987; Dufour et al., 2009). SM contributes to CRR by 
decreasing glycogenesis (decreases demand for glucose uptake) (Cohen et al., 
1995) and by enhancing lactate release (Meyer et al., 2005). Symptom onset 
occurs in healthy individuals when plasma glucose falls further, below 2.8-3.0 
mmol/L, and these are mediated by parasympathetic and sympathetic responses 
rather than adreno-medullary activation (Exton, 1987; DeRosa and Cryer, 2004). 
Glucose sensing by hypothalamic GE and GI neurones plays an important role in 
the CRR (McCrimmon, 2009). CNS involvement in CRR was supported by 
observations that intracarotid glucose infusion in dogs suppressed the CRR to 
hypoglycaemia (Biggers et al., 1989) and intraventricular injection of 2-deoxy-d-
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glucose (2-DG), which competes with glucose for cellular uptake but is not 
metabolisable, enhanced glucagon response to hypoglycaemia (Borg et al., 
1995). Hypothalamic (and NTS) glucose sensing machinery also regulates 
orexigenic and anorexigenic peptide release, with a drop in glucose resulting in 
increased feeding response. AMPK activation in these regions is believed to be 
important for appetite regulation (Kola, 2008) and represent a stimulus to amplify 
CRR (McCrimmon et al., 2006). This is explored in Chapter 5.  
In diabetes, disease progression and frequent exposure to hypoglycaemic events 
lead to impaired CRR (Kleinbaum and Shamoon, 1983; George et al., 1995). This 
is characterised by a shift to lower plasma concentrations to trigger CRR 
thresholds (Mitrakou et al., 1993); lack of endogenous suppression of insulin 
secretion (administered exogenously) and attenuated glucagon and 
sympathoadrenal responses (Kleinbaum and Shamoon, 1983). Impaired CRR is 
associated with a 25 fold (or higher) increased risk of severe iatrogenic 
hypoglycaemia (White et al., 1983) and IAH with a 6 fold higher risk (Geddes et 
al., 2008). The mechanisms leading to impaired CRR are incompletely 
understood so a better understanding is required of the central and peripheral 
neuroendocrine processes mediating these responses.  
1.5 Mechanisms of insulin action and insulin resistance  
The ensuing hyperglycaemia seen in T2D is largely a consequence of inadequate 
insulin action and understanding the mechanisms of both insulin action and IR is 
essential for the continued development of novel therapeutic strategies to combat 
glycaemia dysregulation. Insulin acts on the liver to promote glycogenesis, 
increase expression of lipogenic genes and suppress gluconeogenesis; while in 
WAT, it suppresses lipolysis and enhances lipogenesis and glucose transport 
(Petersen and Shulman, 2018). Insulin also has indirect actions in the CNS (Porte 
et al., 2005) and suppresses glucagon secretion from α-cells (Cooperberg and 
Cryer, 2010). Although these are critical insulin target tissues, 85-90 % of the 
impairment in total body glucose utilisation in T2D is attributed to SM IR 
(Pendergrass et al., 2007), so emphasis will be placed on SM here.  
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1.5.1 Insulin signalling pathway 
A simplified schematic of the insulin signalling pathway in SM is summarised in 
Figure 1.6. Upon insulin binding, the insulin receptor (INSR) autophosphorylates 
and recruits insulin receptor substrates (IRS), of which IRS1 and 2 are believed 
to mediate most of the metabolic effects of INSR activation in SM (White et al., 
1988; Taniguchi et al., 2006). Once bound to the INSR, IRSs become 
phosphorylated at tyrosine residues to propagate either mitogenic or metabolic 
signalling cascades. IRSs also regulate negative feedback loops, primarily by S6 
kinase (S6K) when phosphorylated at serine/threonine sites. Tyrosine-
phosphorylated IRS proteins recruit phosphoinositide-3-kinase (PI3K) 
heterodimers, primarily class I, which in turn catalyse the production of 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) from phosphatidylinositol-4,5-
bisphosphate (PIP2). PIP3 localises downstream effector proteins to the plasma 
membrane, including PDK1 and protein kinase B1 and 2 in SM (PKB, also known 
as AKT).  
Activation of PKB is initiated by PDK1 phosphorylation at threonine 308 (Alessi 
et al., 1997), and kinase is fully activated via phosphorylation of serine 473 by 
mammalian mechanistic target of rapamycin (mTOR) complex 2 (mTORC2). 
Once activated, PKB primarily regulates translocation of GLUT4-containing 
storage vesicles to the plasma membrane to promote glucose uptake (Wang et 
al., 1999). PKB phosphorylates substrates such as GTPase-activating protein 
(GAP), AKT substrate of 160 kDa (AS160, or TBC1D4) and TBC1D1 (Mîinea et 
al., 2005). These, in turn, disinhibit Rab GTPase proteins that control vesicle 
translocation. A second signal for PI3K-mediated GLUT4 vesicle translocation is 
mediated by the Rho GTPase RAC1 (Khayat et al., 2000). The resulting increase 
in intracellular glucose availability drives glycolytic flux and promotes glycogen 
synthesis. Insulin stimulates these by upregulating transcription of HKII and 
regulates glycogen synthase by PKB-mediated inhibition of glycogen synthase 
kinase 3 (GSK3) (O’Brien and Granner, 1996).  
Insulin signalling is tightly regulated by positive and negative feedback 
mechanisms. Negative feedback, resulting in attenuated proximal insulin 
signalling, includes INSR internalisation and dephosphorylation. Receptor 
internalisation is regulated by substrates such as carcinoembryonic antigen-
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related cell adhesion molecule 1 (CEACAM1) (Najjar, 2002; Poy et al., 2002); 
and dephosphorylation is mediated by protein tyrosine phosphatases (PTPases), 
primarily PTP1B (Galic et al., 2005). Once activated, INSR contributes to 
feedforward amplification via activation of NAD(P)H oxidase 4 (NOX4) and 
NOX4-derived H202 inhibition of PTP1B activity (Mahadev et al., 2004; Wu and 
Williams, 2012). 
Besides glycogen and lipid synthesis (in liver), insulin regulates protein synthesis 
by modulating mTOR signalling. Insulin activates mTORC1 by inactivating 
mTORC1 inhibitors tuberous sclerosis complex 2 (TSC2) and proline-rich AKT 
substrate of 40 kDa (PRAS40) (Inoki et al., 2002; Haar et al., 2007). This, in turn, 
phosphorylates components of the protein translational machinery such as S6K, 
and eukaryotic translation initiation factor binding proteins 1 and 2 (4EBP1/2). 
mTOR mediators are also involved in feedback mechanisms to tune insulin 
signalling. These include inhibition of IRS activation by S6K1, PKB 
phosphorylation by mTORC2 (Sarbassov et al., 2005; Hsu et al., 2011; Yu et al., 
2011) and mTORC1-mediated phosphorylation of growth factor receptor bound 
protein 10 (GRB10) which attenuates INSR activity (Hsu et al., 2011). Activation 
of mTOR signalling by insulin enables the integration of other anabolic pathways, 
such as AA sensing, with insulin signalling.   
1.5.2 Pathogenesis of SM insulin resistance 
The pathogenesis of SM IR appears to involve an interplay between increased 
nutrient derived toxic metabolites (lipotoxicity), nutrient stress-mediated toxicity 
(inflammation) and overwhelmed substrate utilisation machinery (endoplasmic 
reticulum stress, ROS) (summarised in Figure 1.7). Impairments in insulin 
signalling pathways are primarily proximal, involving INSR, IRS1, PI3K and PKB. 
This was evidenced by early work showing impaired INSR receptor expression 
and function in human and rat obesity and diabetes (Goldfine et al., 1973; Archer 
et al., 1975). Others demonstrated impaired stimulation of IRS1-PI3K in response 
to insulin in acute and chronically-induced IR (Dresner et al., 1999; Cusi et al., 
2000; Griffin et al., 2000). Impairments in these early responses may mediate 
most of the pathophysiology of IR, but multiple signalling effectors are known to 
be dysregulated to bring these about.  




Of particular interest to this thesis is the contribution of excessive lipid availability, 
impaired mitochondrial function and inflammation to the development of IR.  
1.5.2.1 Lipid-induced IR 
Lipid-induced IR was first observed in rabbits who were resistant to insulin-
induced hypoglycaemia following intravenous lipid infusion (Young., 1962), and 
later supported by observations of an association between elevated NEFAs and 
IR (Chen et al., 1987; Golay et al., 1987). Randle and colleagues first suggested 
that the FA-glucose cycle regulated the impairments in glucose metabolism 
brought about by FAs (Randle et al., 1963; Randle et al., 1964).  
Figure 1.6 Insulin signal transduction pathway in skeletal muscle 
Biochemical pathway by which insulin promotes glucose uptake into SM to maintain 
glycaemia. Inhibitory steps indicated by red arrows and stimulatory transduction in black. 
PTEN, phosphatase and tension homologue. Negative regulator of insulin/PI3K. SIN, 
mammalian stress-activated protein kinase interacting protein 1. GDP, guanosine 
diphosphate; GTP, guanosine triphosphate.  
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In that hypothesis, increased FA availability would enhance FAO, resulting in 
elevated acetyl-CoA and citrate which would, in turn, inhibit PDH and PFK1 and 
suppress glucose oxidation (Randle, 1998). Although extensive in vitro and in 
vivo work originally suggested that this might be the main mechanism behind 
glucose intolerance in T2D, the hypothesis has since been challenged and 
current evidence suggests that the glucose-FA cycle does not account for the 
impairment in insulin-stimulated glucose uptake seen following several hours of 
lipid infusion or in obesity/T2D (Boden et al., 1991; Rahimi et al., 2014).  
Currently, the best described mechanisms implicate increased FFA levels 
(Paolisso et al., 1995), IMCL accumulation (Goodpaster et al., 2000) and 
enhanced generation of lipotoxic metabolites such as long-chain fatty acyl-CoA 
(LCFA-CoA) (Cooney et al., 2006), diacylglycerol (DAG) (Itani et al., 2002), acyl-
carnitines (Aguer et al., 2015) and ceramides (Summers, 2006) in the 
pathophysiology of muscle IR (Boden, 2011). The proposed mechanisms are 
summarised in Figure 1.7. DAG activates protein kinase C-θ (PKCθ), which is 
believed to target IRS1 and guanine exchange factor GIV/Girdin, the latter being 
required for insulin-stimulated glucose uptake (Laybutt et al., 1999; Griffin et al., 
2000). Ceramides action in IR is two-fold: activation of PKCζ which 
phosphorylates PKB at a site that lowers affinity for phosphoinositide (Powell et 
al., 2003) and prevents translocation (Stratford et al., 2001); and by protein 
phosphatase 2A (PP2A)-mediated dephosphorylation of activated PKB (Fox et 
al., 2007; Blouin et al., 2010). Both DAG and ceramide accumulation suggest 











Figure 1.7 Proposed mechanisms of lipid-induced skeletal muscle insulin resistance.   
Diacylglycerol (DAG) is proposed to act via activation of protein kinase θ (PKCθ). Targets of 
PKCθ, although not clearly defined, may include insulin receptor substrate 1 (IRS1) and 
guanine nucleotide-binding protein α subunit-interacting vesicle-associated protein (GIV). 
PI3K, phosphoinositide-3-kinase. Ceramides are proposed to decrease PKB activity via protein 
phosphatase 2A (PP2A) or PKCζ. Incomplete fatty acid oxidation (FAO) may lead to 
acylcarnitine species accumulation which can directly contribute to insulin resistance or lead to 
increased reactive oxygen species levels (ROS). Signalling of species such as palmitate via 
toll-like receptors (TLR4) may contribute to insulin resistance by activation of inflammatory 
signalling pathways, which can also be activated by the effect of increased intracellular fatty 
acid flux on endoplasmic reticulum (ER) stress. JNK, c-Jun N-terminal kinase. IKK, IκB kinase.  
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1.5.2.2 Mitochondrial dysfunction 
The two main fates of lipids entering SM are FAO and storage as TGs. Impaired 
ATP synthesis in T2D is associated with IMCL accumulation and initial 
hypotheses linked the accumulation of lipid species in muscle with the 
development of IR (Pan et al., 1997). This was supported by evidence showing 
decreased mitochondrial activity (Kelley et al., 2002; Fabbri et al., 2017) and SM 
mitochondrial content (Mootha et al., 2003) and increased mitochondrial damage 
(Chomentowski et al., 2011) in insulin resistant humans.  
An increasing body of evidence now suggests that, contrary to the original 
hypotheses, a relative increase in β-oxidation flux itself drives IR. Rodents on a 
high-fat diet (HFD) develop SM IR coupled with an increase in FAO and blocking 
β-oxidation leads to improved insulin sensitivity, despite IMCL accumulation 
(Guerre-Millo et al., 2001; Finck et al., 2005; Koves et al., 2008). FAO is also 
upregulated in response to increased FA availability in diabetic models. However, 
this relative increase in FAO is not accompanied by markers of complete β-
oxidation, such as increased CO2 production, suggesting incomplete FAO (Koves 
et al., 2008). This results in accumulation of the lipotoxic moieties described 
above as well as acyl-carnitine and generation of ROS, which impair insulin 
signalling at the levels of PKB and via activation of inflammatory pathways and 
mitochondrial damage (Samocha-Bonet et al., 2012). 
1.5.2.3 Inflammation 
Impaired insulin signalling primarily affects the metabolic pathway (PI3K/PKB) 
while mitogenic pathways such as the mitogen-activated protein kinase (MAPK) 
cascades remain activated (Cusi et al., 2000). Signalling via MAPK results in 
upregulated inflammatory pathways associated with IR such as the inhibitor κB 
(IκB)/nuclear factor κB (NF-κB) and c-Jun NH2-terminal kinase (JNK) cascades 
(Lee et al., 2003). Activation of IκB/NF-κB signalling pathway is also implicated in 
SFA-induced IR via toll-like receptor 4 (TLR4) (Shi et al., 2006). These signalling 
cascades mediate the expression and release of cytokines/myokines, the best 
described of which in the context of IR being TNF-α, interleukin 10 (IL-10) and IL-
6. TNF-α primarily suppresses insulin-stimulated glucose uptake (Bouzakri and 
Zierath, 2007), whereas IL-10 prevents SFA-induced IR in muscle cells (Kim et 
al., 2004).  
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IL-6 has demonstrated both pro and anti-inflammatory roles depending on 
concentration and length of exposure (Scheller et al., 2011). Figure 1.8 
summarises the contribution of inflammatory markers to SM IR (adapted from Wu 










Figure 1.8 Inflammatory signalling-mediated skeletal muscle insulin 
resistance 
Extracellular cytokines and inflammatory molecules such as arachidonic acid-
derived leukotriene B4 (LTB4), angiotensin II (ANG II), FFAs, TNF-α and 
interleukin 1β (IL1-β) act on their respective receptors (TLRs in the case of FFAs) 
to activate PKC/JNK/NF-κB signalling pathways in muscle cells. These can 
interfere with INSR signalling by disrupting tyrosine phosphorylation and 
enhancing serine/threonine phosphorylation of INSR or IRSs. IFN-γ and IL-6 
activate JAK/STAT signalling pathways that impair insulin signalling, partly via 
suppressor of cytokine signalling (SOCS) proteins-mediated suppression of 
INSR/IRS activation. Adapted from Wu and Ballantyne (2017). 
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1.6 Amino acid metabolism 
Anabolic resistance to feeding underlies the accelerated loss of muscle mass and 
function seen in ageing and T2D so a better understanding of impaired AA 
metabolism is required to better understand its aetiology. 
 
 
The effect of mixed meal consumption on postprandial MPS was established over 
3 decades ago (Rennie et al., 1982), and it was quickly realised that the bioactive 
components necessary and sufficient to maintain MPS were the essential AAs 
(EAA): leucine, isoleucine, valine, lysine, tryptophan, phenylalanine, methionine 
and histidine (Madden et al., 1943). These cannot be synthesised de novo, 
originating from the diet, and, as such, act as important signals for nutritional 
status in the body. Conversely, non-essential AAs (NEAA) such as glycine, 
arginine and serine, which are endogenously synthesised, cannot stimulate MPS 
(Smith et al., 1998). NEAAs are, however, important in the CNS acting as 
neurotransmitters or neurotransmitter precursors. 
 
Of the EAA, the branched-chain AAs (BCAA - leucine, valine, and isoleucine) are 
primarily metabolised in SM, so that their metabolites also have anabolic 
properties. Leucine alone robustly stimulates MPS, even in the absence of other 
EAAs (Buse and Reid, 1975) and its metabolites, such as β-hydroxyl-β-
methylbutarate (HMB), have emerged as potent stimulators of MPS and inhibitors 
of MPB (Van Koevering and Nissen, 1992; Wilson et al., 2009; Wilkinson et al., 
2013). A catabolite of valine, 3-hydroxyisobutyrate (3-HIB) has recently been 
shown to be released from muscle and act in a paracrine manner to regulate 
myocellular lipid uptake (Jang et al., 2016). Interestingly, this bioactive moiety 
has also been implicated in the development of lipid-induced IR, as BCAAs start 
to emerge as potential mediators of IR (Mardinoglu et al., 2018). This is explored 
further in Chapter 4. 
In the postprandial period, the levels of BCAAs (namely leucine) become elevated 
in the brain and are sensed by hypothalamic and NTS nuclei to modulate food 
intake (Heeley and Blouet, 2016). Direct leucine administration into the third 
ventricle of rodents suppresses fast-induced refeeding (Blouet et al., 2009) and 
POMC ARC neurones become activated in response to leucine (Blouet et al., 
2009; Smith et al., 2015).  
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Leucine administration into the medial basal hypothalamus (MBH) during 
pancreatic glucose clamps in rats also decreases plasma glucose due to 
inhibition of HGP, without affecting glucose disposal into SM (Arrieta-Cruz et al., 
2016). Anabolic resistance in central AA sensing is also evidence following high-
SFA feeding in rodents (Arrieta-Cruz et al., 2016). Impaired CNS nutrient-sensing 
dysregulates glucose homeostasis and appetite regulation so a better 
understanding of the influence of AA sensing and availability in these processes 
is required to develop better therapeutic strategies for glycaemic control.  
1.6.1 Amino acid sensing and signalling 
The uptake, release and exchange of AAs across cells and organelles are 
facilitated by the presence of AA transporters (AATs) located in cell and organelle 
membranes. AATs belong to the superfamily of solute carriers (SLC) and there 
are 66 known AATs within 11 of the subfamilies of the SLCs (Kandasamy et al., 
2018). AATs are also classified into systems such as system A, N, ASC, B, L, T, 
X-c and Y+ according to their mode of transport and specificity. For instance, 
stimulation with EAA upregulates the mRNA expression of AATs in SM, such as 
L-type AA transporter 1 (LAT1), sodium-coupled neutral AA transporter 2 
(SNAT2) and CD98 at the plasma membrane and proton assisted AA transporter 
(PAT1) in lysosomes; and this coincides with enhanced MPS (Drummond et al., 
2010, 2011).  
An increase in MPS in response to increased AA availability is accompanied by 
activation and increased expression of mTORC1 related signalling markers 
(Bond, 2016), which enhance anabolic and suppress catabolic processes such 
as initiation of protein translation and autophagy, respectively (Kimball et al., 
1999; Wang et al., 2001; Raught et al., 2004). The upstream regulators of 
mTORC1 activation were largely unknown in AAs sensing and, although not fully 
characterised, are now believed to incorporate AA sensors SLC38A9 (Jung, 
Genau and Behrends, 2015), Sestrin1/2 (Budanov and Karin, 2008; 
Chantranupong et al., 2014) and cellular arginine sensor for mTORC1 
(CASTOR1/2) (Saxton et al., 2016); and signalling pathways implicating MAPK 
kinase kinase 4 (MAP3K4) (Findlay et al., 2007), Rag GTPases 1-4 (Sancak et 
al., 2008) and vacuolar protein sorting 34 (Vps34) (Nobukuni et al., 2005).  
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Although insulin also activates mTORC1, this is not required for EAA-induced 
MPS, given that blocking PI3K/PKB does not block AA-stimulated MPS (Bolster 
et al., 2004). 
Once signals converge at mTORC1, the complex phosphorylates and inhibits 4E-
BP1 which is removed from its association with eukaryotic initiation factor 4F 
(eIF4F) to enable translation initiation (Sonenberg and Hinnebusch, 2009). 
mTORC1 also hyperphosphorylates S6K1 at threonine residue 389, which in turn 
phosphorylates S6 and regulates MPS initiation via eIF4B and elongation via 
eukaryotic elongation factor 2 (eEF2) (Raught et al., 2004) (Figure 1.5). 
Phosphorylated mTORC1 levels are poorly detectable in human SM in response 
to anabolic stimuli (Mitchell et al., 2015), which further supports the existence of 
more than one input relaying AA sensory information.  
Anabolic resistance in older individuals is reflected in impaired S6K1 
phosphorylation in response to AA/protein intake compared to younger 
individuals (Guillet, 2004). However, it is unlikely that this impairment results from 
a reduction in the available AA pool for MPS, considering intracellular EAA 
concentrations are higher in older compared to younger individuals (Cuthbertson 
et al., 2005). A better understanding is still required of the mechanisms impairing 
anabolic sensitivity with age, which is exacerbated in conditions such as T2D and 
following disuse (Wall and van Loon, 2013). Assessments of AA metabolism and 
MPS were made easier by technological advances in detection and sensitivity of 
mass spectrometry, along with the development of stable AA isotope tracers (Kim 
et al., 2016), making it possible to assess dynamic changes in uptake, synthesis 
and breakdown and better understand the development of anabolic resistance. 
This is explored in Chapter 4.    
 
1.7 Purinergic signalling system 
Pioneering work by Geoffrey Burnstock in the 1970s elucidated a role for 
nucleotides and nucleosides in cell-to-cell communication, coining the term 
purinergic signalling (Burnstock, 1972; Burnstock and Verkhratsky, 2009). This 
work questioned the role of ATP and other purine and pyrimidine nucleotides 
such as ADP, uridine triphosphate (UTP), uridine diphosphate (UDP), UDP-
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glucose; and nucleosides (adenosine) as purely universal intracellular energy 
sources, identifying novel extracellular signalling properties (Burnstock et al., 
1970). The idea was received with scepticism and only became accepted when 
the first ATP receptor was cloned (Webb et al., 1993). The purinergic signalling 
field has since grown exponentially and these nucleotides/sides have been 
shown to be implicated in a plethora of physiological and pathophysiological 
processes.  
1.7.1 Mechanisms of nucleotide release 
Intracellular nucleotide release is regulated by processes including vesicular 
exocytosis, macrovesicles and by a variety of channels and transporters 
(Burnstock, 2007; Abbracchio et al., 2009). Large amounts of nucleotides can 
also be released in a non-regulated manner, as a consequence of shear stress 
induced by mechanical strain, hypoxia, membrane damage or stress induced by 
cytotoxic agents (Forrester and Williams, 1977; Kroemer et al., 2013). This also 
occurs during inflammation from disrupted cell membranes where these 
nucleotides/sides act as “danger signals” leading to immune cell recruitment and 
activation (Burnstock, 2007, 2008).  
In the case of ATP, the nucleotide is produced during cellular respiration and 
stored intracellularly in cytosolic granules by the action of the vesicular nucleotide 
transporter (VNUT); and vesicular exocytosis occurs in a SNARE-mediated 
manner (Sudhof and Rothman, 2009; Imura et al., 2013; Moriyama et al., 2017). 
Transporters for ATP release include primarily pannexins hemichannels (Pnx) 
and connexin hemichannels/gap junctions (Cnx); as well as ATP binding cassette 
transporters (ABC), calcium homeostasis modulators (CALHM) and purinergic 
receptor X7 (P2X7) (Taruno, 2018). Levels of extracellular ATP can also increase 
by backward ATP re-synthesis by extracellular activity of adenylate kinase (Dzeja 
and Terzic, 2009; Tsai et al., 2012), by nucleoside diphosphate kinase (NDPK) 
(Yegutkin et al., 2001; Donaldson et al., 2002) and ATP synthases, converting 
AMP to ADP and ATP (Yegutkin, 2008, 2014). These pathways are summarised 
in Figure 1.9.1. 
Once outside cells, the levels of extracellular nucleotides are tightly regulated by 
the actions of cell surface enzymes (Zimmermann, Zebisch and Sträter, 2012).  
Introduction  Chapter 1 
41 
 
There are four main families of nucleotide hydrolysing enzymes, or ecto-
nucleotidases, including the ecto-nucleoside triphosphate diphosphohydrolases 
(ENTPDases), ecto-5’-nucleotidases (5’-NT), ectonucleotide 
pyrophosphatase/phosphodiesterases (ENPPs) and alkaline phosphatases (AP) 
(Zimmermann, 2006). The ENTPDases (such as CD39) are the main nucleotide 
hydrolysing enzymes as they break down nucleoside triphosphate and 
diphosphates into nucleoside monophosphates (such as ATP>ADP>AMP) 
(Kukulski et al., 2011). 5’NT (CD73) then acts to convert AMP and adenosine. 
The CD39/CD73 axis is important in attenuating the inflammatory effects of 
extracellular nucleotides, particularly ATP (Eckle et al., 2007; Friedman et al., 
2009). Adenosine can be taken up by adenosine transporter proteins, such as 
equilibrative nucleoside transporters 1-4 (ENT) and concentrative nucleoside 
transporters (CNTs) (Young et al., 2013; Young, 2016). A summary of 






Figure 1.9.1 Mechanisms of ATP release 
ATP produced via glycolysis and OXPHOS can be released in a non-regulated 
manner as a consequence of mechanical or sheer stress, or via regulated 
mechanisms. Regulated ATP release can occur via vesicular exocytosis, 
membrane-derived microvesicles, connexin (Cnx) and pannexin (Pnx) 
hemichannels, ATP binding cassette (ABC) transporters, calcium homeostasis 
modulators (CALHM) channels or purinergic receptors (eg. P2X7R).  
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1.7.2 Purinergic (P2) receptors 
Extracellular nucleotides and nucleosides are recognised by specific and widely 
distributed purinergic (P2) receptors (P2R). There are two classes of P2Rs, the 
metabotropic P2Y and ionotropic P2X (Burnstock and Kennedy, 1985; Ralevic 
and Burnstock, 1998; Abbracchio et al., 2006). The affinity of P2Rs for 
extracellular nucleotides ranges from nanomolar/low micromolar (100 nM-20 μM) 
to high micromolar/millimolar (300 μM-1 mM) (Valera et al., 1994; Coddou et al., 
2011).  
There are 7 identified ligand-gated P2XRs (P2X1-7) which allow influx of Na+ and 
Ca2+ ions and efflux of K+ (Valera et al., 1994; Abbracchio et al., 2009). P2XRs 
are assembled as hetero or homo-trimers with three ATP-binding sites that all 
need to be engaged for channel/receptor opening. P2X7R forms unique 
macropores and has the lowest affinity for ATP, being implicated in primarily pro-
inflammatory processes such as inflammasome activation, and inflammatory 
cytokine signalling (Leo Bours et al., 2011; Franceschini et al., 2015). 
 
The G-protein coupled P2Y receptors identified to date, of which there are 8, are 
P2Y1, 2, 4, 6, 11, 12, 13 and 14. These display differential specificity for 
nucleotides as well as tissue and cellular distribution and their downstream signal 
transduction is dependent on the G-protein to which they are coupled (Abbracchio 
et al., 2006; Jacobson and Müller, 2016). P2Y1, 2, 4 and 6 activate Gq and 
phospholipase C-β (PLC-β), which in turn generates inositol-1,4,5-triphosphate 
(IP3) triggering the release of Ca2+ from intracellular stores; and DAG, activating 
PKC (Zimmermann, 2016). Activation of Gi by P2Y12, 13 and 14 causes inhibition 
of adenylyl cyclase (AC) and decrease in cyclic AMP (cAMP) levels (Torres et al., 
2002; Zhang, Zhang and Ding, 2017). Signalling via P2Y11, which does not 
appear to be expressed in rodents, only humans, activates Gq and Gs enhancing 
cAMP and [Ca2+]i (Kennedy, 2017). The preferred agonists for P2YRs are ATP 
(P2Y11), UTP (P2Y2, 4), ADP (P2Y1, 12, 13), UDP (P2Y6) and UDP-glucose 
(P2Y14). Other pathways are also modulated by activation of P2YRs, such as 
activation of PI3Kγ, MAPKs and PLC-β2/β3 (von Kugelgen and Harden, 2011; 
Erb and Weisman, 2012). 
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P2Rs can also be activated by ATP analogues such as 2-methylthio-ATP, 2-
cloro-ATP, adenosine-5’-o-(3-thiotriphosphate) (ATPγS), and 2’ (3’)-O-4-
benzoylbenzoyl-ATP (BzATP) (Evans et al., 1995). The thio substitution at 
phosphate ends of ATP makes compounds such as ATPγS more resistance to 
rapid hydrolysis by ecto-nucleotidases. P2R activity can be antagonised by 
nucleotide derivatives such as trinitrophenyl-ATP (TNP-ATP) (Virginio et al., 
1998) as well as pharmacological inhibitors such as suramin (Lambrecht et al., 
2005), truncated forms of suramin (Damer et al., 1998) and pyridoxal 5-
phosphate 6-azolphenul-2’,4’-disulfonic acid (PPADS) (Jacobson et al., 2002). 
Extracellular adenosine can be further inactivated by cell-surface associated 
adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) 
(Franco et al., 2007; Yegutkin, 2008), re-enter cells to replenish intracellular 
stores via ENT/CNT (Boison, 2013; Virtanen et al., 2014) or elicit signalling roles 
by activation of the P1 adenosine receptor family (A1, A2A, A2B, A3) (Ralevic and 
Burnstock, 1998). Activation of these G-protein coupled receptors activates (A1 
and A3) and inhibits (A2A and A2B) AC and consequently increases or decreases 
cAMP levels and [Ca2+]i (Fredholm et al., 2001; Abbracchio et al., 2009). Signal 
transduction then involves the MAPK pathways involving extracellular signal 











1.7.3 Pathophysiology of purinergic signalling 
Extracellular purines and pyrimidines participate in the regulation of highly 
heterogeneous cellular functions across most cell and tissue types, given the 
widespread P2R distribution (Verkhratsky and Burnstock, 2014; Zimmermann, 
2016).  
ATP was first recognised as a neurotransmitter, participating in non-adrenergic, 
non-cholinergic neurotransmission but several roles in physiological and 
pathophysiological processes have since been established for ATP and its 
derivatives. The full range of known functions is beyond the scope of this thesis 
and the reader is referred to comprehensive reviews describing these in more 
detail. Briefly, physiological roles include cellular proliferation and differentiation 
(Kaebisch et al., 2015), neuromodulation and transmission (Burnstock, 2013), 
wound healing (van der Vliet and Bove, 2011), hormone secretion (Burnstock, 
2014) and tissue specific roles in liver (Vaughn et al., 2014), muscle/bone 
Figure 1.9.2. Nucleotide and nucleoside receptor mediated signalling 
Extracellular nucleotides (eg. ATP) activate different ionotropic (P2X) and 
metabotropic (P2Y) receptors, resulting in altered intracellular ion concentrations, 
particularly calcium and altered cAMP levels. Ecto-nucleotidases (eg. ENTPDase 
1/CD39 and 5’NT/CD73) break down ATP to generate ADP, AMP and adenosine. 
Adenosine can be released (or taken up) via the equilibrative transporter (ENT) and 
taken up via the concentrative nucleoside transporter (CNT). Extracellular 
adenosine exerts signalling functions via P1 receptors (A1, A2A, A2B, A3). 
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(Burnstock et al., 2013) platelets (Gachet, 2008) and kidneys (Menzies et al., 
2017). Purinergic signalling also regulates the pathophysiology of conditions such 
cancer (Di Virgilio, 2012), CNS/neurodegenerative conditions (Burnstock, 2008), 
cardiovascular disease (Erlinge and Burnstock, 2008; Burnstock and Pelleg, 
2015) and processes such as immune response (Cekic and Linden, 2016), 
infection (Di Virgilio et al., 2017), and inflammation (Leo Bours et al., 2011; 
Franceschini et al., 2015). With relevance to this thesis, extracellular nucleotides 
act as important mediators of myocyte differentiation and proliferation and have 
been shown to be implicated in obesity and diabetes.  
Extracellular nucleotides are most commonly associated with propagating 
immune responses, where they act as “danger signals”; promoting systemic 
inflammatory responses; inflammasome activation; participating in host-tumour 
interactions and modulating vascular function (vasodilation). In the 
musculoskeletal system, ATP was first seen to participate in the neuromuscular 
junction, being released as a co-transmitter with acetylcholine (Ach) to promote 
contraction (Buchthal and Folkow, 1948). Work in the 1980s then suggested that 
myoblasts and myotubes in culture possibly responded to extracellular ATP via 
ATP-sensitive cation channels (Kolb and Wakelam, 1983). Subsequent studies 
elucidated differential patterns of P2Rs across development and concluded that 
P2XRs are critical for early development of SM but expression reduces 
significantly after birth (Meyer et al., 1999). P2YRs were then found to be 
expressed in developing murine myotubes (C2C12) and embryonic SM (Henning 
et al., 1993).  
Treatment of SM with extracellular nucleotides, primarily ATP, stimulates muscle 
contraction in a P2R-PKC-dependent manner (Teplov et al., 2006) and increases 
[Ca2+]i (Cseri et al., 2002). P2XR-mediated influx of Ca2+ into C2C12 cells 
contributes to phosphorylation of ERK1/2 (Banachewicz et al., 2005; May et al., 
2006), and this was later seen to occur downstream of ATP-mediated signalling 
via P2YRs in human myotubes (May et al., 2006). ATP is released by SM upon 
mechanical (Taguchi et al., 2008) and electrical stimulation (Osorio-Fuentealba 
et al., 2013) and acts in an autocrine manner to stimulate both fast (P2XR) and 
slow (P2YR) calcium transients; with the latter acting to maintain calcium flux 
(Szigeti et al., 2007) and promote gene expression of molecules such as IL-6 
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(Jaimovich et al., 2011). Purinergic signalling modulators also participate in SM 
pathologies, such as Duchenne Muscular Dystrophy (DMD), where loss of α-
sarcoglycan (membrane protein with ecto-ATPase activity) leads to excessive 
release of ATP and enhanced expression of P2XRs, leading to Ca2+ overload and 
muscle fibre death (Hack et al., 1998; Rybalka et al., 2014).  
1.7.4 Purinergic signalling in obesity and diabetes 
Evidence from recent years suggests that purinergic signalling modulators are 
implicated in obesity and diabetes, both at central and peripheral levels (reviewed 
by Burnstock, 2017; Burnstock and Gentile, 2018).  
Main findings suggest that P2Y6Rs are implicated in hypothalamic regulation of 
food intake in DIO mice (Steculorum et al., 2017); ATP enhances lipid 
accumulation in adipocytes (Kita and Arakaki, 2015) and regulates leptin 
secretion via P2Y1R (Laplante et al., 2010); and P2Y11R activation stimulates 
lipolysis (H. Lee et al., 2005). Furthermore, P2YR activation in β-cells promotes 
insulin secretion (Balasubramanian et al., 2014; Wang et al., 2014). Early work 
also suggested that ATP inhibits insulin-stimulated glucose uptake into 
adipocytes and inhibited glucose oxidation (Chang and Cuatrecasas, 1974; 
Halperin, Mak and Taylor, 1978). More recently, studies in rat adipocytes 
demonstrated that ATP treatment caused inflammation and AT IR (Yu and Jin, 
2010). Adenosine signalling via A2B receptors prevents HFD-induced AT 
inflammation and IR (Johnston-Cox et al., 2012); via A1 receptors protects against 
obesity-related IR (Dhalla et al., 2009) and promotes leptin release from 
adipocytes (Cheng et al., 2000; Rice, Fain and Rivkees, 2000); and via A2A 
activation in adipocytes counteracts DIO (De Oliveira Moreira et al., 2017) and 
enhances β-cell proliferation (Matsumoto et al., 2015). Adenosine also promotes 
glucagon release (Loubatières-Mariani et al., 1982) and inhibits GSIS (Ismail et 
al., 1977). 
Extracellular nucleotides and nucleosides appear to play paradoxical roles in 
glucose homeostasis and in the pathophysiology of metabolic conditions. A better 
understanding of the possible involvement of the purinergic signalling system in 
these pathways is therefore required, particularly in the context of SM IR, as this 
is largely unexplored. 
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1.8 Project aims 
Although the understanding of diabetes as a metabolic disease has significantly 
evolved since insulin was discovered in the 1920s, individuals with T1D and T2D 
are still challenged daily with unpredictable fluctuations in blood glucose. As such, 
the main aim of this thesis was to better understand the complex integrated 
physiology of glucose homeostasis and identify therapeutically targetable 
markers involved in the pathophysiology of impaired glucose control. The work 
presented in this thesis aimed to: 
 Elucidate the in vitro (muscle cells) and in vivo (human) mechanisms 
regulating lipid-induced insulin and anabolic resistance in skeletal muscle.  
o Does lipid overflow diminish muscle anabolic sensitivity and 
promote inflammatory cytokine release and mitochondrial 
dysfunction via alterations to the purinergic signalling system 
(Chapter 3). 
 Hypothesis: Palmitate-induced increase in ATP release 
promotes insulin and anabolic resistance in skeletal muscle 
cells 
 
o Does lipid overflow (by high-fat overfeeding) exacerbate insulin and 
anabolic resistance brought about by inactivity in humans (Chapter 
4) 
 Hypothesis: Increased intake of dietary saturated fat (2.5 fold 
increase) exacerbates the development of insulin and 
anabolic resistance in immobilised forearm muscle tissue. 
 
 Pharmacologically target AMPK (as an important whole-body and cellular 
energy sensor) to better understand the peripheral and central regulation 
of blood glucose (Chapter 5).  
 Hypothesis: Peripheral administration of brain permeable 
AMPK activator R481 amplifies the counterregulatory 
response to hypoglycaemia in healthy Sprague Dawley rats. 
 
  
































0.05 % (w/v) Trypsin EDTA Thermo Fisher 25300-062 
2-Deoxy-d-glucose Agilent 103020-100 
2-mercaptoethanol Sigma-Aldrich M3148 
5-BDBD Biotechne 3579 
A438079  Biotechne 2972 




Actrapid Insulin 100 IU/mL Centaur Services 20411387 
Adenosine tri-phosphate (ATP) Sigma-Aldrich A9187 
Adenosine-5'-(γ-thio)-triphosphate 
tetralithium salt (ATPγS) 
Biotechne 4080 
Amino acid solution (50x MEM) Thermo Fisher 11130051 
Ammonium persulfate (APS) Sigma-Aldrich A3678 
Apyrase Sigma-Aldrich A6410 
ATPLite luminescence assay system PerkinElmer 6016947 
BD Vacutainer® fluoride/oxalate tubes Thermo Fisher 12947676 
BD Vacutainer® PST Lithium Heparin 
tubes 
Thermo Fisher 12947676 
BD Vacutainer® SST II tubes Thermo Fisher 12927696 
Benzamidine Sigma-Aldrich 12072 
Bio-Rad protein assay dye reagent Bio-Rad 500-0006 
Biotrace nitrocellulose membranes 
(0.2µm pore)  
VWR 732-3031 
Bromophenol blue sodium salt Sigma-Aldrich B5525 
BSA Factor V, fatty acid free Sigma-Aldrich 10775835001 
BSA lyophilised powder  Sigma-Aldrich A2153, 
BSA standard (2 mg/mL) Thermo Fisher 11811345 
Cotton buds Williams Medical D500 
D-glucose Sigma-Aldrich G7021 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich D2650 
DMEM glucose free Fisher 11966 
DMEM high glucose Sigma-Aldrich D5671 
DMEM no glucose or phenol red Fisher 12307263 
Drawing up needle 18G Williams Medical  D5789 
EDTA pH 8 Sigma-Aldrich  E1644  
EGTA pH 8 Melford E1102 
EMLA 5 g crème Williams Medical XD-102059 
Ensure Plus Abbott Nutrition N/A 
FCCP Agilent 103015-100 
Fluo-4 Direct calcium assay reagent Life Technologies F10471 
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Foetal bovine serum Gibco 11573397 
Glucose 50 % w/v solution (IV infusion, 
POM, 25 g in 50 mL) 
Centaur Services 30098718 
Glucose uptake-Glo assay Promega J1341 
Glycerol Sigma-Aldrich 49767 
Glycine Melford G0709 
Glycolytic stress kit Agilent 103020-100 
Grade 3 MM Chr blotting paper Fisher 11330744 
Heparin sodium Centaur service 30172843 
HEPES Sigma-Aldrich H0877 
Hexamethonium bromide Sigma-Aldrich H0879 




Hypo needle 25G Williams Medical K2126 
Hypromellose Sigma-Aldrich H3785 
L-glutamine Fisher 25030-024 








Methanol Sigma-Aldrich 34860 
Microlance needle 21G x 1.5 Williams Medical  D5887 
Mito stress test kit Agilent 103015-100 
Mouse Interleukin-6 (IL-6) Duoset 
ELISA 
R&D Systems DY406 
Mouse Macrophage migration inhibitory 
factor (MIF) Duoset ELISA 
R&D Systems DY1978 
Oligomycin Agilent 103015-100 
Palmitic acid Sigma-Aldrich P0500 
Penicillin/streptomycin Fisher 15070-063 
Phenylmethylsulphonyl fluoride (PMSF) Sigma-Aldrich P7626 
Phosphate buffered solution (PBS) Thermo Fisher 10209252 
Poly-L-lysine hydrobromide Sigma-Aldrich P1274 
Ponceau S solution red Sigma-Aldrich P7170 
PPADS Tocris 0625/10 












Rat Adrenaline ELISA Demeditec DEE5100 
Rat C-peptide ELISA Mercodia 10-1150-01 
Rat Glucagon ELISA Mercodia 10-1281-01 
Rotenone/Antimycin Agilent 103015-100 
SBI-0206965 Cayman 18477 
Seeblue plus 2 pre-stained protein 
standard 
Life Technologies LC5925 
Skimmed milk powder Oxoid LP0031 
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Sodium bicarbonate Sigma-Aldrich S5761 
Sodium chloride (NaCl) Sigma-Aldrich S7653 
Sodium Dodecyl Sulphate (SDS) Melford B2008 
Sodium fluoride NaF Sigma-Aldrich S7920 
Sodium hydroxide NaOH Sigma-Aldrich  
Sodium orthovanadate (Na3VO4) Sigma-Aldrich S6508 
Sodium Pyrophosphate Tetrabasic 
Decahydrate - NaPPi 
Sigma-Aldrich S6422 
Sodium pyruvate Sigma-Aldrich P5280 
Standardised chow diet – EU rodent 
diet 14% 
Lab Diet 5LF2 
Sterile water for injections  Medisave WIA210 
Sucrose Melford S0809 
Suramin hexasodium salt Tocris 1472/50 
TEMED Sigma-Aldrich T7024 
Terumo Luer Slip tip Syringe 5 mL Medisave UK Ltd BS-05S 
Terumo Tuberculin Syringe 1mL Medisave UK Ltd BS-01T 
Tris (hydroxymethyl) aminomethane 
(TRIS) 
Melford B2005 
Triton 100x VWR M143 
Tween 80® Sigma-Aldrich P6474 
Tween® 20 Sigma-Aldrich P2287 
Vetivex saline solution (0.9%)  Centaur services 30227005 
 
2.1.2 Equipment 
Table 2.2 General equipment 
Equipment Supplier  
Accu-Check glucose meter Roche 
BODPOD Body Composition System COSMED 
Cobas 8000 modular analyser  Roche Diagnostics 
Doppler ultrasound (1000 Apogee) 10MHz 
transducer probe (L10LC). 
Shantou Institute of Ultrasonic 
Instruments 
Dynamometer, hand-held T.K.K 5001, Takei Scientific 
Odyssey CLx LI-COR Biosciences 
PHERAstar FS microplate reader BMG Labtech 
Seahorse XFe96 Bioanalyser Agilent Technologies 
TC20 Automated Cell counter Bio-Rad 
DCi8 S Widefield inverted microscope  Leica Microsystems 
YSI 2300 Stat Plus, Glucose Analyzer YSI Life Sciences 
BeneCast fibreglass casting tape BeneCare Medical 
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Table 2.3 Software 
Software Supplier 
Brachial Analyser for Research software, 
Version 6 
Medical Imaging Applications 
GraphPad Prism 8 GraphPad Software 
Image Studio Lite Ver 5.2 LI-COR Biosciences 
Nutritics Education v4.315 Nutritics 
Wave Desktop Agilent Technologies 
LAS X Life Science Leica Microsystems 
 
Table 2.4 Cell culture materials 
Consumable Supplier  Catalogue number 
60 mm tissue culture treated dishes Starstedt 83.3901 
96 well plate - Clear flat bottom  Starlab E2996 
DMEM high-glucose Sigma-Aldrich D5671 
DMEM low glucose Thermo Fisher 11966, 
DMEM low glucose, no phenol red Thermo Fisher 12307263 
DMEM Seahorse XF base medium Agilent 103193 
Earl’s balanced salt solution 10x  Sigma-Aldrich E7510 
Foetal bovine serum (FBS) Gibco 11573397 
Horse serum Thermo Fisher 10368902 
L-glutamine Thermo Fisher 25030 
Penicillin/streptomycin solution 5,000  
U/mL 
Thermo Fisher 15070 
Seahorse XFe96 culture microplate  Agilent 101085-004 
T75 cm2 flasks  Starstedt 83.3911.002 
Cryovials Corning 430659 





Table 2.5 Glucose clamping equipment 
Consumable Supplier  
Catalogue 
number 
25G dual channel stainless steel swivel Instech Labs 375/D/25 
3-way Y connector, 22ga, sterile Instech Labs SCY22 
Catheter for rat carotid artery, PU 1.9-3Fr 





Catheter for rat jugular vein, PU 3 Fr 30 cm, 




Clear animal enclosure, 15i n H, holes for 
MWATER and MFEEDER 
Instech Labs MTANK/WF 
Counter-balanced lever arm for rats (15 cm) Instech Labs MCLA 
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Luer stub, 22G (blue) x 0.5 in (12 mm), non-
sterile 
Instech Labs LS22 
Pin-port injectors Instech Labs PNP3M 
PinPorts, 22G red Instech Labs PNP3F22R 
Protective aluminium cap for magnetic rat 
vascular access button 
Instech Labs VABRC 
Co-extruded PE/PVC tubing for 22G, 




Pump 11 Elite infuse only programmable 
syringe pump 
Instech Labs HA1100 
Tether for magnetic 2 channel rat VAB, 12 in Instech Labs VABR2T/25 
Vascular access button for rat, magnetic, 2 
channel, 22G, injector 
Instech Labs VABR2B/22 
Water bottle for MTANK Instech Labs MWATER 
2.1.3  Antibodies 
Table 2.6 Primary antibodies 
Antibody Supplier Catalogue number 
GAPDH Sigma Aldrich G9545 
pS473 PKB  Cell signalling 9271 
pS536 NF-κB p65 Cell signalling 13346 
pS79 ACC Cell signalling 3661 
pT172 AMPK Cell signalling 2535 
pT389 p70S6K1 Cell signalling 9205 
Total ACC Merck Millipore 05-1098  
Total AMPK Cell signalling 2793S 
Total p70S6K1 Cell signalling 9202 
Total PKB  Cell signalling 9272 
Total β-Actin Biotechne NB600-501 
p44/42 MAPK (ERK1/2) Cell Signalling 4370 
 
Table 2.7 Secondary antibodies 
Antibody Supplier Catalogue number 
Alexa Fluor 680 goat anti-mouse IgG Thermo Fisher A21057 
Anti-IgG (Rabbit) Goat polyclonal Ab VWR ROCK611-132-122 
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2.2 In vitro methods 
2.2.1 Cell culture  
All cell lines used were maintained in culture under sterile conditions, handled 
only in category-2 biological safety-rate hoods and maintained at 37°C in 
humidified 5% CO2 incubators. 
The C2C12 (ATCC CRL-1772, Mus musculus) murine myoblast cell line was 
kindly gifted by colleagues at the University of Dundee. The cells’ ability to retain 
differentiation potential during prolonged cultivation (Yaffe, 1968) make them a 
useful tool in muscle biology. C2C12 myoblasts were cultured in differing media 
according to the stage of differentiation. When relevant, cells were also deprived 
of AAs for treatments. Media characteristics are described in Table 2.8.  
GT1-7 murine hypothalamic neurones were kindly gifted by Dr. Pamela Mellon of 
the University of San Diego. Media characteristics for GT1-7 culture are described 
in Table 2.9 
 





High glucose (25 mM) DMEM supplemented with 10 % FBS     
4 % (v/v) l-glutamine, 2 % penicillin/streptomycin (pen/strep) 
Plating  
medium 
Glucose-free DMEM with 4 % l-glutamine supplemented with 
5.5 mM glucose, 10 % FBS and 2 % pen/strep 
Differentiation 
medium 
Glucose-free DMEM with 4 % l-glutamine supplemented with 




Earl’s balanced salt solution 1 x, supplemented with sodium 
bicarbonate (2.2 g/L) and 0.34 mM AA solution. 
Freezing 
medium 
Growth medium supplemented with 10 % DMSO.  
Seahorse XF 
DMEM 
Glucose-free XF DMEM with 5.5 mM glucose, 2.5 mM sodium 
pyruvate, 2 mM l-glutamine, pH 7.4 




Table 2.9. GT1-7 culture media 
 
 
2.2.1.1 Culturing and passaging of cell lines 
C2C12 myoblasts were maintained in culture in 75 cm2 flasks (T75) containing 10 
ml of growth medium and incubated in humidified 5 % CO2 incubators, at 37oC. 
Cells were passaged every 48 hours (60-70 % confluence) and maintained for no 
more than 10 subsequent passages (below passage 30). When passaging cells to 
maintain and expand culture, these were plated at 1x106 per flask in T75 flasks. 48 
hours later, media was aspirated, flasks washed with pre-warmed sterile phosphate 
buffer solution (PBS) and subsequently incubated with 2 mL of trypsin/EDTA (0.05 
%) for 3-5 minutes at 37oC. Cells were mechanically displaced from the bottom of 
the flask and observed under the microscope to ensure detachment before the 
effects of trypsin were neutralised by the addition of 5 mL of growth medium. The 
cell suspension was then centrifuged at 1000 rpm for 5 minutes to separate trypsin 
in the media from cell pellet. Media was then aspirated and cell pellet resuspended 
in 1 mL of growth media by gently pipetting up and down with a p1000 pipette with 
a filter tip. Cells (1 x106) were resuspended in fresh growth media and transferred 
to a new T75 flask. For experiments, cells were counted using an automated cell 
counter (TC10, Bio-Rad) and the volume corresponding to the desired seeding 
density was resuspended in plating medium. Table 2.10 summarises the seeding 




Medium  Components 
Stock  
medium 
High glucose (25 mM) DMEM supplemented with 10 % FBS    
4 % (v/v) l-glutamine, 2 % penicillin/streptomycin (pen/strep) 
Plating 
medium 
Glucose-free DMEM with 4 % l-glutamine supplemented with 
7.5 mM glucose, 10 % FBS and 2 % pen/strep 
Experimental 
medium 
Glucose-free DMEM with 4 % l-glutamine supplemented with 
2.5 mM glucose, without serum. 
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Table 2.10 C2C12 myoblast seeding density  
Culture platform Density per well/dish 
60 mm dish 2 x 105 
Clear F-bottom 96 well plate 5 x 103 
Black F-bottom 96 well plate 5 x 103 
Seahorse XFe96 microplate 1.6 x 103 
 
GT1-7 cells were maintained in 75 cm2 flasks (T75) stock medium (Table 2.9) at 
50-80 % confluence and every 3 to 4 days, cells were passaged according to the 
method described above, with the difference that this cell line is non-adherent, 
requiring a pre-coat in culture flasks with poly-L-lysine (PLL) (10 ng/mL). Flasks 
were coated with PLL for 30 minutes before solution was collected and flasks 
washed with PBS and allowed to dry before cells were added. GT1-7 cells were 
plated 24 hours before experimentation in 60 mm dishes at 450,000 cells/dish in 
plating medium (Table 2.9). A 2 hour incubation period in experimental medium 
was conducted before each experiment.  
2.2.1.2 Differentiating C2C12 myoblasts 
C2C12 myoblasts were maintained in culture at sub confluence before 
differentiation. To initiate differentiation, cells were plated in plating media at 
densities indicated in Table 2.10 and were incubated for 48 hours. After 48 hours 
(100 % confluence), growth media was replaced with differentiation media. Media 
was changed every day for 6 consecutive days to replenish glucose and remove 
waste. Cells were differentiated for a total of 7 days, when mature myotubes were 
used for experimentation. Cells were also plated at 2 x105 cell/dish in glass-bottom 
FluoroDish culture dishes and differentiated as above for live cell imagining. 
Images were taken using a Leica DMi8 inverted widefield system, fitted with a 
Hammamatsu digital camera C11440 ORCA-flash 4.0, LED external light source 
EL600, HC Plan-Apochromat x40 objective, motorised stage, and temperature-
controlled environmental chamber (Pecon) and controlled by Leica Application 
Suite X on a PC. Images were taken at days 1, 3, 5 and 7 of differentiation and 
processed using LAS X Life Science software.    
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2.2.1.3 Freezing cells 
C2C12 myoblast and GT1-7 cell stocks were maintained in liquid nitrogen for long 
term storage. To freeze C2C12 myoblasts, cells were passaged (as above) until 
reaching the pellet stage, when they were resuspended in freezing medium (Table 
2.8). Cells were frozen at 1 x 106/mL in cryovials and transferred to polystyrene 
insulators before being slow frozen at -80 oC overnight and subsequently 
transferred to liquid nitrogen. GT1-7 cells were passaged as above until the pellet 
stage, when the cells were resuspended in DMEM supplemented with 25 mM 
glucose and 10 % DMSO and frozen down at 1 x 106/mL in cryovials and frozen as 
described for C2C12 cell line.   
2.2.2 Preparation of cell lysates and media collections 
All C2C12 myotube experiments were conducted after 7 days of differentiation. 
Depending on treatments, cells were either incubated in differentiation medium 
(day 6 to 7) or deprived of serum (maximum of 16 hours) or in the morning of day 
7 (maximum 2 hours). Treatments were carried out in serum free media (serum 
free DMEM or EBSS) supplemented with the desired treatments. Experiments in 
dishes were terminated by media collection (placed immediately on ice) and one 
warmed PBS wash. PBS was then replaced with ice cold lysis buffer, following 
which cells were scraped, on ice, and cell lysates were collected into eppendorf 
tubes and frozen at -20 0C. Lysis buffer contained magnesium and calcium 
chelators to remove cofactors for protein kinases and was supplemented with 
serine/threonine protein kinase inhibitors, protein tyrosine phosphatase inhibitors, 
and protease inhibitors (Table 2.11). For analysis, lysates were thawed on ice and 
insoluble cellular debris removed by centrifugation at 14,800 rpm, at 4 oC, for 20 
minutes; before supernatants were transferred to separate tubes. Media was 
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Table 2.11 Lysis buffer preparation 




1x Lysis buffer  
Tris HCL pH7.4 1 M 25 mM 
NaF 750 mM 50 mM 
NaCl 4 M 0.1M 
EDTA pH 8 0.5 M 1 mM 
EGTA pH 8 0.2 M 5 mM 
Triton 100x 100 % 1 % 
NaPPi 50 mM 10 mM 
Total volume  500 mL 
 
b. Lysis buffer + inhibitors for lysate preparation 
Reagent Final lysis buffer 
1 x lysis buffer 1 mL 
Sucrose 92 mg / mL 
2-Mercaptoethanol (0.1 % v/v) 1 µL/mL  
Na3VO4 (1 mM) 2 µL/mL 
Benzamidine (1 Mm) 2 µL/mL 
PMSF (1 mM) 2 µL/mL 
2.2.3 Cell treatments 
2.2.3.1 Essential amino acid treatment 
The composition of the mixed essential amino acid solution used to treat C2C12 
myotubes is summarised in Table 2.12 





(mg/mL) 50 X 
Concentration 
(mM) 50 X 
Final 
concentration 
(mM) 1 X 
L-Arginine 
hydrochloride 
211.0 6320 29.95 0.60 




210.0 2100 10.0 0.2 
L-Isoleucine 131.0 2620 20.0 0.4 
L-Leucine 131.0 2620 20.0 0.4 
L-Lysine 
Hydrochloride 
183.0 3625 19.81 0.39 
L-Methionine 149.0 755 5.07 0.10 
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L-Phenylalanine 165.0 1650 10 0.2 
L-Threonine 119.0 2380 20 0.4 
L-Tryptophan 204.0 510 2.5 0.05 
L-Tyrosine 181.0 1800 9.95 0.02 
L-Valine 117.0 2340 20.0 0.4 
 
2.2.3.2 Palmitate preparation 
Palmitic acid was dissolved in 90 % ethanol and heated to 70 oC for 10 minutes at 
a stock concentration of 100 mM. The stock was then conjugated to a 10 % (w/v) 
solution of fatty acid free bovine serum albumin (BSA) made up in the solvent of 
interest (different media), and incubated at 37oC for 1 hour. Conjugated stocks 
were 10-100 times more concentrated than target concentrations to maintain 
ethanol content in cell treatment below 0.5 % and BSA below 1 %. Control cells 
were treated with BSA with relevant ethanol concentration, in the absence of 
palmitate.  
 
2.2.3.3 R481/R419 preparation 
R481/R419 were kindly provided by Rigel Pharmaceuticals (San Francisco, 
California). Both drugs were suspended in a solution of hypromellose (HPMC) (0.5 
% w/v + 0.1 % Tween-80 v/v), which was also used as the vehicle control for 
experiments using those compounds. HPMC solution was prepared by heating ¾ 
of the total volume of distilled water necessary to make a 0.5 % w/v solution to 70 
°C under sterile conditions. The appropriate mass of hypromellose was 
subsequently added to the solvent and the mixture stirred with a magnetic stirrer 
for 2 minutes. The remaining volume of water was then added (cold), solution 
removed from heat and stirred until it reached 37 °C. At this stage, the appropriate 
volume of Tween-80 was added (final 0.1 % v/v) and solution stirred until combined. 
Solution was cooled to room temperature before R481/R419 was added. To make 
R481/R419 the relevant mass was weighed onto a sterile container able to fit a 
magnetic stirrer, HPMC (0.5 % + 0.1 % Tween-80) then added to the powder and 
solution stirred at maximum rpm for approximately 2 hours. Both vehicle and 
compound preparations were aliquoted into small volumes and frozen at -20 °C 
before use.  
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2.2.4 Protein expression analysis 
2.2.4.1 Total protein content determination  
The total protein of each lysate was assessed using the Bradford assay method 
(Bradford, 1976). An initial assessment was conducted to determine whether cell 
lysate dilution was necessary and, when required, dilutions were conducted in lysis 
buffer (Table 2.11) before performing the assay.  
 
The assay was adapted for use in a clear flat-bottomed 96 well plate, where 1 µl of 
sample was incubated with 200 µl of Bradford reagent, before absorbance was 
read at 595 nm in a PHERAstar microplate reader (BMG LABTECH). Absorbance 
values were compared to a standard curve plotted with known concentrations of 
BSA.  
 
2.2.4.2 Preparation of homemade gels for SDS-PAGE 
Gels were prepared according to Table 2.13 in mini-PROTEAN® Tetra handcast 
equipment from Bio-Rad. Gels with different acrylamide percentages (10-15 %) 
were used accordingly, to accommodate for the different molecular weights of the 
proteins of interest.    
 
Table 2.13. Acrylamide gel composition 
 
2.2.4.3 SDS-PAGE  
Samples were prepared for SDS-PAGE by combining a calculated volume of 
sample supernatant with sample buffer (Table 2.14) and lysis buffer (Table 2.11). 
Samples were prepared at 1 μg/μL. Samples were then heated to 37 oC for 10 
minutes before 20 µg were loaded onto each well of the relevant handmade gel. 
Running conditions were set at 90 volts (V) for 15 minutes followed by 150 V for 
60-95 minutes, in running buffer (Table 2.14).  
 
Reagent (2x gels) Upper stacking 4 % 10 % acrylamide 15 % acrylamide 
ddH2O 2.8 mL 4.15 mL 2.3 mL 
0.5 M Tris pH 6.8 1.25 mL   
1.5 M Tris pH 8.8 - 3.15 mL 3.15 mL 
30 % acrylamide 850 μL 3.75 mL 5.6 mL 
10 % SDS 50 μL 110 µL 110 µL 
20 % APS 50 μL 55.4 µL 55.4 µL 
TEMED 5.35 μL 11 µL  11 µL 
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Table 2.14. SDS-PAGE buffers 
Buffer Components 
Running buffer 25 mM Tris, 192 mM glycine, 0.1 % SDS 
Transfer buffer 20 % (v/v) methanol, 48 mM Tris-base, 39 mM Glycine, pH 8.3 
TBS-T 150 mM NaCl, 20 mM Tris/HCL pH 7.4, 0.05 % (v/v) Tween-20 
Sample buffer 
125 mM Tris-HCL pH 6.8, 20 % (v/v) glycerol, 4 (w/v) % SDS 
and bromophenol blue with 1/1000 dilution of 2-
mercaptoethanol 
2.2.4.3 Protein transfer into nitrocellulose membranes 
Wet electrotransfer was conducted following SDS-PAGE to transfer the separated 
proteins onto nitrocellulose membranes. The sandwich method was used by 
placing a nitrocellulose membrane against the gel and stacking filter paper and 
sponges on both sides before mounting them onto a cassette and tank where a 
current could be applied. Nitrocellulose membranes non-specifically bind proteins 
and enable for protein quantification with immunodetection methods. A current of 
100 V was applied for 60-75 minutes. Rapid visualisation of transfer efficiency was 
conducted using a reversible non-specific protein stain, Ponceau-S Red, which was 
subsequently washed off with transfer buffer (Table 2.14).  
2.2.4.4 Immunodetection 
Immediately after the protein transfer, nitrocellulose membranes were blocked with 
a solution of 5% (w/v) dried semi-skimmed milk in TBS-T, for 1 hour, at room 
temperature. Blocking the membrane prevents non-specific binding of the 
antibodies to proteins in the membrane with open recognition sites. The block was 
washed off with TBS-T and membranes incubated with primary antibodies, either 
overnight at 4 oC or for 1 hour at room temperature. Suppliers and catalogue 
numbers summarised in Table 2.6 and dilutions and solvents are summarised in 
Table 2.14. The primary antibodies were then removed and membranes washed 6 
times (5 minutes each) with TBS-T. Membranes were then incubated with 
secondary antibody preparations for 1 hour, at room temperature, before this was 
removed and membranes washed 6 additional times (10 minutes each) in TBS-T. 
All secondary antibodies were conjugated to fluorescent dyes, which enabled the 
simultaneous imaging of multiple proteins on each membrane with high sensitivity. 
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Suppliers in Table 2.7, dilutions and solvents in Table 2.15. Blots were 
subsequently imaged for fluorescence at 680 nm and 790 nm using the LI-COR 
Odyssey Imaging System. 
 
Table 2.15. Antibody preparations 
Protein Dilution Solution Species 
Incubation 
conditions 
Alexa Fluor 680 anti-
mouse IgG 
1/10000 TBST Goat 
1 hour RT 
Anti-IgG anti-rabbit 
polyclonal Ab 
1/10000 TBST Goat 
1 hour RT 
GAPDH 1/10000 2.5% (w/v) BSA/TBS-T Rabbit 1 hour RT 
p44/42 MAPK 
(ERK1/2) 
1/1000 2.5% (w/v) BSA/TBS-T Rabbit 
4⁰ C overnight 
pS473 PKB 1/1000 2.5% (w/v) BSA/TBS-T Rabbit 4⁰ C overnight 
pS536 NF-κB P65 1/1000 2.5% (w/v) BSA/TBS-T Mouse 4⁰ C overnight 
pS79 ACC 1/1000 2.5% (w/v) BSA/TBS-T Rabbit 4⁰ C overnight 
pT172 AMPK 1/1000 2.5% (w/v) BSA/TBS-T Rabbit 4⁰ C overnight 
pT389 p70-S6K1 1/1000 5% (w/v) milk/TBS-T Mouse 4⁰ C overnight 
Total ACC 1/1000 2.5% (w/v) BSA/TBS-T Rabbit 4⁰ C overnight 
Total AMPK 1/1000 2.5% (w/v) BSA/TBS-T Rabbit 4⁰ C overnight 
Total p70-S6K1 1/1000 2.5% (w/v) BSA/TBS-T Rabbit 4⁰ C overnight 
Total PKB 1/1000 2.5% (w/v) BSA/TBS-T Rabbit 4⁰ C overnight 
Total β-Actin 1/10000 2.5% (w/v) BSA/TBS-T Mouse 1 hour RT 
 
2.2.4.5 Western blot analysis 
Densitometric analysis of bands of interest was conducted using the Image Studio 
Lite (Ver 5.2) software. Regions of interest were drawn around the detected bands 
of interest, including areas for background detection and signal measured using 
pixel intensity. Levels of phosphorylated proteins were normalised to levels of total 
protein of interest or to loading controls β-actin or GAPDH. When relevant, changes 
in relative protein expression were normalised to control groups (designated a 
value of 1) within experiments. 
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2.2.5 Quantification of ATP 
The extracellular concentration of ATP was measured using a commercially 
available assay kit and used according to manufacturer’s instructions (ATPLite, 
PerkinElmer). This bioluminescence plate-based assay uses firefly luciferase-
mediated reaction between ATP and d-luciferin to generate light. Emitted light is 
directly proportional to ATP concentration, making this assay highly sensitive. The 
following illustrates the reaction: 
ATP + D-Luciferin + O2      Oxyluciferin + AMP + PPi + CO2 + Light 
 
ATP assays were conducted on media collected from cells in culture. Briefly, 100 
µl of media supernatant was used per sample, in black-walled 96 well plates. 
Mammalian cell lysis solution (50 μL) was added to each sample and mixed on an 
orbital shaker for 5 minutes before substrate solution (50 μL) was added and plate 
mixed in the same manner. Following this step, the plate was dark-adapted for 10 
minutes before luminescence was read using the PHERAstar microplate reader. 
ATP concentrations were calculated in pmol/L or normalised to total protein 
assessed from lysates from the same experiment using the Bradford method to 
generate ATP concentrations in pmol/mg. 
 
The same methodology was used to measure the levels of intracellular ATP from 
intact cells. Briefly, GT1-7 cells were plated in black-walled 96 well plates at 5 x 104 
per well in plating medium (Table 2.9) and incubated overnight at 37 °C. Cells were 
subsequently incubated for 2 hours in serum free experimental medium (2.5 mM 
glucose), followed by 30 minute incubation in fresh serum free experimental 
medium supplemented with R481/vehicle. As above, cell lysis buffer and substrate 
solution were then added and luminescence read.  
2.2.6 Intracellular calcium  
Changes in intracellular calcium were assessed using the fluorescent calcium 
indicator Fluo-4 Direct. C2C12 myotubes were plated in clear, flat bottomed 96 well 
plates at a seeding density of 5x103 cells/well in plating medium and differentiated 
(as before) for 7 days. Cells requiring overnight serum deprivation were incubated 
for 16 hours with EBSS prior to the start of the experiment, whereas others were 
maintained in differentiation media for the 7 days. On the day of the experiment, 
cells were serum starved for up to 2 hours before being incubated with Fluo-4 
magnesium, luciferase 
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Direct-containing phenol red free media (supplemented with 25 mM HEPES and 
5.5 mM glucose) for 60 minutes at 37oC. Following incubation, fluorescence was 
captured using a PHERAstar FS plate reader with 485 nm and 520 nm excitation 
and emission wavelengths, respectively. Measurements were recorded every 0.2 
seconds with compounds used to stimulate calcium responses being injected after 
30 seconds. Changes in calcium were expressed as relative fluorescent units 
normalised to a baseline value of 1. 
2.2.7 Assessment of cellular metabolism 
Cellular metabolism was assessed by measuring changes to oxygen consumption 
rate (OCR) as a measure of mitochondrial function and extracellular acidification 
rate (ECAR) as a proxy for glycolytic rate using the Seahorse Bioscience XFe96 
extracellular flux analyser (Agilent).  
2.2.7.1 Mitochondrial stress test 
Mitochondrial stress tests were performed according to manufacturer’s instruction 
with refinements described below (Agilent, UK). C2C12 myoblasts were seeded at 
1.6x103 cells/well in Seahorse XFe96 cell culture microplates in 200 μL of plating 
media and subsequently differentiated, as described above, for 7 days. On the day 
prior to the experiment, Seahorse XFe96 sensor cartridges were hydrated with 
Seahorse XF calibrant solution and maintained at 37 oC in a non-CO2 incubator 
overnight. For experiments assessing the chronic effect of palmitate on 
mitochondrial function, treatments were conducted for 16 hours prior to the 
experiment, in EBSS (supplemented as described in Table 2.8). Cells were treated 
with increasing concentrations of palmitate (250-750 μM) conjugated as described 
above, to 2 % FA-free BSA. On the day of the experiment, media was aspirated 
and cells washed with Seahorse XF DMEM before being incubated for 1 hour with 
XF DMEM, at 37oC in a non-CO2 incubator. Overnight treatments were re-
introduced at this stage. During this time, cartridges were loaded with inhibitors or 
compounds of interest to be injected during the assay. For mitochondrial stress 
tests, cartridges were loaded with Oligomycin (final concentration 2 μM), FCCP 
(final concentration 1 μM) and Rotenone/Antimycin A (1:1 ratio, final concentration 
1 μM). Oligomycin inhibits mitochondrial complex V, or ATP-synthase, and the 
resulting decrease in OCR is reflective of oxygen consumption associated with ATP 
synthesis. Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) 
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transports protons (H+) through the inner mitochondrial membrane, interfering with 
the proton gradient and therefore uncoupling oxidative phosphorylation and 
allowing for maximum oxygen consumption. Rotenone and antimycin A inhibit 
mitochondrial complexes I and III, respectively blocking the remainder of the 
respiratory chain. The cartridges were then calibrated in the Seahorse bioanalyser. 
Following 1 hour de-gas, cell plate was loaded onto the machine with pre-loaded 
cartridges and protocol (Table 2.16) initiated. 
 Table 2.16 Mitochondrial stress test protocol steps 
 Baseline Oligomycin FCCP Rotenone + Antimycin A 
Cycles 4 4 4 4 
Mix (min) 03:00 03:00 03:00 03:00 
Injection - Port A Port B Port C 
Measure (min) 03:00 03:00 03:00 03:00 
 
Upon completion of the assay, cell plates were removed from the analyser and 
remaining media aspirated. Cells were lysed using sodium hydroxide (50 mM, 100 
μL/well) and protein quantified in the lysates using the protein quantification 
methods described above, with minor alterations. Briefly, sodium hydroxide was 
used instead of lysis buffer in standard curve wells. Changes in OCR and ECAR 
were normalised to total protein concentrations. Calculations of cellular metabolic 
parameters were done according to Table 2.17. 
 
Table 2.17 Mitochondrial stress test parameter calculation  
Parameter Equation 
Basal respiration 
(last rate measurement before oligomycin injection) – 
(non-mitochondrial respiration) 
Oligomycin-sensitive OCR 
(last rate measurement before oligomycin injection) – 
(minimum rate measurement after oligomycin injection) 
Maximal respiration 
(maximum rate measurement after FCCP) –             
(non-mitochondrial respiration rate) 
Spare respiratory capacity (maximal respiration) – (basal respiration) 
Proton leak 
(minimum rate measurement after oligomycin injection)  
– (non-mitochondrial respiration) 
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2.2.7.2 Glycolysis stress test 
Glycolytic stress tests were conducted in the same manner as the mitochondrial 
stress tests with the following differences: during the de-gas incubation period, 
cells were deprived of glucose to assess their non-glycolytic ECAR (baseline) 
before testing the cells’ ability to respond to different stimuli and inhibitors. The 
glycolysis stress test measures glycolysis as the ECAR reached by a given cell 
after the addition of a saturating amount of glucose (10 mM). Glycolytic capacity 
is then assessed by shutting down oxidative phosphorylation with oligomycin (2 
μM) and driving the cell to maximise glycolytic rate. The cells glycolytic reserve 
is assessed as the difference between the response to glucose and the maximum 
rate achieved following oligomycin injection as an indication of the cellular 
capacity to respond to energetic demand. Finally, 2-deoxyglucose (50 mM) was 
used to suppress glycolysis and achieve a measure of non-glycolytic acidification. 
Effect of acute treatments on glycolytic rate was assessed by injecting 
compounds prior to glucose, followed by the steps above.  Protocol in Table 2.18 
and calculation of different glycolytic parameters described in Table 2.19. 
Table 2.18 Glycolysis stress test protocol steps 
 Baseline Glucose Oligomycin 2-DG 
Cycles 4 4 4 4 
Mix (min) 03:00 03:00 03:00 03:00 
Injection - Port A Port B Port C 
Measure (min) 03:00 03:00 03:00 03:00 
 
Table 2.19 Glycolysis stress test parameter calculation  
Parameter Equation 
Glycolysis 
(Maximum rate measurement before oligomycin injection) – 
(last rate measurement before glucose injection) 
Glycolytic 
capacity 
(Maximum rate measurement after oligomycin injection) –   
(last rate measurement before glucose injection) 
Glycolytic 
reserve 
(Glycolytic capacity) – (Glycolysis) 
Non-glycolytic 
acidification 
Mean ECAR prior to glucose injection 
Methods  Chapter 2 
67 
 
2.2.8 Extracellular cytokine quantification 
The levels of extracellular cytokines present in conditioned media from treated cells 
were quantified using enzyme linked immunosorbent assays (ELISAs). MIF and IL-
6 were measured using mouse Duo-set ELISA kits (Biotechne), performed 
according to manufacturer’s instructions. Briefly, assays were conducted on 96 well 
microplates incubated overnight with the capture antibody of interest. Following 
incubation, antibody was washed off (0.05 % Tween® 20 in PBS) and replaced 
with blocking solution (1 % BSA in PBS) and incubated for 1 hour. Following a 
second wash step, standards and samples were loaded onto the plate and allowed 
to bind to capture antibodies for 2 hours, after which the plate was incubated with 
detection antibody for an additional 2 hours. Once washed off, this was replaced 
with streptavidin-horseradish peroxidase (HRP)-conjugated antibody and 
incubated for 20 minutes at room temperature, protected from light. Finally, a wash 
was performed and substrate solution (50 % v/v H2O2, 50 % v/v 
tetramethylbenzidine) added to each well and incubated for precisely 20 minutes 
before a stop solution (2 N H2SO4) was added to stop the colour changing reaction. 
At this point, absorbance was read in a PHERAstar plate reader at 450 nm. 
Wavelength correction was performed by subtracting substrate reading at 570 nm 
from those at 450 nm. After wavelength correction, data were analysed using a 4-
parameter logistic curve fitting/regression (S-shaped). MIF Duoset specificity: 25.0 
ng/mL of recombinant human MIF reads as 551 pg/mL (2.2 % cross-reactivity). 
Detection range 125 – 8000 pg/mL. IL-6 Duoset sensitivity: 50 ng/mL 
human/rat/porcine recombinant IL-6 assayed demonstrates no cross-reactivity or 
interference. Detection range 15.6 – 1000 pg/mL. 
2.2.9 Glucose uptake assay  
Glucose uptake into C2C12 myotubes was assessed using the Glucose Uptake-
Glo assay (Promega), according to manufacturer’s instructions. This non-
radioactive plate-based assay uses a bioluminescence method to detect 2-
deoxyglucose-6-phosphate (2DG6P), which is formed upon entry of 2-DG into 
cells and cannot be metabolised further by glycolytic enzymes. Briefly, C2C12 
myotubes were differentiated in 96-well plates for 7 days (as above). On day 7, 
wells were washed with PBS before 2 hour incubation in DMEM (11966; 5.5 mM 
glucose) starved of serum, at 37 °C.  
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Media was replaced with serum free, glucose free DMEM and incubated for 1 
hour at 37 °C. Cells were then pre-treated with relevant treatment stated in each 
experiment and subsequently incubated for 15 minutes with 100 μM 2-DG 
(dissolved in PBS). To terminate the reaction a stop buffer was added to lyse the 
cells (acid detergent solution) and this was neutralised by the addition of a high-
pH buffer solution (neutralising solution). A detection reagent containing glucose-
6-phosphate dehydrogenase (G6PDH), NADP+, reductase, luciferase and 
proluciferin substrate were then added. 2DG6P is oxidised by G6PDH to 6-
phosphodeoxygluconate and this reduces NADP+ to NADPH, which is used by 
the reductase enzyme to convert proluciferin to luciferin. Luciferin is used by the 
luciferase to produce a luminescent signal that is proportional to the concentration 
of 2DG6P. Luminescence was detected with 0.3-1 second integration using the 










Figure 2.1 Glucose uptake assay 
Schematic representation of glucose uptake experiments. PA, palmitate; SF, 
serum-free DMEM; GF, glucose-free, 2-DG, 2-deoxy-d-glucose 
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2.3 In vivo methods 
2.3.1 Experimental animals 
All experimental procedures were conducted under a Home Office Project 
License and in accordance with the University of Exeter and Home Office 
regulations (UK) as well as Animals (Scientific Procedures) Act (1986). Efforts 
were maximised to employ the 3Rs, reduction, replacement and refinement, 
when possible, and animal welfare carried out routinely with help from staff at the 
Biomedical Services Unit, Living Systems Institute (University of Exeter). 
Unless otherwise stated, procedures were performed in male Sprague-Dawley 
rats (75-400 g), obtained from Charles River Laboratories (Margate, UK), some 
of which were pre-implanted with carotid artery and jugular vein catheters 
exteriorised via vascular access buttons and protected with button caps. Animals 
were group housed (groups of 2 or 3) when not undergoing procedures and had 
ad libitum access to food (standardised chow diet, LabDiet, comprised of 27% 
protein, 13 % fat and 59 % carbohydrate in palatable pellet form) and water while 
being maintained in temperature (22-23 °C) and humidity (55 %) controlled 
facilities with a dark and light cycle of 12 hours respectively.  
2.3.2 Compounds 
Compounds were obtained from commercial sources and adequately prepared 
for experimental use in a sterile manner. Suppliers and catalogue numbers listed 
in Table 2.1. Compounds used in animals were administered intravenously (i.v.), 
orally or intraperitoneally (i.p.) in adequate buffers and volumes concordant with 
The Laboratory Animal Science Association (LASA) guidelines.  
2.3.4 Feeding studies 
The effect of different compounds on feeding behaviour was assessed in healthy, 
male, Sprague-Dawley rats throughout the studies presented in Chapter 5. 
Unless otherwise stated, animals were singly housed during feeding studies and 
had ad libitum access food (standardised chow) and water. Food assessments in 
response to R481 were conducted as follows: Ad libitum food measurements 
were performed by injecting rats with R481/vehicle (i.p.) shortly before the start 
of their dark-phase, where they are most active and consume the largest amount 
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of calories in the day, and food measurements taken after 1 and 4 hours. For 
assessment of hyperinsulinaemia-induced feeding, animals were fasted for 16 
hours, following which they were administered R481/vehicle (orally) and injected 
with insulin (0.75 U/Kg) one hour later. Food was introduced after 60 minutes and 
intake measured 1 and 4 hours later. The effect of fasting on feeding behaviour 
was also assessed by fasting rats for 16 hours, administering R481/vehicle (i.p.), 
immediately re-introducing food and measuring intake after 1, 2 and 4 hours. 
Weights were monitored before and after all feeding studies. 
2.3.5 Intraperitoneal glucose tolerance test (IPGTT) 
Healthy male Sprague-Dawley rats were fasted for 16 hours, and fasting blood 
glucose measured from a tail vein sample (made using a 21 gauge needle) and 
measured using a hand-held glucometer (AccuCheck, Roche). Approximately 15 
minutes prior to first tail vein prick rat tails were coated with local anaesthetic 
(lidocaine and prilocaine, EMLA 5 %). For studies using SBI-0206965 and 
hexamethonium, compounds were administered (i.p.) 30 minutes prior to 
administration of R481/R419/vehicle (i.p.) and glucose (2 g/Kg; i.p.). Blood 
glucose was measured 15, 30, 60 and 120 minutes after glucose administration.  
2.3.6 Insulin-induced hypoglycaemia 
Rats were fasted (16 hours) and basal blood glucose measured, as above. 
Animals were then administered R481/vehicle by oral gavage and 60 minutes 
later with insulin 0.75 U/Kg (i.p.). Blood glucose was measured 30 minutes after 
insulin administration, as above.  
2.3.7 Glucose clamping 
2.3.7.1 Hyperinsulinaemic-euglycaemic clamping 
The hyperinsulinaemic-euglycaemic clamp was first developed as a method to 
assess insulin sensitivity in humans (DeFronzo, Tobin and Andres, 1979), but 
has since been adapted for use in rodents. Gold-standard glucose clamping in 
rats is performed in conscious, freely moving animals, which have undergone 
surgical implantation of carotid artery and jugular vein catheters. Catheters are 
externalised via connection to a vascular access button (VAB) which can be 
directly accessed using a syringe (combined with a pinport adaptor) or a tether, 
allowing for continuous venous infusion and arterial sampling.  
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A magnetic vascular access button cap is placed over the buttons to allow rats to 
be group-housed when not undergoing procedures. Catheters are maintained 
patent over time with the use of a heparinised glucose lock solution which 
prevents blood from entering the catheters and blocking them. During a 
hyperinsulinaemic-euglycaemic clamp, insulin is infused at a constant dose, 
aimed to induce a steady state of hyperinsulinaemia, concomitantly with a 
variable dose of dextrose to maintain euglycaemia; while allowing for sampling 
via the carotid artery for measures of glucose and hormones. Here, healthy, male, 
Sprague-Dawley rats underwent catheter implantation surgery at Charles River 
(Margate, UK) seven days before being transported to the Biomedical Services 
Unit (Living Systems Institute, Exeter). Daily health checks and weight monitoring 
were conducted during a 7 day acclimatisation period following arrival. During 
acclimatisation, catheter patency was checked (every 3-4 days) by drawing 
catheter content, flushing with sterile saline (0.9 % NaCl) and re-locking the 
catheters with a heparinised glucose lock solution (100-500 U/mL heparin in 50 
% w/v glucose solution). The day before the clamp study, rats were weighed and 
food removed for 16 hours. After the 16 hour fast, rats were re-weighed and basal 
glucose samples taken (from the arterial catheter). R481/vehicle was then 
administered (i.p.) and 60 minutes later another blood sample was taken, venous 
catheter unlocked and animals connected to magnetic tethers. Insulin and 
dextrose infusions were started simultaneously, marking the start of the clamp. 
Insulin infusion was maintained constant, while glucose infusion rate was 
changed in response to blood glucose levels measured from blood samples 
collected every 10 minutes throughout the clamp. Small (<50 μL) samples were 
taken every 10 minutes and larger samples (~150 μL) were collected every 30 
minutes. To collect a blood sample, the content of the carotid catheter was 
removed using a syringe attached to the pinport at the end of the tether with a 
pinport adaptor. A small amount of blood (<50 μL) was taken to ensure no lock 
solution was present in the sample. Blood was then collected. Catheters were 
flushed with saline and re-locked with heparinised glycerol solution. Note that lock 
solution on the day of clamping was not comprised of glucose and heparin, rather 
glycerol and heparin (300 U/mL heparin in 80-100 % glycerol) to ensure that 
residual lock solution in the catheter did not alter blood glucose reading from 
samples.  
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Large samples were centrifuged at 5,000 rpm for 10 minutes at 4 °C and plasma 
fraction transferred to separate storable eppendorf tubes and immediately frozen 
at -20 °C.  
Target blood glucose during euglycaemic clamp was 5.5 mmol/L glucose. Clamp 
duration was 120 minutes, after which animals were disconnected from the 
clamping apparatus and sacrificed by intravenous injection of pentobarbitone 
sodium (20% w/v, 200 mg/mL administered at 60-100 mg/Kg). Animals were 
exsanguinated via carotid artery catheter using a syringe with pinport adaptor and 
blood processed for plasma preparations by centrifugation at 3,500 rpm for 15 
minutes, at 4 °C. Plasma was collected and stored at -20 °C.  
2.3.7.2 Hyperinsulinaemic-hypoglycaemic clamping 
Hyperinsulinaemic-hypoglycaemic clamps are useful to assess the 
counterregulatory response to hypoglycaemia under controlled conditions. 
Clamps were performed as above with small adjustments. A bolus dose of insulin 
(80 mU/Kg/min) was administered for 10 minutes as rats were connected to the 
tethers, followed by continuous infusion as before. A variable 20 % dextrose 
solution was infused based on glucose infusion rates aiming to maintain blood 
glucose at 3 mmol/L. Clamps were terminated after 90 minutes and animals 
sacrificed as above.   
2.3.7.3 Calculating glucose infusion rates 
Once blood glucose concentration is clamped (at steady state), maintained by a 
variable glucose infusion, the glucose infusion rate equates to glucose uptake by 
tissues. The following equation was used to calculate glucose infusion rate (GIR, 
in mg/Kg/min) during glucose clamps: 
𝐺𝐼𝑅 =  
𝑉𝑜𝑙𝑢𝑚𝑒 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑖𝑛𝑓𝑢𝑠𝑖𝑜𝑛 (µL/min) × mass infused glucose (mg) 
𝑤𝑒𝑖𝑔ℎ𝑡 (𝐾𝑔)
 
(where volume of glucose infusion was the variable rate infused during clamp, 
mass of glucose corresponds to glucose solution (eg. 20 % or 50 % w/v glucose 
= 0.2 or 0.5 mg) and weight refers to rat weight).   
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2.3.8 Plasma hormone and metabolite analysis 
Plasma glucagon analysis was performed using Mercodia Glucagon ELISA 
(Uppsala, Sweden) according to manufacturer’s instruction. Briefly, pre-coated 
plates were loaded with 10 μL per well of calibrant or plasma along with 50 μL of 
enzyme conjugate and incubated at 4°C for 20 hours, shaking at 800 rpm.  
The following day, six wash steps were performed using wash buffer and well 
subsequently incubated for 3 minutes with TMB substrate. The reaction was 
stopped with stop solution and absorbance read at 450 nm. Assay specificity: 
highly specific. Does not detect GLP-1, GLP-2 or mini-glucagon. Detects mouse 
(7 %) human (1 %) and rat (1 %) glicentin. Detection range 7-627 pg/mL). 
Plasma adrenaline was analysed using Demeditec Adrenaline ELISA (Kiel, 
Germany) according to manufacturer’s instruction. Standards and samples were 
pipetted onto two 48 well plates (10 μL) and diluted in 90 μL of distilled water. 
Subsequently, 25 μL of TE buffer were added per well and the plate incubated 
for 1 hour at room temperature, shaking at 600 rpm. Two wash steps were then 
performed with wash buffer and 150 μL of acylation buffer added to each well. 
Acylation reagent (25 μL) was then pipetted onto each well and the plate 
incubated for 20 minutes at room temperature. Two more wash steps were 
performed before plates were incubated for 10 minutes at room temperature in 
the shaker with 100 μL hydrochloric acid in each well. The steps above describe 
the preparation of the extraction plates. The samples from this plate were then 
transferred to a microtiter plate (90 μL/sample), to which 25 μL of enzyme solution 
were added. Plate was incubated for 1 hour at RT, followed by 2 hrs at 37°C. The 
samples from this plate were then transferred into adrenaline microtiter plates 
(100 μL). Adrenaline antiserum (50 μL) was added to each well and plate 
incubated for 1 hour at RT, in the shaker, followed by an overnight incubation at 
2-8°C. Four wash steps were then performed and plates incubated with 100 μL 
enzyme conjugate, per well, for 30 minutes, at RT. Four more wash steps were 
undertaken. Finally, 100 μL substrate was added per well and plate incubated for 
30 minutes at RT, protected from light. Reaction was stopped with stop solution 
(100 μL) and absorbance read at 450 nm within 10 minutes. Assay analytical 
sensitivity: 3.3 pg/mL; detection range 0.5 – 80 ng/mL. 
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Levels of C-peptide in plasma were measured using Mercodia rat C-peptide 
ELISA (Uppsala, Sweden) according to manufacturer’s instructions. Briefly, 
samples and calibrators (10 μL) were incubated with assay buffer for 1 hour at 
room temperature in a shaker (800 rpm). This was followed by six wash steps 
using wash buffer. Subsequently, 100 μL of enzyme conjugate were added to 
each well and plate incubated for another hour under the same conditions. 
Washes were repeated and were followed by a 15 minute incubation with 200 μL 
of substrate TMB.  
Reaction was stopped with 50 μL stop solution, plate briefly shaken and 
absorbance read at 450 nm within 30 minutes. Highly specific (tested cross-
reactivity with insulin (0.0006 %), proinsulin (5 %), proinsulin Des 31-32 (3 %), 
proinsulin Split 32-33 (2 %), proinsulin Des 64-65 (74 %), proinsulin Split 65-66 
(10%). Detection range 0.015 – 0.85 ng/mL. 
2.4 Human methods 
2.4.1 Participant characteristics and screening 
Thirteen healthy, recreationally active, young (18-40 y) males volunteered to 
participate in the study presented in Chapter 4. Participants were recruited from 
the University of Exeter student and staff bodies as well as the local community 
via poster and social media advertisement. Upon first contact with potential 
participants, these were provided with a participant information sheet (Appendix 
A) that they were asked to read before attending a screening visit. At the start of 
the screening visit, subjects were duly informed about the nature of the study, 
including potential risks of the experimental procedures being undertaken, before 
informed consent was obtained. Exclusion criteria applied to subjects that 
presented with a body mass index (BMI) below or above 18 and 30 Kg.m-2, 
respectively, were smokers, had a history of thrombosis, epilepsy or 
schizophrenia or any disorders of cardiovascular, metabolic or motor nature. 
Exclusions were also applied to individuals with elevated blood pressure at the 
time of screening as well as those chronically using nutritional supplements or 
pharmaceuticals; or that had taken part in blood donations or research studies in 
the three months leading to this study.  
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After clarifying details of the study with the investigator, participants were asked 
to complete a medical health questionnaire (Appendix B) as well a physical 
activity questionnaire (International physical activity questionnaire, iPAQ, long-
last self-administered format, 2002) (Appendix C). Following this, heath 
parameters such as height, body mass, BMI, blood pressure and body 
composition were measured. Body composition regarding fat and lean mass was 
assessed using air-displacement plethysmography with the BODPOD Body 
Composition System (COSMED). The screening visit was concluded with a 
brachial ultrasound assessment to ensure that the investigator was able to locate 
the brachial artery. Before leaving, participants were provided with a three-day 
diet diary, in which they were asked to record their habitual food and drink intake, 
in detail.  
This was used at the end of the study to assess habitual energy intake using a 
nutrition analysis software (Nutritics Education v4.315). In addition, participants 
were made aware that they were free to withdraw at any stage of the study with 
no disadvantages to themselves. Upon completion of the study, all participants 
received an inconvenience allowance. The Ethics Committee of Sport and Health 
Sciences of the University of Exeter approved all aspects of the studies described 
in this thesis. Clinical trial was registered at www.clinicaltrials.gov under 
registration number NCT02980952. No adverse effects were recorded during the 
study. Subject characteristics are presented in Table 2.20. 
Table 2.20 Participant characteristics 
 CON (n=8) HFD (n=5) 
Age (y) 25.4 ± 2.42 23.8 ± 2.82 
Height (m) 1.76 ± 0.04 1.80 ± 0.03 
Body mass (Kg) 74.27 ± 6.39 68.5 ± 1.32 
 BMI (Kg·m-2) 23.7 ± 1.38 21.2 ± 0.72 
Body fat (%) 19.2 ± 4.41 16.1 ± 8.59 
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2.4.2 Experimental Design 
This study represents a randomised controlled trial where participants were 
subjected to 7 days of single forearm immobilisation by means of a forearm cast. 
During the immobilisation period, participants were fed a controlled diet 
comprised of packaged meal plans including ingredients and recipes to prepare 
and consume at home. Subjects were randomised (www.randomization.org) into 
control (CON) eucaloric diet or a high-fat diet (HFD), where they consumed 50 % 
of their daily caloric intake in excess. Subjects visited the laboratory on 4 
occasions after the screening visit. An initial baseline test day was performed to 
measure the parameters of interest before the start of the immobilisation period, 
followed by a visit in which the cast was fitted and two consecutive test visits 2 
and 7 days after the start of the immobilisation period. Experimental visit design 




Figure 2.2. Schematic summary of study design 
2.4.2.1 Experimental visits 
Participants visited the laboratory for three experimental visits. The first baseline 
visit occurred up to ten days before the start of the immobilisation period, with two 
consecutive visits taking place at days 2 and 7 of immobilisation. During the 
baseline visit, participants arrived in the laboratory in the fasted state (12 hour 
fast) and voided their bladders before being weighed in digital scales, and settling 
in a bed in the Nutritional Physiology labs, where they would remain for the 
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duration of the test day in a semi-supine position. At this point, an antegrade 
cannula was inserted in an antecubital vein in the dominant arm for stable isotope 
infusion. A second cannula was then inserted retrograde in a heated superficial 
dorsal hand vein in the dominant arm, after which the hand was inserted in an 
air-warming unit (hotbox, heated to 55oC) for arterialised-venous blood sampling. 
Blood arterialised using this method generates oxygen saturation levels akin 
those of arterial samples (Liu et al., 1992), providing an approach which is both 
practical and safe and has been validated for measures of glucose, insulin, 
glucagon, AAs and non-esterified FAs (Abumrad et al., 1981). A final cannula 
was inserted retrograde in a deep antecubital vein in the contralateral arm, used 
for sampling of venous blood draining directly from the forearm muscle bed 
(Gallen and Macdonald, 1990). All cannulae were maintained patent using a 0.9 
% saline infusion. Following the first venous baseline sample, taken as the 
cannula was inserted, a total of two postabsorptive blood samples and nine 
postprandial samples were taken, occurring at 20 minute intervals.  
Preceding every blood sample, measurements were taken using a Doppler 
ultrasound to assess arterial diameter and blood velocity, which would later be 
used to calculate blood flow and factor into measures of nutrient uptake. 
Immediately after the baseline blood sample (at t = -120 minutes), a single 
intravenous dose of the isotope tracer (2 µmol.Kg-1 L-[D5]-Phenylalanine and 7.6 
µmol.Kg-1 L-[1-13C]-Leucine) was administered to prime the reserves of leucine 
and phenylalanine in the body and this was immediately followed by a stable 
continuous infusion (0.05 µmol.Kg-1.min-1 L-[D5]-Phenylalanine and 0.13 µmol.Kg-
1.min-1 L-[1-13C]-Leucine). The start of the infusion marked the start of a 120 
minute postabsorptive period where two additional blood samples were taken (t 
= -20 and t = 0) before a mixed meal test drink was given. The ingested volume 
of the drink (Ensure Plus, Abbott Nutrition) was adjusted between participants so 
that 0.2 g fat, 0.3 g protein and 1.1 g carbohydrates per Kg of body weight were 
consumed and finalisation of the drink marked the start of the 180 minute 
postprandial period. Simultaneous arterialised-venous and deep venous blood 
samples (AV-V) were taken at 20 minute intervals during the 180 minute 
postprandial period. At the end of the test day, participants were provided with a 
meal and asked to perform a grip strength test using a hand-held dynamometer. 
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The two consecutive experimental visits were undertaken in the same manner as 
the baseline visit, except day 2 after immobilisation, which was void of a tracer 
infusion and grip strength assessment. Experimental visit design is summarised 
in Figure 2.2. 
The AV-V model was applied in this study to assess dynamic changes to forearm 
glucose and amino acid metabolism. Two pool AV-V amino acid and glucose 
kinetics across the forearm muscle bed were calculated according to the 
principles and calculations detailed in Wolfe and Chinkes (Wolfe and Chinkes, 
2005). Nutrient concentrations do not differ substantially in arterial circulation in 
the body and arterialised venous blood accurately represents brachial artery 
glucose and amino acid concentrations (Forster et al., 1972; Macdonald, 1999; 
Wolfe and Chinkes, 2005). Implicit in using this approach is the assumption that 
the sampling sites represent delivery and drainage from muscle tissue with little 
contribution from fat and skin tissues. This is an acknowledged assumption but 
is supported by evidence suggesting that at least 85% of arterial delivery is to the 
muscle tissue (Zierler and Rabinowitz, 1963; Pozefsky et al., 1976).  
As a result, a systematic but slight overestimation of muscle metabolic balance 
may occur. Taking into account those assumptions, the metabolic measures 






Figure 2.3 Experimental test day schematic 
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2.4.3 Control of energy intake 
Energy intake was controlled throughout the entire immobilisation period. 
Participants were provided with pre-packaged meals and recipes ready to cook. 
Subjects were instructed to consume only the provided food in addition to water 
and non-caloric drinks and to refrain from vigorous physical activity, particularly 
48 hours before each test visit. Food was provided for two days on the casting 
visit and for the remaining five days after two days of immobilisation. Energy 
intake was based on individual requirements taking into account participants’ 
basal metabolic rate and physical activity. Basal metabolic rate (BMR) was 
calculated using the Henry equations (Henry, 2005) based on age, gender, 
weight and height (e.g. BMR of male (18-30y): 14.4*weight + 313*height + 113). 
Physical activity was not monitored throughout the study but was evaluated 
during the screening visit using a self-completed questionnaire (International 
Physical Activity Questionnaire) (Hagstromer, Oja and Sjostrom, 2006), which 
generated a physical activity level (PAL) based on a metabolic equivalent (MET) 
score. The product of the calculated PAL score of each individual and the BMR 
was used as the calculated total energy expenditure (TEE) for each day. 
Participants in the CON group were fed in energy balance with protein content of 
the diet being maintained at 1.2 g.Kg-1.d-1, carbohydrates (CHO) at 50-55 % daily 
energy intake and total fat and fibre comprised the remaining energy intake. 
Participants in the HFD group were fed an additional 50 % of their calculated 
TEE, mostly comprised of fat, while protein was maintained at 1.2 g.Kg-1.d-1 and 
CHO at 30-35 %. 
2.4.4 Limb immobilisation 
On the second visit to the laboratory, 7-15 days after the baseline test visit, 
participants reported to the Nutritional Physiology labs to have a forearm cast 
fitted on their non-dominant arm. Firstly, stockinette and undercast padding were 
applied to protect the skin covering the forearm from the elbow to the tips of the 
fingers. Secondly, a fibrecast (BeneCast, BeneCare Medical) cast was fitted to 
the arm by soaking the fibrecast in warm water and applying in from the elbow, 
distally, and moulding it to best fit the forearm and immobilise the wrist. Once dry 
and hardened, the cast extended from 5 cm distal of the antecubital fossa to 2 
cm proximal of the fingertips. Participants were provided with a sling and 
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instructed to wear it during the daytime to keep the hand elevated above the 
elbow. A waterproof cover was provided to keep the cast dry while showering. 
Casts were removed at the end of the last test day using a cast saw. Application 
and removal of the casts was performed by trained personnel.  
2.4.5 Brachial artery diameter and blood velocity measurements 
Brachial artery diameter and mean blood velocity were measured using high-
resolution ultrasound imaging in duplex mode (~12 MHz, Apogee, 1000. SIUI). 
For luminal diameter measures, the probe was placed at the distal portion of the 
biceps brachii, approximately 5-10 cm proximal to the antecubital fossa of the 
non-dominant arm, while the arm was placed away from the body with the elbow 
slightly flexed. Brightness mode (B or 2D-mode) ultrasound was used to locate 
the brachial artery and enabled the length and lumen of the artery to be 
insonated, at a 60o angle, at which point a two-second recording was taken. Mean 
blood velocity was assessed at the same anatomical position by integration of the 
pulsed-wave Doppler signal for a minimum of 8 cycles (~10-20 seconds) 
(Hoskins, 1990). Arterial diameter and volumetric blood flow were analysed using 
the Brachial Analyser for Research software (V 6.8.5, Medical Imaging 
Applications) (Mancini et al., 2002).  
2.4.6 Assessment of grip strength 
Grip strength was assessed by maximal voluntary contraction using a hand-held 
dynamometer (T.K.K 5001, Takei Scientific). Assessments were performed at the 
end of the baseline visit and at the end of the last day of immobilisation after casts 
were removed and participants were provided with a meal and given time to 
readjust to not wearing a cast. Maximum voluntary contraction was measured 12 
times on each arm and the mean of the last three readings was used as a 
measure of grip strength (Kg).   
2.4.7 Processing blood samples 
Simultaneous arterialised-venous and deep venous blood samples were taken 
and processed immediately for storage as plasma and serum. Whole blood was 
collected in sodium fluoride and potassium oxalate-coated vacutainers and 
rotated at room temperature for 2 minutes before blood glucose was measured 
(YSI 2300 PLUS, Yellow Springs, OH, USA). 
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For plasma collection, blood was collected in lithium heparin-coated vacutainers 
and centrifuged at 2,900 g for 10 minutes at 4oC. For serum, blood was collected 
in silica particle-coated tubes and allowed to clot at room temperature for 30-60 
minutes before centrifuging the samples at 2,900 g for 10 minutes at 4oC. Plasma 
and serum samples were frozen in liquid nitrogen and subsequently stored at -
80oC. Stored samples were used for biochemical analysis. 
2.4.7.1 Plasma, serum and whole blood analysis 
Glucose: Glucose concentration of arterialised-venous and deep venous blood 
was measured in whole blood in a clinical glucose analyser (YSI 2300 Stat Plus, 
Glucose Analyzer; YSI Life Sciences). Glucose uptake (mmol/min) was 
determined as the product of the arterialised-venous difference in glucose 
concentration (mmol/L) and arterial blood flow (mL/min) at each time point. 
Insulin: Insulin was analysed using a commercially available immunoassay kit 
(DRG Instruments GmbH, Germany) according to manufacturer’s instructions. 
Endogenous serum insulin was measured in arterialised-venous serum during 
the immobilisation period in fasting as well as postprandial samples. Serum 
samples for analysis were thawed on ice. Briefly, 25 µL of sample or standard 
were dispensed into wells (in duplicate) of a microtiter 96 well plate. Enzyme 
conjugate (mouse monoclonal anti-insulin antibody conjugated to biotin) was 
dispensed onto each well (25 µL) and plate briefly shaken (10 seconds in plate 
shaker) and incubated at room temperature for 30 minutes. Wells were 
subsequently washed three times with wash solution. Wells were emptied and 
dried (striking on absorbent paper) and subsequently incubated with 50 µL of 
enzyme complex (streptavidin-HRP) for 30 minutes at room temperature. Wash 
steps were repeated followed by a 15 minute incubation in substrate solution 
(tetramethylbenzidine). The enzymatic reaction was stopped by dispensing 50 µL 
of stop solution (H2SO4) into each well. Absorbance was read at 450 nm. Assay 
sensitivity range: 1.76 – 100 µIU/mL. 
Insulin sensitivity indices HOMA-IR (Matthews et al., 1985) and Matsuda 
(Defronzo, 1999) were calculated using the following equations: 
HOMA-IR = fasting insulin (µU/L) x fasting glucose (nmol/L)/22.5. 
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Matsuda index = 10,000/√ ([fasting glucose x fasting insulin] x [mean glucose x 
mean insulin during 180 minute postprandial period]) 
Amino acids: Analysis of endogenous leucine and phenylalanine plasma levels 
was conducted by the University of Texas and performed using gas 
chromatography-mass spectrometry (GC-MS), as described previously (Wolfe 
and Chinkes, 2004). Analytical method (provided by collaborators) was as 
follows: Briefly, 10 μL internal standards of leucine and phenylalanine were added 
to the plasma samples. Plasma samples were deproteinised on ice with 500 μL 
of 15 % 5-sulfosalicylic acid. Free AAs were purified by acid-washed cation 
exchange columns (AG 50W-X8 resin: Bio-Rad, CA, USA) and AAs eluted from 
the column with 8 mL of 2N ammonium hydroxide. The eluate was subsequently 
dried under vacuum with a Speed-Vac rotary dryer (Savant Instruments, 
Farmingdale, NY, USA). Samples then underwent derivatization by adding 40 μL 
of N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide with 1 % tert-
Butyldimethylchlorosilane and 40 μL of acetonitrile to samples. Samples were 
vortexed and heated to 95°C for 40 minutes (Bornø et al., 2014). Samples were 
subsequently analysed by GC-MS (7890 GC coupled with a 5975 inert MSD; 
Agilent Technologies) in duplicate using electron impact ionisation and selected 
ion monitoring for measurement of isotope ratios (Zabielski et al., 2013) by 
injecting 1 μL of sample splitless mode (injector temperature 280 °C). Peaks were 
resolved using an HP5-MS 30 m × 0.25 mm ID × 0.25 μm capillary column 
(Agilent). Helium was used as carrier gas at a flow rate of 1.2 mL/minute. The 
temperature ramp was set from 80 – 245°C at 11 °C/minute, followed by 280°C 
at 40°C/minutes (Zabielski et al., 2013). Selected ion recording conditions were 
used to monitor fragments m/z 336, 341 and 346 for phenylalanine and m/z 274 
and 280 for leucine. The reagents used above have not been included in the list 
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Net amino acid balance 
Leucine and phenylalanine net balance was calculated according to the Fick 
principle: 
𝑁𝐵 = 𝐵𝐹 × (𝐶𝐴 − 𝐶𝑉) 
(where NB is the net balance, BF is blood flow, CA is the arterialised venous 
concentration and CV is the deep venous concentrations of the specific amino 
acid adjusted for steady-state conditions (Zierler and Rabinowitz, 1963; Hoskins, 
1990). 
 
2.5 Statistical analysis 
Significant differences between two groups were determined using unpaired t-
tests. In Western Blotting experiments, significance in phosphorylated or total 
protein expression relative to control (normalised to 1) was determined using a 
One-sample t-test. Comparisons between three or more groups of treatments 
were compared using One-way ANOVA. Repeated measures data were 
analysed using a two-way or three-way ANOVA with repeated measures. In 
instances where data sets with repeated measures were missing values or values 
were excluded from analysis as they were generated in response to erroneous 
data collection, a mixed-effects analysis was performed. In human studies, 
repeated measure ANOVA analysis was conducted with day (Baseline vs Day 2 
vs Day 7) and time (post-absorptive and postprandial period during experimental 
day) as within-subject factors, and diet intervention (CON vs HFD) as between-
subjects’ factor. In the case of significant interactions, donated by P<0.05, 
multiple comparisons were made using Bonferroni’s posthoc tests. Statistical 
analysis was performed using GraphPad Prism (Prism 8, GraphPad, La Jolla, 
CA, USA). Unless otherwise specified, results were represented as mean ± 
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Introduction 
Skeletal muscle accounts for 40-50 % of total body mass and handles 30 % of 
basal and 90 % of insulin-mediated glucose disposal (DeFronzo et al., 1981; Katz 
et al., 1983). In T2D 85-90 % of the impairment in total body glucose utilisation is 
attributed to muscle IR (Pendergrass et al., 2007). The aetiology behind loss of 
insulin sensitivity, which is a predominant feature in metabolic conditions such as 
obesity and T2D, is incompletely understood, but it is well accepted that 
behaviours such as inactivity and chronic overeating and consequentially 
enhanced lipid availability, play an important role in its development. It is also 
increasingly recognised that in addition to attenuated insulin sensitivity, 
individuals with these conditions suffer from loss of muscle mass and strength 
and that excess lipid may modulate muscle protein synthesis in response to AAs 
(anabolic resistance, explored further in Chapter 4) impairing not only function 
but also growth (Stephens et al., 2015). 
There is ample evidence suggesting that increased FFAs (Paolisso et al., 1995), 
IMCL accumulation (Goodpaster et al., 2000; Malenfant et al., 2001) and 
enhanced generation of lipotoxic metabolite are strongly associated with the 
development of SM IR (Belfort et al., 2005). The metabolic flexibility in utilisation 
of glucose and/or lipids during post-absorptive and post-prandial periods is also 
impaired, leading to metabolic inflexibility (Kelley and Mandarino, 2000). 
Intravenous lipid infusion, which elevates plasma FFAs, induces IR in individuals 
with and without diabetes (Boden, 1999). In contrast, acutely lowering elevated 
FA levels improves insulin sensitivity in obese individuals with and without 
diabetes (Santomauro et al., 1999). Furthermore, FA transporter expression and 
rate of FA uptake are upregulated in obesity and T2D in an effort to lower 
circulating lipid levels (Bonen et al., 2004). This leads to an initial increase in β-
oxidation that ultimately fails to match demand and causes incomplete fat 
oxidation, leading to build-up of lipotoxic moieties and ROS generation (Muoio 
and Neufer, 2012; Aon, Bhatt and Cortassa, 2014). Mitochondrial dysfunction is 
also observed in obese humans, demonstrating decreased activity of CPT1, 
citrate synthase and ATP synthase, compared to lean individuals (Simoneau et 
al., 1999; Kim et al., 2000). The resulting increase in lipid metabolites, including 
ceramides (Summers, 2006), LCFA-CoA (Cooney et al., 2006), DAG (Itani et al., 
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2002) and acylcarnitines (Aguer et al., 2015) impair insulin action and glucose 
metabolism (mechanisms summarised in Figure 1.6).  
Systemic low-grade inflammation also features in metabolic disease and is 
associated with the pathophysiology of IR. SM inflammation is emerging as an 
important autocrine regulator of muscle metabolic function and 
paracrine/endocrine mediator of systemic IR and T2D (DeFronzo and Tripathy, 
2009). Inflammatory markers contribute to SM IR through the mechanisms 
summarised in Figure 1.8. Importantly for this study, SFAs act as inflammatory 
moieties by signalling via TLRs (TLR2 and TLR4 in SM) and transducing signals 
via PKC, JNK and IKK/NF-κB signalling pathways (Wei et al., 2008). Expression 
of TLRs (Wei et al., 2008) and NF-κB pathway (Green et al., 2011; Patsouris et 
al., 2014) are upregulated in SM of individuals with obesity and diabetes. FA 
treatment of muscle cells activates IKK/NF-κB signalling pathways and 
upregulates the expression and release of myokines such as IL-6 and 
chemokines that promote immune cell migration and activation and contribute to 
SM IR (Wu and Ballantyne, 2017). A fraction of SM inflammation in metabolic 
disease is also attributed to immune cell infiltration, particularly macrophages and 
T lymphocytes, primarily localised in muscle adipose depots (Khan et al., 2015).  
SFAs are believed to be the main culprits in the development of lipid-induced IR, 
as evidence suggests that mono and poly-unsaturated fatty acids (PUFA) play 
paradoxical roles and may negate the effects of SFA (Fedor and Kelley, 2009; 
Jans et al., 2012). However, the physiological balance between these species is 
disturbed in pathophysiology so that SFA/PUFA ratio increases (Imamura et al., 
2016). Palmitic acid (palmitate) is the most abundant dietary derived and 
synthesised SFA in the body, accounting for 20-30 % of all FAs (Carta et al., 
2017), and, as such, is extensively used in vitro to study mechanisms of IR. In 
line with this, palmitate treatment impairs insulin signalling in several models of 
SM (Aas et al., 2005).  
Although there is a clear association between elevated lipid availability and the 
development of insulin and anabolic resistance, the mechanisms by which these 
develop are not fully understood. There is, therefore, a need to elucidate the 
processes that regulate glucose and AA metabolism, which may help identify 
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viable therapeutic targets to ameliorate the pathophysiology of metabolic 
disease. One such candidate may be ATP. 
ATP, along with other nucleotides and nucleosides acting as extracellular 
signalling molecules, has emerged as an important mediator of a plethora of 
physiological and pathophysiological processes (as introduced in Chapter 1). 
Early work postulated an association between purinergic signalling and diabetes 
(Mikhail and Awadallah, 1977; Tang et al., 1996) and there is now a better 
understanding of the involvement of ATP and adenosine in the pathophysiology 
and treatment of diabetes (Atkinson and Eisenbarth, 2001; Antonioli et al., 2015). 
Relevant to this study, ATP has been reported to induce IR and inflammation in 
AT (Yu and Jin, 2010); ADP blocks INSR signalling and PKB activation in 
hepatocytes via P2Y13 (Chatterjee and Sparks, 2012); hyperglycaemia 
stimulates nucleotide release from blood, smooth muscle and endothelial cells 
(Solini et al., 2005; Nilsson et al., 2006); CD39-null mice demonstrate impaired 
hepatic insulin sensitivity and glucose clearance (Enjyoji et al., 2008); and ATP 
stimulates insulin release from β-cells and islets (Tozzi et al., 2018). Adenosine 
is also an important regulator of insulin sensitivity and glucose homeostasis in 
liver (Figler et al., 2011; Johnston-Cox et al., 2012) and AT (Csóka et al., 2014), 
often playing paradoxical roles to its nucleotide counterparts.  
The effect of purinergic signalling on glucose homeostasis and inflammation in 
SM remains understudied. However, as SM is a major regulator of impaired 
insulin sensitivity and glucose metabolism in diabetes, it is important to elucidate 
the contribution of extracellular purinergic mediators in this pathophysiology. ATP 
is released from SM following electrical stimulation, contraction and exercise and 
acts in an autocrine and paracrine manner via a wide range of P2Rs, leading to 
increased [Ca2+]i (Cseri et al., 2002; Ito et al., 2018) and transactivation and 
transinhibition of pathways such as MAPK/ERK and PKC (von Kugelgen and 
Harden, 2011; Erb and Weisman, 2012).  
Given the role of extracellular ATP (eATP) in systemic inflammation and glucose 
homeostasis, it was hypothesised that eATP may, in part, mediate the metabolic 
impairments brought about by SFA treatment in muscle cells. 
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The aim of this study was, therefore, to establish whether elements of the 
purinergic signalling system are involved in FA-induced SM insulin and anabolic 
resistance and exacerbate inflammatory cytokine release. This was approached 
by utilising a SM cell model (C2C12 myotubes) of FA-induced IR, displaying loss 
of anabolic sensitivity, mitochondrial dysfunction and upregulated inflammatory 
cytokine secretion (features of metabolic disease pathophysiology) in response 
to palmitate treatment.  
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  Results 
3.1 Differentiation of C2C12 myotubes at physiological glucose 
concentration 
The C2C12 murine myoblasts cell line was used as these have been extensively 
characterised in culture as a tool to study SM metabolism. Conventional culture 
of C2C12 myoblasts and differentiation into myotubes is conducted under 
hyperglycaemic conditions (25 mM glucose). Here, a more physiologically 
relevant approach was taken and cells were differentiated and experimented on 
under euglycaemic conditions, at 5.5 mM glucose (Figure 3.1).  
Prior to differentiation or experiments, cells were maintained in media 
supplemented with 25 mM glucose, 10 % FBS, 4 % L-glutamine and 2 % 
Pen/Strep. For differentiation, upon reaching 70-80 % confluence, myoblasts 
were plated into 60 cm dishes in DMEM supplemented with 5.5 mM glucose and 
10% FBS. After 24 hours, myoblasts were displayed as individual fusiform or star-
shaped mononucleated (Figure 3.1A). After 48 hours (90-100 % confluence), 
media was changed to DMEM supplemented with 5.5 mM glucose and lower 
serum content, 2 % horse serum (Day 1). At day 3 of differentiation, cells began 
to align (Figure 3.1B) and by day 5, cells fused and became elongated (Figure 
3.1C). After 7 days of differentiation, myotubes were fully formed and displayed 
Y-shaped morphology (Figure 3.1D). These morphological changes are 
consistent with those observed when differentiating myoblasts in hyperglycaemic 
conditions (25 mM) (Burattini et al., 2004). This differentiation protocol was used 
for all experiments described in this chapter.  
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Figure 3.1. Differentiation of C2C12 myoblasts at physiological glucose 
concentration  
C2C12 mouse myoblasts differentiated in culture for 7 days under physiological 
glucose concentration (5.5 mM). A) Day 1 of differentiation after 24 hour culture in 
25 mM glucose. B) Day 3 myoblasts grown to confluence after 48 hour culture at 
5.5 mM glucose. C) Observable myotubes at day 5. D) High density of myotubes 
at day 7 of differentiation. Scale bar = 100 μm (red line).  
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3.2 Insulin and mixed essential amino acids increase phosphorylation of 
anabolic signalling proteins in C2C12 myotubes 
Insulin and AA sensitivity were assessed in C2C12 myotubes by treating cells 
with insulin (0-100 nM), mixed essential AA (3.34 mM, referred to throughout as 
AA) or a combination of both for 60 minutes and determining changes to protein 
phosphorylation within the PI3K/PKB and mTOR signalling pathways. At 10 nM, 
insulin caused a 2.7 ± 0.02 fold increase in PKB phosphorylation (Figure 3.2A) 
(n=4; P<0.0001) and 1.4 ± 0.06 fold increase in phosphorylation of p70-S6K1 
(Figure 3.2B; n=7; P<0.001) which increased further in a concentration-
dependent manner to 5.4 ± 0.2 and 1.6 ± 0.06 fold at 100 nM, respectively 
(P<0.001 for both). AAs (3.34 mM) significantly increased the levels of 
phosphorylated p70-S6K1 (n=7; P<0.01) and this response was further enhanced 
in the presence of insulin (P<0.01 for 50 nM insulin + AA versus AA control; Figure 
3.2C). These responses provided a model of anabolic sensitivity to work within 
this study. 
3.3. Palmitate treatment blunts insulin and amino acid-induced activation 
of anabolic signalling proteins in C2C12 myotubes 
To assess the effect of and generate a model of palmitate-induced insulin and 
anabolic resistance, C2C12 myotubes were serum and AA deprived for 15 hours 
before anabolic sensitivity was assessed. Cells were incubated for 15 hour in 
serum free EBSS (supplemented with 5.5 mM glucose and 0.3 mM AAs), with 
increasing concentrations of palmitate (0-750 μM) conjugated to bovine serum 
albumin (BSA, 0.1% w/v) or BSA (0.1 % w/v) controls. Following 15 hour 
treatment, cells were treated with insulin (20 nM) and AAs (3.34 mM) alongside 
palmitate (or BSA controls) for 60 minutes. In the absence of palmitate, insulin 
and AAs significantly increased the levels of phosphorylated PKB (n=6; 
P<0.0001) but pre-treatment with 500 μM palmitate prevented this response 
(P>0.99 for 500 μM versus 500 μM + insulin and AAs; Figure 3.3A). In BSA 
controls, insulin and AA treatment significantly increased p70-S6K1 
phosphorylation (n=5; P<0.001; Figure 3.3B) and this response was significantly 
blunted in cells treated with 750 μM palmitate (P>0.99 for 750 μM palmitate 
against 750 μM + insulin and AAs). 
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Figure 3.2 Insulin and mixed essential amino acids increase 
phosphorylation of anabolic signalling proteins in C2C12 myotubes 
C2C12 myotubes treated for 60 minutes with increasing concentrations of 
insulin and mixed essential amino acids (AA). Representative immunoblots 
for PKB (pS473) normalised to PKB (A) and p70-S6K1 (pT389) normalised 
to p70-S6K1 (B) with densitometric analysis below for C2C12 myotubes 
treated with increasing concentrations of insulin (0-100 nM) for 60 minutes 
(One-sample t-test in comparison to control; **P<0.01; ***P<0.001; n=4-7). 
Actin and GAPDH were used as loading controls. C) Representative 
immunoblot for p70-S6K1 (pT389) normalised to p70-S6K1 for C2C12 
myotubes treated for 60 minutes with AA (3.34 mM) or combined with insulin 
(0-50 nM) for 60 minutes (One-way ANOVA with multiple comparisons with 
Bonferroni’s; **P<0.01; n=3).  









Figure 3.3. Palmitate treatment blunts insulin and amino acid-induced 
activation of anabolic signalling proteins in C2C12 myotubes 
C2C12 myotubes treated for 16 hours with palmitate and treated acutely 
with insulin and mixed essential amino acids. Representative immunoblots 
for PKB (pS473) normalised to actin (A) and p70-S6K1 (pT389) normalised 
to actin (B) with densitometric analysis below for C2C12 myotubes treated 
with increasing concentrations of palmitate (0-750 μM) for 16 hours and 
insulin (20 nM) and amino acids (AA, 3.34 mM) for 60 minutes (One-way 
ANOVA with multiple comparisons; ***P<0.001; ns P>0.05; n=5-6). 
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3.4 Palmitate treatment enhances inflammatory cytokine release in C2C12 
myotubes 
The extracellular levels of myokines IL-6 and macrophage migration inhibitory 
factor (MIF) were quantified to establish the effect of palmitate treatment on 
inflammatory cytokine secretion in this model. Palmitate treatment (500 μM; 16 
hours) significantly increased the levels of IL-6 (n=6; P<0.05; Figure 3.4A) and 
MIF (n=5; P<0.001; Figure 3.4B) in C2C12 myotubes. 
3.5 Palmitate treatment impairs mitochondrial function in C2C12 myotubes 
To assess the effect of palmitate treatment on C2C12 myotube mitochondrial 
function, extracellular flux assays were performed. Cells were incubated for 16 
hours with palmitate (250-750 μM) as described above, followed by 1 hour 
incubation in XF basal medium (supplemented with 5.5 mM glucose, 2 mM l-
glutamine and 2.5 mM sodium pyruvate) and oxygen consumption measured 
using the Seahorse Extracellular Flux Analyser (Agilent, UK). Basal oxygen 
consumption was assessed (pmoles/min/μg) before and after cells were injected 
with oligomycin (2 μM) to inhibit mitochondrial complex V and assess ATP-
synthase activity; FCCP (1 μM), which uncouples mitochondrial membranes to 
allow for maximal respiration to ensue; and rotenone/antimycin in a 1:1 mix (1 
μM) to inhibit the remainder of the respiratory chain. Representative extracellular 
flux trace during a mitochondrial stress test shown in Figure 3.5A. Palmitate 
treatment for 16 hours at 250 μM increased basal OCR, whereas, at 500-750 μM, 
it significantly decreased basal OCR compared to control (n=26-28; P≤0.01, 
P<0.001 and P<0.001 for 250, 500 and 750 μM palmitate against control, 
respectively; Figure 3.5B). Oligomycin-sensitive OCR, a measure of ATP 
synthase activity, was maintained after 250 μM palmitate (P>0.05 against 
control), but significantly decreased with 500 μM and 750 μM palmitate treatment 
(P<0.001 for both against control; Figure 3.5C). Furthermore, following 
uncoupling with FCCP, cells treated with 250 μM demonstrated increased spare 
respiratory capacity (P<0.001), but this was decreased in cells treated with 500-
750 μM palmitate (P<0.001 and P<0.001 for 500 and 750 μM against control, 
respectively; Figure 3.5D). Proton leak was significantly increased with palmitate 
treatment (P<0.001 for all concentrations against control) (Figure 3.5E). 
 
















Figure 3.4 Palmitate treatment enhances inflammatory cytokine release 
in C2C12 myotubes 
Extracellular cytokine levels measured by ELISA after palmitate treatment. 
Palmitate (500 μM) significantly enhanced the levels of IL-6 (A) and MIF (B) 
after 16 hour treatment in C2C12 myotubes, compared to BSA (0.1 % w/v) 
controls (Two-tailed unpaired t-test; *P<0.05; ***P<0.001; n=6 and n=5 
respectively). 
 













Figure 3.5. Palmitate treatment impairs mitochondrial function in C2C12 
myotubes 
Extracellular flux analysis of C2C12 myotubes incubated for 16 hours with palmitate (250-750 
μM) conjugated to 0.02% BSA or BSA controls. A) Representative extracellular flux assay 
demonstrating oxygen consumption rate (OCR; pmoles/min/μg) at baseline and after acute 
injection of oligomycin (2 μM), FCCP (1 μM) and rotenone/antimycin A (R/A; 1:1 ratio; 1 μM) 
at the indicated stages (n=26-28). B) Mean basal OCR before oligomycin (pmoles/min/μg) 
(*P<0.05; ***P<0.001 against control). C) Oligomycin-sensitive OCR measured as the 
difference between average baseline OCR and average OCR after oligomycin (***P<0.001 
against control). D) Spare respiratory capacity, calculated as the difference from baseline 
levels to highest response after FCCP (***P<0.001 compared to control). E) Proton leak 
measured as a difference from oligomycin-insensitive OCR and non-mitochondrial respiration 
(OCR before FCCP minus OCR after R/A) (***P<0.001 against control). All group statistics 
performed using One-way ANOVA with Bonferroni’s multiple comparisons analysis. 
1 
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3.6 Apyrase treatment hydrolyses ATP released after palmitate treatment 
but does not alter effect on IL-6 and MIF in C2C12 myotubes 
To test the hypothesis that eATP may modulate FA effects on anabolic signalling 
and inflammation, the effect of palmitate on eATP levels was examined 
(measured using luminescence based plate assay). Palmitate treatment at 500 
μM, but not 250 μM, increased the levels of eATP in C2C12 myotubes after 16 
hours (n=7; P<0.001; Figure 3.6A). This response was abolished by apyrase, an 
ATP-diphosphohydrolase which catalyses the conversion from ATP to ADP and 
ADP to AMP. Apyrase (0.5 units/mL) decreased the palmitate-induced increase 
in eATP in C2C12 myotubes treated for 16 hours with palmitate (500 μM; or BSA 
controls) ± apyrase and incubated for 1 hour with insulin (20 nM) and AAs (3.34 
mM) (Figure 3.6B).  
To test whether eATP contributed to palmitate-induced cytokine release, C2C12 
myotubes were co-treated with palmitate (500 μM; or BSA controls; 16 hours) 
and apyrase (0.5 units/mL). Apyrase did not alter IL-6 (Figure 3.6C) or MIF 
(Figure 3.6D) secretion in the presence or absence of palmitate.  
3.7 Apyrase treatment does not alter palmitate-induced insulin and anabolic 
resistance in C2C12 myotubes 
C2C12 myotubes were treated with palmitate (500 μM) and apyrase (0.5 
units/mL; 16 hours) followed by treatment with insulin (20 nM) and AAs (3.34 mM) 
for 1 hour. Palmitate significantly blunted insulin and AA-mediated 
phosphorylation of PKB (n=6; P<0.001; Figure 3.7A-B) and p70-S6K1 (n=6; 
P<0.05; Figure 3.7A,C) whilst apyrase treatment did not alter insulin/AA-mediated 
phosphorylation in BSA controls or affect palmitate-induced insulin/anabolic 
resistance (P>0.05). Phosphorylation of ERK1/2 was significantly increased by 
palmitate (n=6; P<0.001) and was unchanged in the presence of insulin and AA 
± apyrase (n=6; P<0.001 and P≤0.001 against control with same treatments; 
P>0.05 against palmitate; Figure 3.7D).  
Subsequent experiments assessed the effect of direct treatment with ATP, or 
non-hydrolysable ATPγS, on intracellular signalling and inflammation, to better 
replicate the continuous release of ATP by exercising muscle in vivo (Crecelius 
et al., 2013; Zarębska et al., 2018).  










Figure 3.6. Apyrase treatment hydrolyses ATP released after palmitate 
treatment but does not alter effect on IL-6 and MIF secretion in C2C12 
myotubes 
A) Palmitate (500 μM; 16 hours) significantly increased eATP measured using 
luminescence based assay ATPLite (One-way ANOVA ***P<0.001; n=7) B) 
C2C12 myotubes treated with palmitate (500 μM) or BSA (0.1 % w/v; 16 
hours) ± apyrase (0.5 units/mL) and spiked with insulin (20 nM) and AAs (3.34 
mM) for 1 hour (One-way ANOVA with Bonferroni’s multiple comparisons 
analysis; ***P<0.001 for palmitate against control and $$$P<0.001 for 
palmitate + apyrase against palmitate; n=6). C) Palmitate (500 μM; 16 hours) 
modestly enhanced levels of extracellular IL-6 (non-significant) and this was 
not altered with apyrase (0.5 units/mL) (n=6). D) Palmitate (500 μM; 16 hours) 
treatment enhanced extracellular MIF and this was not altered by apyrase (0.5 
units/mL) (One-way ANOVA with Bonferroni’s multiple comparisons analysis 
*P<0.05 for palmitate against control, ns=not significantly different for apyrase 
effect; n=5). Cytokine levels measured by ELISA.  




Figure 3.7 Apyrase does not alter palmitate-induced insulin and anabolic 
resistance in C2C12 myotubes 
C2C12 myotubes treated for with palmitate (500 μM) or BSA (0.1 % w/v; 16 hours) ± 
apyrase (0.5 units/mL) and treated with insulin (20 nM) and AAs (3.34 Mm) for 1 hour. A) 
Representative immunoblots for PKB (pS473), total PKB, p70-S6K1 (pT389), p70-S6K1, 
ERK 1/2 (pThr202/Tyr204) and Actin. B) Densitometric analysis for phosphorylated PKB 
normalised to total PKB represented as the effect of palmitate and apyrase on insulin and 
AA-treated controls (fold change from insulin and AA treated cells) (***P<0.001 for 
palmitate against control and ns=not significant for the effect of apyrase on palmitate 
response; n=6). C) Densitometric analysis for phosphorylated p70-S6K1 normalised to 
total p70-S6K1 represented as in B (*P<0.05 for palmitate against control; n=6). D) 
Densitometric analysis for phosphorylated ERK normalised to actin (***P<0.001; n=6). All 
groups compared using One-way ANOVA with Bonferroni’s multiple comparisons.  
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3.8 Intracellular calcium levels increase in response to ATP in a 
concentration-dependent manner in C2C12 myotubes 
To test whether intracellular calcium was altered by ATP treatment in C2C12 
myotubes, cells were acutely injected with ATP and real-time changes to [Ca2+]i 
assessed using a fluorescent dye. ATP increased [Ca2+]i in C2C12 myotubes in 
a concentration-dependent manner (Figure 3.8A), with significant incremental 
changes occurring from 30 μM to 200 μM ATP (n=6; P<0.05 to P<0.001 for 30 
μM and 200 μM against control; Figure 3.8B). 
3.9 Treatment with ATPγS does not impair anabolic signalling pathway 
activation by insulin or amino acids 
C2C12 myotubes were treated with ATPγS (16 hours) to test the hypothesis that 
eATP may elicit anabolic blunting and pro-inflammatory cytokine release on 
muscle cells. Hydrolysis of palmitate-induced eATP with apyrase showed no 
effect on anabolic sensitivity or inflammatory cytokine secretion (Figure 3.6-7). 
Direct treatment with ATPγS (50 μM or 100 μM; 16 hours) did not alter the 
phosphorylation of PKB induced by insulin (20 nM; n=6; Figure 3.9A) and p70-
S6K1 induced by AA treatment (3.34 mM; n=6; Figure 3.9B), (P>0.05 for 50 μM 
and 100 μM ATPγS against control).  
3.10 Treatment with ATPγS attenuates levels of pro-inflammatory markers 
in C2C12 myotubes 
Treatment with ATPγS (16 hours) significantly increased the levels of IL-6 from 
non-detectable at baseline to ~20 and ~40-fold higher with 50 μM and 100 μM, 
respectively (n=6; P≤0.01 and P<0.001 for 50 μM and 100 μM respectively; 
Figure 3.10A). Levels of pro-inflammatory cytokine MIF were significantly 
reduced following 100 μM ATPγS treatment (n=6; P≤0.01; Figure 3.10B). The 
expression of phospho-NF-κB (Ser536) (p65 subunit) was moderately but not 
significantly attenuated by ATPγS (n=6; Figure 3.10C). These data go against the 
hypothesis that ATPγS would upregulate multiple inflammatory markers in these 
cells, akin to palmitate. 
 
 



















Figure 3.8 Intracellular calcium levels increase in response to ATP in a 
concentration-dependent manner in C2C12 myotubes 
A) Representative intracellular calcium transients in response to increasing 
concentrations of ATP (0-200 μM) measured using fluorescent dye Fluo-4 in 
a plate based assay (n=6). B) Area under the curve analysis for data shown 
in A. ATP increased intracellular calcium in a concentration-dependent 
manner from 30 μM to 200 μM (One-way ANOVA with Bonferroni’s multiple 
comparisons *P<0.05, **P<0.01, ***P<0.001; n=6). Solid line represents 
mean, grey shading represents SEM.  










Figure 3.9 Treatment with ATPγS does not alter insulin and amino acid-
mediated anabolic signalling pathway activation in muscle cells 
Assessment of the impact of ATPγS treatment (16 hours) on the intracellular 
signalling response to insulin and amino acids through Western blotting in 
C2C12 myotubes. A) Representative immunoblot and densitometric analysis 
for  phosphorylated PKB normalised to total PKB following treatment with 50-
100 μM ATPγS (16 hours) and 1 hour insulin (20 nM) or control treatment 
(***P<0.001 for all insulin groups against control; n=6). B) Representative 
immunoblot and densitometric analysis for phosphorylated p70-S6K1 
normalised to total p70-S6K1 in response to ATPγS treatment (16 hours) and 
1 hour treatment with AAs (3.34 mM) (*P<0.05 for all AA-treated groups 
against control; n=6). Groups compared using One-way ANOVA with 
Bonferroni’s multiple comparisons analysis.  















Figure 3.10 Treatment with ATPγS attenuates pro-inflammatory markers 
in C2C12 myotubes 
A) ATPγS (16 hours) caused a concentration-dependent increase in the levels 
of IL-6 from non-detectable levels (ND) to concentrations ~20 and ~40-fold 
higher with 50 μM and 100 μM respectively (*P<0.05, ***P<0.001 against 
control; n=6). B) ATPγS (16 hours) concentration-dependently decreased 
levels of MIF, reaching statistical significance at 100 μM (*P<0.05 against 
control; n=6). C) Representative immunoblot and densitometric analysis 
showing mild attenuation (not statistically significant) of phosphorylated NF-
κB (pS536) normalised to actin (n=6). All groups compared with One-way 
ANOVA with Bonferroni’s multiple comparisons analysis.  
Results         Chapter 3 
104 
3.11.1 ATPγS treatment leads to phosphorylation of anabolic signalling 
proteins in an insulin and amino acid-mimetic manner. 
Acute treatment with ATPγS (100 μM; 15 minutes) significantly elevated the 
levels of phosphorylated PKB (n=5; P<0.05; Figure 3.11.1A) in the absence of 
insulin or AAs. At 50 μM and 100 μM ATPγS significantly increased the levels of 
phosphorylated p70-S6K1 (n=5; P<0.05 and P<0.01, respectively; Figure 
3.11.1B). This suggests that eATP acts in an insulin and AA-mimetic manner to 
activate PI3K/PKB and mTOR signalling.  
3.11.2 Acute effect of ATPγS on anabolic signalling is attenuated by broad 
spectrum but not P2X4R and P2X7R antagonists. 
To test whether the acute ATPγS effect on PKB and S6K1 (seen in Figure 3.11.1) 
was P2R-mediated, C2C12 myotubes were treated with ATPγS (15 minutes) after 
pre-treatment with P2R antagonists (45 minutes). As anticipated, ATPγS (50 μM) 
significantly increased the levels of phosphorylated p70-S6K1 (n=6; P<0.0001 
against control) and this was completely prevented by broad spectrum P2R 
antagonists PPADS (100 μM) and suramin (100 μM) (P<0.001 for PPADS and 
suramin against ATPγS control; Figure 3.11.2A,B). P2X4R antagonist 5-BDBD (5 
μM) nor P2X7R antagonist A438079 (100 μM) modified the ATPγS-induced 
response (P>0.05 against ATPγS control). The levels of phosphorylated PKB 
were modestly, but not significantly, increased following ATPγS treatment (Figure 
3.11.2A,C), consistent with earlier observation (Figure 3.11.1A). This modest 
effect was significantly prevented by PPADS pre-treatment (n=6; P<0.05 for 
PPADS against ATPγS control) and attenuated by suramin (Figure 3.11.2A,C). 
Phosphorylation of ERK, used as a positive control for P2R-mediated ATP effects 
(May et al., 2006), was increased following ATPγS treatment (n=6; P<0.001 for 
ATPγS against control) and significantly prevented by both PPADS and suramin 
treatment but not 5-BDBD or A438079 (P<0.001 for both PPADS and suramin 
against ATPγS control; Figure 3.11.2A,D). PPADS and suramin decreased PKB 
phosphorylation to levels below those seen in controls. This supports the notion 
that tonic release of nucleotides maintains ‘resting’ signalling transduction via 
P2Rs (Lazarowski, Boucher and Harden, 2000). 
 








Figure 3.11.1 ATPγS treatment leads to phosphorylation of anabolic 
signalling proteins in an insulin and amino acid-mimetic manner. 
Treatment of C2C12 myotubes with ATPγS (15 minutes). A) Representative 
immunoblots of PKB (pS473) and total PKB with densitometric analysis 
showing significant increase in phosphorylation after ATPγS treatment (100 
μM; *P<0.05; n=5). B) Representative immunoblot of p70-S6K1 (pT389) and 
densitometric analysis for phosphorylated protein normalised to actin showing 
significant increase in response to 50 and 100 μM ATPγS (*P<0.05 compared 
to control; n=6). Groups compared with One-way ANOVA with Bonferroni’s 
multiple comparison analysis.  
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3.12 ATPγS acutely enhances glucose uptake in an insulin-mimetic and 
concentration-dependent manner 
The acute effects of ATPγS on the insulin signalling pathway led to the question 
of whether this would translate to an increase in insulin-independent glucose 
uptake into myotubes. This was tested by assessing the effect of acute ATPγS 
treatment on 2-DG uptake (as a proxy for glucose uptake) in C2C12 myotubes, 
using insulin treatment as a positive control. As anticipated, insulin (200 nM, 30 
minutes) significantly enhanced glucose uptake into myotubes (n=9; P<0.01; 
Figure 3.12). In the absence of insulin, ATPγS (30 minutes) significantly 
increased glucose uptake in a concentration-dependent manner, with 
concentrations above 50 μM showing an effect similar or more potent than that 
observed after insulin treatment (n=9; P≤0.01 and P<0.001 for 50 and 100 μM 
ATPγS, respectively, against control; Figure 3.12).  
3.13 Palmitate alters insulin and ATPγS-mediated glucose uptake 
To establish whether the ATPγS effect on glucose uptake was maintained after 
palmitate treatment C2C12 myotubes were treated with palmitate (500 μM; 16 
hours) or BSA controls (0.1 %; w/v) and glucose uptake measured in response 
to insulin (200 nM) or ATPγS (100 μM), as above. Palmitate treatment prevented 
both insulin and ATPγS-mediated glucose uptake (n=8; P<0.05 for insulin against 
palmitate with insulin; P<0.05 for ATPγS against palmitate with ATPγS; Figure 
3.13).  
  



















Figure 3.12 ATPγS acutely enhances glucose uptake in an insulin-
mimetic and concentration-dependent manner 
Glucose uptake in C2C12 myotubes pre-treated for 15 minutes with insulin 
and ATPγS following 15 minute incubation with 2-DG (100 μM) ± insulin and 
ATPγS, measured using luminescence based assay. Insulin (200 nM) 
significantly increased 2-DG uptake (**P<0.01) and this was matched and 
superseded with 50 and 100 μM ATPγS respectively. Data represented as fold 
change from control which is normalised to control mean (One-way ANOVA 
with Bonferroni’s multiple comparisons analysis *P<0.05; ***P<0.001 for 50 
and 100 μM ATPγS against control; n=9). 

















Figure 3.13 Palmitate alters insulin and ATPγS-induced glucose uptake 
in C2C12 myotubes 
Glucose uptake measured after treatment with palmitate (16 hours) or BSA 
controls and insulin and ATPγS (30 minutes) in C2C12 myotubes. Uptake 
observed in BSA controls after 15 minute incubation with insulin (200 nM) or 
ATPγS (100 μM) and subsequent 15 minute incubation with 2-DG (100 μM) 
was significantly prevented by palmitate treatment (500 μM; 16 hours) (One-
way ANOVA with Bonferroni’s multiple comparisons analysis; *P<0.05 
between insulin groups; $P<0.05 between ATPγS groups; n=8). Data 
represented as mean ± SEM for relative luminescence units (RLU). 
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3.14.1 Treatment with ATPγS (long-term) enhances glucose metabolism of 
C2C12 myotubes in a P2R-mediated manner 
C2C12 myotubes were treated for a short (15 minutes) and longer period (16 
hours) with ATPγS (with PPADS or suramin) to investigate whether the acute 
increase in glucose uptake was reflective of a P2R-mediated increase in glucose 
metabolism.  
Glycolytic rate was estimated by extracellular acidification rate (ECAR) in 
response to ATPγS (100 μM; 16 hours) with or without suramin (100 μM) and 
acutely in response to glucose (5.5 mM), oligomycin (2 μM) and 2-DG (50 mM). 
In the absence of glucose, glycolytic rate was unchanged between treatments 
(n=22-24; P>0.05; Figure 3.14.1A,B). In response to 5.5 mM glucose injection, 
ATPγS treated cells showed significantly higher rates of glycolysis, and this was 
significantly attenuated by suramin (n=22-24; P<0.05 and P<0.01 for ATPγS 
against control and P<0.05 for ATPγS against suramin; Figure 3.14.1A,C).  
3.14.2 ATPγS acutely increases glycolysis in a P2R-dependent manner 
distinct from the long-term effect 
Glycolytic rate was measured prior to (baseline) and following acute injection with 
ATPγS (100 μM) ± PPADS (100 μM) or suramin (100 μM) and treatment effect 
assessed after injection of glucose (5.5 mM), oligomycin (2 μM) and 2-DG (50 
mM). In the absence of glucose, acute injection of ATPγS significantly increased 
ECAR (P<0.001) and this response was blocked by PPADS but not suramin 
(P<0.001 for PPADS against ATPγS; n=22-24; Figure 3.14.2A,B). Suramin not 
only did not block the ATPγS response, but in the first measurement after 
injection (~ 8 minutes) showed a significantly higher effect on ECAR than ATPγS 
alone, albeit this was transient and quickly returned to levels matching the ATPγS 
response (P<0.001 for suramin against ATPγS; Figure 3.14.2A,C). Upon glucose 
addition, the rate of glycolysis was higher with ATPγS which was blocked by 
PPADS but not suramin (P<0.05 for ATPγS against control, P≤0.001 for PPADS 
against ATPγS; Figure 3.14.2A,D). These data indicate that short and long-term 
ATPγS treatment regulates glucose metabolism with differential P2R activation.   
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3.15 Amino acid treatment increases extracellular ATP levels leading to 
changes in intracellular calcium in C2C12 myotubes 
Preliminary observations suggested that insulin and AAs (combined) acutely 
increases the levels of eATP (data not shown). To test this and possible eATP-
mediated responses, the levels of eATP and intracellular calcium were measured 
after treatment with insulin and/or AAs. Treatment with AAs (3.34 mM; 1 hour) 
moderately increased the levels of eATP in C2C12 myotubes, whereas insulin 
(50 nM) did not (n=3; P=0.07 for AA against control; Figure 3.15). As [Ca2+]i 
increases in response to eATP in these cells (Figure 3.8), these were also treated 
acutely with AA (3.34 mM) and insulin (20 nM) to examine changes to [Ca2+]i. AA 
treatment (3.34 mM) significantly increased [Ca2+]i which was not observed with 
insulin treatment, and blocked after co-treatment with insulin (P<0.01 against AA; 
Figure 3.15B,D). Interestingly, when AAs were injected after apyrase pre-
treatment (0.5 units/mL; 60 minutes) the calcium response was dampened 
(P<0.05 for apyrase group against AA group), suggesting that the increase in 
calcium was, at least in part, mediated by eATP acting in an autocrine/paracrine 



























Figure 3.14.1 ATPγS treatment enhances glycolysis in C2C12 myotubes 
which is attenuated by suramin 
A) Representative extracellular flux assay demonstrating changes to glycolytic 
rate as estimated by extracellular acidification rate (ECAR) in response 
treatment with ATPγS (100 μM; 16 hours) ± suramin (100 μM) or vehicle; as 
well as acute injection of glucose (5.5 mM), oligomycin (2 μM) and 2-
deoxyglucose (2-DG, 50 mM) at the indicated points (Two-way ANOVA with 
repeated measures and Bonferroni’s multiple comparisons analysis *P<0.05 
and **P<0.01 for ATPγS against control and $P<0.05 for suramin against 
ATPγS; n=22-24). B) Non-glycolytic acidification demonstrating mean ECAR 
prior to glucose injection. C) Glycolysis measured as the change in ECAR 
following glucose injection compared to baseline levels (One-way ANOVA 
with Bonferroni’s multiple comparisons analysis *P<0.05 for ATPγS against 
control). Suramin treatment returns ECAR to control levels (P>0.05 for 
suramin against control) abolishing ATPγS response. 






Figure 3.14.2 Acute ATPγS treatment alters glycolytic rate in C2C12 myotubes 
in a P2R-regualated manner 
A) Representative extracellular flux assay demonstrating changes to glycolytic rate 
as estimated by extracellular acidification rate (ECAR) in response to acute 
injections of ATPγS (100 μM) ± suramin (100 μM), PPADs (100 μM) or vehicle; 
followed by acute injection of glucose (5.5 mM), oligomycin (2 μM) and 2-
deoxyglucose (2-DG, 50 mM) at the indicated points (Two-way ANOVA with 
repeated measures ***P<0.001(drug), ***P<0.001(time), ***P<0.001(interaction) (n=22-24) 
B) Acute response to treatment measured by difference between last measurement 
before glucose and last baseline measurement (***P<0.001 against control 
$$$P<0.001 against ATPγS C)  Acute response after one cycle (***P<0.001 against 
control $P<0.05 against ATPγS). D) Glycolysis measured as a difference between 
last measurement before oligomycin and last baseline reading (*P<0.05 against 
control $$$P<0.001 against ATPγS) E) Glycolytic reserve measured as oligomycin 
effect. One-way AVOVA with Bonferroni’s multiple comparisons analysis.  
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Figure 3.15 Amino acid treatment of C2C12 myotubes increases 
extracellular ATP and intracellular calcium 
A) Change in eATP following AA (3.34 mM) and insulin (50 mM) treatment 
(1 hours) in C2C12 myotubes (One-way ANOVA with Bonferroni’s multiple 
comparisons analysis P=0.07 for AAs against control). B) Representative 
curves of changes in intracellular calcium in response to AAs (3.34 mM), 
insulin (20 nM) or both measured using Fluo-4 in a plate based assay (n=3). 
C) Representative curves of changes in intracellular calcium in response to 
AAs (3.34 mM) (same data as in B) or following apyrase pre-treatment (0.5 
units/mL; 1 hour). D) Area under the curve analysis for data shown in B and 
C (One-way ANOVA with Bonferroni’s multiple comparisons **P<0.01 
against AA; n=3).  
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Discussion 
In the present study, C2C12 myotubes were used to assess the potential 
involvement of the purinergic signalling system in mechanisms regulating insulin 
and anabolic resistance in SM. Palmitate treatment was used to induce insulin 
and anabolic resistance in these cells. Extracellular ATP was enhanced following 
palmitate treatment but modulation of eATP demonstrated that the nucleotide did 
not appear to regulate the FA-induced effects on intracellular signalling or 
inflammatory cytokine release. Interestingly, eATP appeared to show potential 
novel anti-inflammatory effects as well as insulin mimetic actions on glucose 
uptake and intracellular metabolism.  
Assessing anabolic sensitivity in C2C12 myotubes differentiated at 
physiological glucose concentration 
To assess the effect of elevated FA exposure separately from the effects of 
hyperglycaemia on insulin and anabolic resistance in vitro, C2C12 myotubes 
were differentiated under physiological glucose concentrations, 5.5 mM, unlike 
standard culture conditions where cells are maintained and differentiated at 25 
mM glucose (hyperglycaemic). Here, across the 7 days of differentiation, cells 
demonstrated morphologically identical features from myotubes cultured at 
supraphysiological glucose conditions (Burattini et al., 2004), showing alignment 
and fusion of myoblasts by day 3, elongation and myotube formation by day 5 
and fully formed Y-shaped myotubes by day 7. Glucose concentration during 
differentiation of C2C12 myotubes has often been overlooked as a factor of 
experimental outcomes. Data concerning glucose concentration during 
differentiation are scarce and subject to debate. For instance, Grzelkowska-
Kowalczyk and colleagues showed that differentiating myotubes in high glucose 
concentrations (15 mM) for three days led to a 2-fold decrease in myoblast fusion 
and decrease in myogenic transcription factor expression compared to 
euglycaemic controls (5 mM glucose) (Grzelkowska-Kowalczyk et al., 2013). In 
contrast, Fulco and colleagues, who considered 25 mM glucose as euglycaemic 
and 5 mM glucose as glucose restriction, showed that differentiation at 5 mM 
glucose for 48 hours impaired myogenesis and activated AMPK, an important 
sensor of energy stress (Fulco et al., 2008). These studies, however, provide no 
methodological details about the frequency of glucose replenishment in these 
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cells or difference between myotubes after full differentiation, which is not 
achieved until days 5-7 (Burattini et al., 2004). Importantly for this study, glucose 
was replenished in fresh media every 24 hours during differentiation to avoid 
glucose depletion and experiments were conducted after 7 days, ensuring fully 
formed myotubes were always used.  
Insulin and AAs represent important anabolic stimuli that regulate SM glucose 
metabolism and protein synthesis. Impaired insulin-stimulated glucose uptake 
and intracellular utilisation (insulin resistance) and AA-stimulated protein 
synthesis (anabolic resistance) are key contributing factors to loss of muscle 
mass and function in metabolic disease (Ferrannini et al., 1996; Park et al., 2009; 
Cruz-Jentoft et al., 2010). Here, insulin and AA treatments were used to establish 
a SM cell model of anabolic sensitivity by assessing activation of PI3K/PKB and 
mTOR signalling pathways in C2C12 myotubes. Insulin treatment (20 nM, 60 
minutes) increased phosphorylation of PKB at serine 473, an important site for 
full kinase activation (Sarbassov et al., 2005), in a concentration-dependent 
manner. This is well-established and consistent with data showing a 2-3-fold 
increase in phosphorylation of PKB after insulin treatment (100 nM, 15 minutes) 
in C2C12 myotubes (Sun et al., 2017; Vlavcheski and Tsiani, 2018) and ex-vivo, 
in insulin-infused soleus muscles (0.6-100 nM for 50 minutes) (Zheng and Cartee, 
2016). In human SM, 3 hour insulin infusion increases PKB phosphorylation 5-
fold (Cozzone et al., 2008). Here, insulin also enhanced phosphorylation of p70-
S6K1, consistent with previous findings (Conejo et al., 2001) and augmented the 
AA-induced phosphorylation of p70-S6K1. AA alone (3.34 mM, 60 minutes) 
caused a 2-fold increase in p70-S6K1 phosphorylation at threonine 389, an 
mTOR regulated site indispensable for p70-S6K1 activation (Shimobayashi and 
Hall, 2014). The effect of AAs on p70-S6K1 phosphorylation is also well 
documented, particularly of EAAs, such as lysine, methionine, phenylalanine, 
tryptophan and threonine, which enhance phosphorylation of p70-S6K1 1.6-2-
fold in C2C12 myotubes (2 mM, 30 minutes) and leucine which increases it 6-fold 
(Atherton et al., 2010). These data helped establish a good model of anabolic 
sensitivity in mature C2C12 myotubes that was used to test the overarching 
hypothesis of this study.  
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Palmitate treatment as a model of skeletal muscle metabolic impairment  
A model of FA-induced metabolic dysfunction was subsequently used to test this 
hypothesis. Insulin resistance, inflammatory cytokine production and 
mitochondrial dysfunction are characteristics of FA-induced metabolic 
dysfunction in SM and were used here as markers of a well-developed model 
(replicating earlier studies) to study the mechanisms regulating these features.   
In agreement with the hypothesis, treatment with palmitate (500-750 μM; 16 
hours) prevented the phosphorylation of PKB and p70-S6K1 induced by insulin 
and AAs (60 minutes). These findings concur with others showing that 24 hour 
treatment with palmitate (600 μM) suppressed PKB and p70-S6K1 
phosphorylation in response to insulin treatment (100 nM for 15 minutes) (Yang 
et al., 2013) and palmitate (400 μM; 6 hours) caused a 40 % decrease in insulin-
stimulated PKB phosphorylation (100 nM for 10 minutes) in C2C12 myotubes 
(Sinha et al., 2004). Importantly, at these concentrations, palmitate has been 
shown to cause IR in muscle cells without impairing cell viability, for up to 24 
hours (Pimenta et al., 2008; Yang et al., 2013). Palmitate treatment also 
attenuated the insulin and AA effect on phosphorylation of p70-S6K1. This is 
likely a combination of blunted insulin signalling, as demonstrated by impaired 
PKB phosphorylation and previous findings (Yang et al., 2013) and 
desensitisation to AA treatment after exposure to high concentrations of 
palmitate. Indeed, treatment with lipotoxic ceramides diminishes intracellular AA 
availability and attenuates insulin and AA-induced S6K1 phosphorylation (Hyde 
et al., 2005) and intravenous lipid infusion in humans prevents the otherwise ~2-
fold increase AA-stimulated protein synthesis (Stephens et al., 2015). The effect 
of high concentrations of palmitate on C2C12 myotubes shown here provided a 
good model of FA-induced insulin and anabolic resistance.  
Inflammation plays an important role in the development of SM IR, in part, via 
increased influx of FAs and inflammatory cytokines from AT (and SM itself). 
These induce SM inflammation and alter metabolism to promote IR (Wu and 
Ballantyne, 2017). For instance, palmitate treatment in L6 myotubes activates 
IKK/IκB/NF-κB signalling, resulting in a 30% decrease in insulin-stimulated 
glucose uptake (Sinha et al., 2004).  
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Furthermore, conditioned media (CM) from palmitate-treated macrophages 
activates PKCθ and ε in L6 myoblasts (Samokhvalov et al., 2009) causing 
reduced PI3K signalling and glucose uptake in GLUT4-overexpressing cells 
(Kewalramani et al., 2011) and causes TLR2/4-mediated IR in L6 myotubes 
(Nguyen et al., 2007). Elevated TNF-α levels present in the CM impaired insulin-
stimulated glucose uptake in C2C12 myotubes via activation of p38 MAPK 
(Talbot et al., 2014). Others have demonstrated attenuated insulin signalling in 
muscle cells from TNF-α-mediated activation of p38 MAPK, via IKK/IκB/NF-κB 
signalling (De Alvaro et al., 2004).   
Plasma TNF-α levels are elevated in severe inflammation and implicated in IR 
and diabetes (Swaroop et al., 2012). TNF-α-induced AT IR (Atsumi et al., 2007) 
and catabolic effects on muscle glucose metabolism (Benigni et al., 2000) are 
mediated by macrophage migration inhibitory factor (MIF). Plasma MIF levels are 
upregulated in chronic inflammatory metabolic disorders including in obesity and 
T2D (Church et al., 2005; Skurk et al., 2005; Morrison and Kleemann, 2015) and 
the cytokine participates in HFD-induced IR, as demonstrated by improved 
glucose tolerance and protection from HFD-induced IR in MIF knockout mice 
(Finucane et al., 2014). These observations, added to the ability of SM to release 
MIF (Miyatake et al., 2014) led to the hypothesis that palmitate treatment would 
increase MIF levels in C2C12 myotubes. Indeed, palmitate treatment (16 hours) 
caused a 3-fold increase in MIF in these cells. MIF release from palmitate-treated 
muscle cells has been shown on one other occasion, in response to 18 hour 
treatment with 500 μM palmitate in C2C12 myotubes (Pillon et al., 2014). 
Although the direct consequence of elevated MIF levels in this system remains 
unexplored, one report indicated that 24 hour treatment of liver and SM cells with 
recombinant MIF did not impact insulin signalling, whereas it significantly 
attenuated insulin-induced glucose uptake into adipocytes (Cui et al., 2018). It is 
plausible that MIF is released from these cells as they are metabolically 
compromised, in a similar way that MIF is secreted during ischaemia (Dayawansa 
et al., 2014), hypoxia (Simons et al., 2011) and AA starvation (Chuang et al., 
2012). Further work is required to establish its origin and downstream effects. 
In addition to MIF, palmitate treatment (16 hours) led to a significant increase in 
the extracellular levels of IL-6 in C2C12 myotubes.  
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IL-6 was one of the first established myokines, and has been extensively 
characterised for its paradoxical effects on inflammation (reviewed by Scheller et 
al., 2011; Muñoz-Cánoves et al., 2013). Transient and short-term action of 
muscle-derived IL-6 benefits SM hypertrophy, myogenesis and regeneration and 
contributes to whole-body glucose homeostasis, stimulating glucose production 
(Fischer, 2006; Wolsk et al., 2010; Pedersen and Febbraio, 2012; Eckardt et al., 
2014). Conversely, long-lasting elevated circulating IL-6 is a feature of pro-
inflammatory conditions and is associated with muscle wasting and IR (Kern et 
al., 2001; Pradhan et al., 2001; Rui et al., 2002). Consistent with findings here, 
palmitate (600 μM for 24 hours) induced a 10-fold increase in IL-6 gene 
expression and increased release in C2C12 myotubes (Yang et al., 2013) and 
this was reproduced by Jove and colleagues who showed that 16 hour treatment 
with palmitate (500 μM) caused a 3.5-fold increase in IL-6 mRNA in the same 
cells (Jové et al., 2005). The latter also showed a 3-fold induction in extracellular 
IL-6 after palmitate treatment and both effects were PKC and NF-κB-dependent. 
As such, IL-6 release was used as a positive control for palmitate-induced 
responses in SM. The role of elevated IL-6 here, however, remains to be 
determined as the levels of the myokine were also increased following ATPγS 
treatment (in the absence of palmitate) in these cells (discussed below).  
Mitochondrial respiration was also assessed, given the role played by 
mitochondrial dysfunction and increased mitochondrial oxidative stress in T2D 
and IR (Sergi et al., 2019). Here, palmitate treatment (16 hours) at concentrations 
> 500 μM impaired basal oxygen consumption as well as ATP synthase activity 
and spare respiratory capacity in C2C12 myotubes. At lower concentration (250 
μM), these parameters were increased. Increased FA availability is likely leading 
to increased rates of FAO in these cells. At 250 μM palmitate, FAO remains 
coupled to ATP synthesis (St-Pierre et al., 2002) as basal OCR and ATP 
synthase activity were increased relative to control cells and these cells were able 
to respire maximally in response to exogenous uncoupling with FCCP. The 
oxidation of FAs generates ROS, such as superoxide, which in turn activate 
uncoupling protein (UCPs) that allow proton re-entry into the mitochondrial 
matrix, independently of ATP synthase (proton leak) (Andrews et al., 2005; 
Busiello et al., 2015).  
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Mitochondrial uncoupling, as well as intrinsic antioxidant activity by enzymes 
such as superoxide dismutases, control the levels of ROS within cells (Lambert 
and Brand, 2009). However, with excess FAO, ROS production increases to 
supersede the effect of antioxidant mechanisms and uncoupling, leading to build-
up of lipotoxic metabolites, cellular oxidative stress (Cross et al., 1987), 
mitochondrial damage and impaired insulin signalling (Anderson et al., 2009). 
This suppresses mitochondrial respiration and ATP production, which was 
observed here in response to palmitate (> 500 μM) by reduced ATP synthase 
activity and impaired spare respiratory capacity. This is consistent with data 
showing increased ROS, mitochondrial DNA damage, activated JNK signalling 
and IR in palmitate-treated L6 myotubes (Yuzefovych et al., 2010). The latter 
demonstrated these effects at a wider range of palmitate concentrations (100 μM 
to 1 mM). Assessing changes to markers of mitochondrial function and FAO such 
as activation of AMPK, ACC, lipotoxic metabolites, ROS and expression of UCPs 
would help clarify the concentration-dependent differences observed here.  
The data discussed above demonstrate reduced anabolic sensitivity, enhanced 
inflammation and diminished mitochondrial function induced by high 
concentrations of palmitate during long-term exposure in C2C12 myotubes. This 
generated a good model with which to test the involvement of the purinergic 
signalling system in these responses.  
Contribution of purinergic signalling system to palmitate-induced IR and 
inflammation 
It was hypothesised that the effects of palmitate treatment on anabolic sensitivity 
and inflammation may be regulated by eATP, given its roles in inflammation and 
glucose metabolism. Here, palmitate treatment (500 μM, 16 hours) significantly 
increased the levels of eATP in C2C12 myotubes, which has only been reported 
once in muscle cells (Pillon et al., 2014). Pillon and colleagues demonstrated that 
CM from palmitate-treated (500 μM, 18 hours) myotubes had potent monocyte 
chemoattractant properties, which were prevented by apyrase. Importantly, as 
SFAs are cytotoxic (Yang et al., 2013) and ATP is released in response to cellular 
damage (Lazarowski et al., 2003), the group eliminated cytotoxicity as a source 
of increased eATP showing that myotube viability was not affected using MTT 
reduction, lactate dehydrogenase and caspase-3 cleavage as markers.  
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Elevated eATP can originate from increased release or decreased extracellular 
degradation of the nucleotide (Robson et al., 2001; Robson et al., 2006). Future 
experiments would investigate the origin of palmitate-induced eATP seen here by 
inhibiting ATP release using pannexin (Pnx) and connexin (Cnx) channel 
blockers, measuring activity of endogenous ecto-nucleotidases and inhibiting 
extracellular hydrolysis by CD39 and CD73. It is plausible, however, given the 
work by Pillon and colleagues (Pillon et al., 2014), that palmitate acting via TLR4-
NF-κB upregulates Pnx3 channel expression to increase ATP release.   
Here, apyrase prevented palmitate-dependent increase in eATP but did not alter 
baseline or palmitate-induced secretion of IL-6 or MIF, nor did it alter the blunted 
insulin and AA-dependent phosphorylation of PKB or p70-S6K1. This was also 
the case for palmitate-induced phosphorylation of ERK. Extracellular hydrolysis 
of ATP by apyrase may result in upregulated signalling via AMP and adenosine, 
and these can have opposing roles to ATP, particularly in inflammation and 
immune responses (Beldi et al., 2008; Faas et al., 2017). Furthermore, ATP may 
activate highly sensitive P2R in an autocrine manner (Ostrom et al., 2000). This 
is observed in the vascular epithelium, where ATP is released due to endothelial 
damage (Lohman et al., 2012). Treatment of endothelial cells with high 
concentrations of glucose and palmitate (24 hours), results in upregulated 
expression of P2X4R and P2X7R, release of inflammatory cytokines and 
upregulated IL-6 mRNA expression (Sathanoori et al., 2015). The effect on 
cytokine release and IL-6 expression were prevented by P2X4R and P2X7R 
blockade (at 24 hours) but treatment with apyrase did not prevent these effects 
at 24 hours, only after 48 hours (Sathanoori et al., 2015). This suggests that 
extracellular ATP may elicit P2R-mediated roles that are not negated by the use 
of apyrase alone. Subsequent experiments in this study therefore assessed the 
effect of direct and continuous treatment with eATP on anabolic sensitivity and 
inflammation.  
Effects of ATP treatment on skeletal muscle inflammation and metabolism 
Activation of P2XRs by ATP results in rapid Ca2+ influx and downstream 
activation of MAPK, PKC and Ca2+-calmodulin-dependent protein kinases 
(CAMK) (Ostrom, Gregorian and Insel, 2000; Cseri et al., 2002).  
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Activation of P2YRs (dependent on activated G-protein) stimulates IP3-mediated 
release of Ca2+ from intracellular stores, increases DAG to activate PKC, inhibits 
adenylyl cyclase and reduces cAMP levels (von Kugelgen and Harden, 2011; Erb 
and Weisman, 2012). Here, treatment of C2C12 myotubes with ATP resulted in 
a concentration-dependent increase in [Ca2+]i. This was consistent with Ca2+ 
transients in primary mouse myotubes in response to ATP (180 μM), which were 
mediated via P2X4, 5, 7 and P2Y1 and 4 receptors (Deli et al., 2007; Buvinic et 
al., 2009). Extracellular nucleotide treatment in myotubes has demonstrated 
steep and rapid increases in [Ca2+]i, suggestive of P2XR activity (Cseri et al., 
2002) and increases in IP3, suggestive of P2YR activity (Häggblad and 
Heilbronn, 1987; Keresztes et al., 1991). Pharmacological activation of P2Y1 in 
human myotubes also causes an IP3-mediated increase in [Ca2+]i which results 
in ERK1/2 activation (May et al., 2006). The [Ca2+]i peaks observed here were 
rapid and transient, but remained concentration-dependently elevated, 
suggesting involvement of both P2XR and P2YRs. Receptor specific agonists 
would be used in future to identify the P2Rs mediating [Ca2+]i changes in these 
cells and contribution of P2XRs assessed by using medium free of calcium.  
In the absence of palmitate, ATPγS (16 hours) concentration-dependently 
increased and decreased the levels of IL-6 and MIF, respectively, in C2C12 
myotubes. IL-6 and ATP are released at high levels during muscle contraction 
and exercise (Steensberg et al., 2000; Pedersen and Fischer, 2007; Osorio-
Fuentealba et al., 2013). The expression of IL-6 in muscle is regulated by 
intracellular Ca2+-mediated signalling involving Ca2+-dependent phosphatase 
calcineurin (Allen et al., 2010) and action of p38 MAPK and CAMK (Weigert et 
al., 2007) and the cytokine regulates its own expression via JAK2/STAT3 
signalling (Naka et al., 1997; Schmitz et al., 2000).  
ATP-P2YR-mediated increase in [Ca2+] is also associated with elevated 
expression of IL-6 mRNA and activation of ERK and NF-κB pathways (Buvinic et 
al., 2009). Buvinic and colleagues demonstrated that electrical stimulation (ES) 
of primary rat myotubes led to ATP release via Panx1 channels, which acted in 
an autocrine manner on P2XRs and P2YRs to increase [Ca2+]i; and treatment 
with exogenous ATP in these cells increased IL-6 mRNA (Buvinic et al., 2009).  
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ES of primary myotubes and muscle fibres also increases eATP, which augments 
expression and extracellular levels of IL-6 in a P2R-IP3-Ca2+-dependent manner 
(Bustamante et al., 2014). As treatment with apyrase did not prevent the 
palmitate-induced increase in IL-6, in this study, it is plausible that ATPγS-
mediated IL-6 release occurs via a separate mechanism. For example, in 
myotubes palmitate partly mediates IL-6 secretion by activation of the pro-
inflammatory NF-κB pathway (Jové et al., 2005). In this study, ATPγS decreased 
the phosphorylation of p65 NF-κB, suggesting that this pathway is unlikely to 
mediate IL-6 secretion. IL-6 is a pleiotropic myokine, demonstrating pro and anti-
inflammatory effects in SM (Pedersen and Fischer, 2007; Muñoz-Cánoves et al., 
2013) so a better understanding is required of the functional implications of 
ATPγS-induced IL-6 secretion. Contrary to expectation, ATPγS treatment 
decreased the levels of pro-inflammatory cytokine MIF and decreased activation 
of NF-κB signalling pathway. Together with increased IL-6 (which may act in an 
anti-inflammatory manner), these data pose the question of whether continuous 
ATP exposure may be immunomodulatory in SM.  
Although not fully characterised, ATP has demonstrated anti-inflammatory 
properties. In microglia, eATP inhibits the release of inflammatory cytokines from 
lipopolysaccharide(LPS)-primed cells (Ogata et al., 2003), suppresses release of 
nitric oxide from BV-2 cells (Brautigam et al., 2005) and decreases TNF-α and 
ROS levels in primary cells (Boucsein et al., 2003). In human immune cells, ATP 
inhibits LPS-stimulated production of pro-inflammatory cytokines and up-
regulates anti-inflammatory signals, mediated via P2Y11R (Vitiello et al., 2012). 
Furthermore, ATP suppresses TNF-α and IL-12 in LPS-treated macrophages 
(Haskó et al., 2000). To date, no anti-inflammatory roles of eATP on SM have 
been reported. A better understanding is therefore required of the role of eATP 
on SM inflammation, as, although direct treatment with ATPγS decreased MIF 
levels, apyrase treatment did not aggravate the palmitate-stimulated increase in 
MIF.   
Independently of palmitate, ATPγS pre-treatment (16 hours) did not alter insulin-
stimulated phosphorylation of PKB or AA-dependent increase in p70-S6K1 
phosphorylation, suggesting that long-term exposure to eATP does not impair 
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anabolic sensitivity and almost certainly does not mediate the palmitate-induced 
effects on C2C12 myotubes.  
Importantly, palmitate, eATP, IL-6 and MIF all participate in the regulation of 
glucose metabolism in SM, raising interesting questions about the relationship of 
these molecules to one another. For instance, acute treatment of C2C12 
myotubes with ATPγS, better mimicking the transient and high levels of eATP 
resulting from muscle contraction and exercise, caused a concentration-
dependent increase in the phosphorylation of PKB and p70-S6K1 in the absence 
of insulin and AAs. These responses were abolished by PPADS and suramin but 
not by P2X4R or P2X7R antagonists. The insulin-like actions of ATP were further 
expanded to show a concentration-dependent increase in glucose uptake in 
C2C12 myotubes that was comparable to the insulin effects. A similar insulin 
mimetic effect of eATP was demonstrated by Osorio-Fuentealba and colleagues 
(Osorio-Fuentealba et al., 2013), who showed that eATP, released from ES or 
exogenously administered, promotes glucose uptake in L6 myotubes, primary 
myotubes and muscle fibres through mobilisation of GLUT4 via a PI3Kγ-PKB-
AS160 signalling cascade. In their study, treatment of primary myotubes with ATP 
(100 μM, 15 minutes) caused a >2-fold increase in 2-NBDG uptake which was 
prevented by apyrase (2 units/mL; 30 minutes) and suramin (100 μM) (Osorio-
Fuentealba et al., 2013). Interestingly insulin-induced uptake was not blocked by 
apyrase or suramin, which taken together with observations that eATP did not 
alter INSR activation, suggests that eATP-induced glucose uptake is insulin-
independent. Furthermore, akin findings in this chapter, ATP (100 μM) 
significantly enhanced PKB (S473) phosphorylation after 15, 30 and 60 minutes 
in muscle cells (Osorio-Fuentealba et al., 2013).  
Groups that demonstrated eATP-mediated glucose uptake in SM did not 
investigate which P2Rs may be activated (Osorio-Fuentealba et al., 2013). Data 
presented here suggest that the ATPγS-induced increase in PKB and p70-S6K1 
phosphorylation did not occur downstream of P2X4R or P2X7R but was mediated 
by P2YRs, as it was prevented by both PPADS and suramin. P2Y2R is the most 
likely candidate receptor as both antagonists show moderate affinity towards 
P2Y2R (Burnstock, 2005) and this is highly expressed in mature myotubes 
(Banachewicz et al., 2005).  
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This would also concur with findings by Kim and colleagues, who demonstrated 
P2R-mediated glucose transport in C2C12 myotubes, suggested to occur via 
P2Y2, 4 or P2X1 (Kim et al., 2002).  
Interestingly, eATP regulation of p70-S6K1 in SM had not been described. Similar 
data were recently reported by Ito and colleagues (Ito et al., 2018). The group 
demonstrated P2Y2R-mediated increase in p70-S6K1 phosphorylation (T389) in 
response to eATP treatment (> 10 μM; 30 minutes) in C2C12 myotubes. This 
anabolic response and eATP-induced increase in [Ca2+]i were blocked by 
depletion of intracellular Ca2+ and P2Y2R knockdown. ATP-mediated effects 
occurred by activation of a P2Y2R/PI3K/PLC/IP3R pathway, acting via class III 
PI3K (Vps34) and not class I (PI3K/PKB) which primarily regulates insulin 
signalling. Interestingly, data in this chapter showed AA-dependent increase in 
[Ca2+]i, which was blocked by apyrase; AA-mediated increase in eATP and 
increased p70-S6K1 phosphorylation in response to AA and ATPγS 
(independently). Given that AA signalling results in mTORC1 activation partly via 
Vps34 (Nobukuni et al., 2005), it will be interesting to determine whether 
treatment with AAs regulates this pathway and whether AA-induced muscle 
hypertrophy requires ATP release.  
The AA-mediated increase in eATP and [Ca2+]i seen here was not mimicked by 
insulin; and co-treatment with insulin abolished the AA effect. The impact of 
insulin treatment on eATP has not been previously studied but it was 
hypothesised that insulin would increase [Ca2+]i, as calcium influx was believed 
to be necessary for insulin-stimulated glucose uptake into SM fibres (Lanner et 
al., 2006), even though others have shown that insulin does not increase total 
[Ca2+]i in various muscle models (Klip, Li and Logan, 1984; Cheung, Constantine 
and Bonventre, 1987). Data in this chapter suggests that insulin does not alter 
eATP release or [Ca2+]i. Although very sensitive methods were used in Lanner 
et. al. (Lanner et al., 2006) to measure [Ca2+]i, their methodology relied on ES of 
fibres prior to measurements. Evidence from other groups (Kim et al., 2002; 
Osorio-Fuentealba et al., 2013), taken together with data presented here, 
suggests that eATP likely modulates the intracellular calcium levels during ES, 
so it is possible that the insulin effect observed by the group was partly eATP-
mediated.  
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Although insulin itself does not alter [Ca2+]i, it may modulate the effect of other 
stimuli, such as AA. In future, more sensitive methods such as single cell 
ratiometric calcium imaging would be used to better understand this relationship.  
In this study, treatment with ATPγS (15 minutes) enhanced glucose transport into 
myotubes in an insulin-independent manner. Extracellular ATP-mediated glucose 
uptake has been reported but, to date, no evidence exists of altered intracellular 
glucose metabolism in response to eATP in SM. Here, for the first time, ATPγS 
treatment (short and long-term) altered glycolytic rate in a P2R-dependent 
manner. Unexpectedly, ATPγS also increased extracellular acidification in the 
absence of glucose, which was enhanced by suramin, so further work is required 
to understand this response. The acute increase in glycolysis was blocked by 
PPADS but not suramin suggesting differential P2R regulation of these effects. 
This may also suggest that more acute effects may be regulated by P2XRs as 
PPADS selectively inhibit P2XR and only moderately antagonise P2YRs, while 
suramin antagonises P2YRs with higher affinity than P2XRs (Burnstock, 2018). 
In vascular endothelial cells exogenous ATP increases ECAR and upregulates 
the key glycolytic enzymes PFK-B3 and HK as well as GLUT-1 expression (Lapel 
et al., 2017). This has not been observed in SM so future experiment would aim 
to assess the effect of eATP treatment on SM glycolytic machinery. 
The effect of eATP on glucose metabolism may be indirectly mediated by 
autocrine and paracrine IL-6 and/or MIF signalling. For instance, IL-6 increases 
basal and insulin-stimulated glucose uptake in L6 myotubes and primary 
myotubes (Al-Khalili et al., 2006) and increases glucose oxidation in human 
primary myotubes, mediated by activation of AMPK (Glund et al., 2007), which 
also promotes FAO (Carey et al., 2006). MIF inhibits insulin-stimulated glucose 
uptake into AT (Atsumi et al., 2007) and is implicated in HFD-induced AT 
inflammation and IR in mice (Finucane et al., 2014). Contrastingly, MIF deficiency 
(knockout) impairs glucose tolerance and hyperinsulinaemia in mice and MIF 
regulates TNF-α effects to increase glycolysis and lactate production in myotubes 
(Benigni et al., 2000). More recently, MIF was shown to decrease insulin-
mediated glucose uptake and phosphorylation of PKB in soleus muscle and 
AICAR-mediated glucose transport in extensor digitorum longus (EDL) muscle of 
mice (Miyatake et al., 2014).  
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The relationship between IL-6, eATP and MIF may therefore be important in the 
regulation of SM glucose homeostasis. For example, Miyatake and colleagues 
demonstrated a 70 % reduction in MIF release following ES of C2C12 myotubes 
(Miyatake et al., 2014). Although an acute effect of eATP on MIF secretion was 
not assessed here, it would be interesting to determine whether the decrease in 
MIF following contraction is caused by eATP and whether increased glucose 
transport requires inhibition of MIF release. An increase in intracellular ATP 
availability from upregulated glycolysis in these cells should also result in 
inhibition of AMPK (Jørgensen, Jensen and Richter, 2007) further enabling 
mTOR activation (seen here). AMPK activation was not yet investigated here, but 
others showed that treatment with eATP (100 μM; 30 minutes) did not alter AMPK 
phosphorylation (Thr172) in C2C12 myotubes (Ito et al., 2018). MIF, on the other 
hand, regulates AMPK activation in a variety of tissues. In the heart, MIF (acting 
via CD74 receptors) promotes glucose uptake during hypoxia by activating 
AMPK, which protects cardiomyocytes during ischemia-reperfusion injury (Miller 
et al., 2008) and MIF deficiency is believed to increase susceptibility to 
myocardial ischaemia in older cardiac patients (Ma et al., 2010). MIF-CD74-
mediated signalling also protects hepatocytes in metabolic models of liver injury 
(Heinrichs et al., 2014) and regulates cardioprotective signalling mechanisms in 
a mouse model of T1D (STZ), via activation of AMPK, PKB and ERK (Tong et al., 
2010). Conversely, MIF-CD74 inhibits AMPK activation in lung adenocarcinoma 
cell lines, enhancing mTOR activation (Brock et al., 2012) and decreases AICAR-
mediated glucose uptake into muscle (Miyatake et al., 2014). AMPK is an 
important whole body and cellular energy sensor, and it appears that MIF may 
also act as a cellular stress signal, as MIF levels are elevated during energetic 
stress (hypoxia, ischaemia, sepsis, inflammation) and seen here to increase after 
palmitate treatment, when anabolic and mitochondrial function are compromised. 
MIF was also upregulated after glucose deprivation in C2C12 myotubes (3 hours, 
1 mM glucose compared to 5.5 mM; data not shown). In future, it will be 
interesting to elucidate the relationship between eATP and MIF (and possible 
AMPK activation) and how these might regulate SM glucose metabolism.  
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Insulin-independent mechanisms to upregulate glucose transport and utilisation 
have high therapeutic value, as these may help regulate glycaemia in insulin-
deficient and resistant states. As acute stimulation with ATPγS demonstrated 
insulin-mimetic effects these treatments were conducted following palmitate 
treatment to assess whether insulin-independent glucose uptake would be 
sustained. Palmitate treatment impaired ATPγS-stimulated glucose uptake, to a 
similar extent that it inhibited insulin-dependent glucose uptake, suggesting a 
level of purinergic resistance. However, others have shown that eATP-mediated 
glucose uptake was preserved in insulin resistant SM fibres from HFD-fed mice 
(Osorio-Fuentealba et al., 2013). A better understanding of purinergic resistance 
is therefore required, and in this study future experiments would aim to assess 
the effect of palmitate treatment on ATPγS-induced activation of anabolic 
signalling proteins and ATP-induced increase in [Ca2+]i. Interestingly, recent 
findings suggest that contraction protects C2C12 myotubes from palmitate-
induced IR (Nieuwoudt et al., 2017). In these cells, ES increases basal glucose 
uptake and PKB phosphorylation and electrically stimulating cells before 
palmitate treatment prevented the ~50 % decrease in insulin-stimulated glucose 
uptake and recovered insulin sensitivity and PKB response (Nieuwoudt et al., 
2017). It is plausible, given data shown here and by others (Jaimovich et al., 
2011; Osorio-Fuentealba et al., 2013) that the effect of ES on basal insulin 
signalling is dependent on eATP arising from contraction. This may also 
represent a role for eATP as an exercise mimetic, acting as a stimulus for glucose 
uptake during increased energy demand.  
Summary and future work 
For the first time, treatment of C2C12 myotubes with a non-hydrolysable 
purinergic receptor agonist led to upregulated glucose transport coupled with an 
increase in glucose metabolism. Manipulating eATP by hydrolysis with apyrase 
or directly treating cells with ATPγS demonstrated that palmitate-induced effects 
on anabolic sensitivity and inflammation are unlikely to be mediated by eATP, as 
originally hypothesised. Instead, cells may release ATP in response to long-term 
SFA exposure in an effort to recover impaired glucose and protein metabolism, 
particularly when the requirement for glucose uptake is high, such as during 
exercise.  
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Further experimentation is required to elucidate the whole body metabolic effects 
of extracellular nucleotides and nucleosides. For instance, UTP, a potent P2Y2R 
agonist, promotes glucose uptake in C2C12 myotubes (100 μM, 20 minutes, 1.8-
fold increase) in a similar manner to ATP (2-fold increase compared to vehicle) 
(Kim et al., 2002). Furthermore, adenosine, acting via P1 receptors, increases 
insulin-stimulated glucose uptake in SM (Vergauwen, Hespel and Richter, 1994; 
Takasuga et al., 1999; Liu et al., 2001) and AT (Takasuga et al., 1999) (reviewed 
by Koupenova and Ravid, 2013). Given the wide range and pattern of expression 
of P2Rs (Volonté et al., 2006; Burnstock and Verkhratsky, 2009) and P1Rs 
(Sheth et al., 2014) across different tissues and their differential affinity for 
multiple nucleotides and nucleosides, an in vivo approach will be more relevant 
to establish these effects going forward. In rodents, it would be possible to assess 
the effect of P2Y2R agonists and antagonists on glucose metabolism during 
hyperinsulinaemic-euglycaemic clamps, coupled with glucose tracers to assess 
insulin sensitivity and glucose metabolism in metabolic tissues. It would also be 
valuable to assess these responses following HFD-induced obesity and in 
models of diabetes to further elucidate the involvement of the purinergic signalling 
system on whole-body energy metabolism. 
These advancements have the potential to become highly translatable to human 
health and disease as ATP is readily available as an oral supplement. Oral ATP 
supplementation has already demonstrated beneficial effects on exercise 
tolerance, and post-exercise hypertrophy and recovery (Wilson et al., 2013; de 
Freitas et al., 2018) so the added observation that it may decrease glycaemia 
and upregulate protein synthesis would make it a valuable therapeutic target 
and/or tool for conditions characterised by insulin and anabolic resistance.  
             
         








The effect of high-fat overfeeding on glucose and 










Introduction  Chapter 4 
131 
Introduction 
Adequate maintenance of SM mass is a key determinant of quality of life and 
metabolic health and is driven by the balance between muscle protein synthesis 
(MPS) and muscle protein breakdown (MPB). The inability of SM to appropriately 
synthesise new protein in response to anabolic stimuli such as protein and AA 
ingestion is termed anabolic resistance and represents an important contributing 
factor for the loss of muscle mass and function observed during ageing, disuse 
and critical illness (Rennie, 2009; Wall and van Loon, 2013; Wall et al., 2015). 
This loss of muscle mass and strength is also aggravated and occurs more 
rapidly in metabolic disease, such as in T2D (Park et al., 2006; Leenders et al., 
2013). Importantly, health/disease states where anabolic resistance is evident 
are also associated with reduced insulin sensitivity (Stuart et al., 1988; Mikines 
et al., 1991; Alibegovic et al., 2009; Dirks et al., 2016), and it is believed that that 
lipid overflow contributes to the development of both phenomena, as discussed 
in Chapter 3. The relationship between insulin and anabolic resistance and the 
likely contribution of elevated FA availability to impaired AA metabolism and 
protein synthesis are incompletely understood and a better elucidation of these 
mechanisms is required to develop therapeutic approaches to improve metabolic 
health and quality of life. 
It is clear from data demonstrated and discussed in Chapter 3, that lipid overflow 
impairs intracellular anabolic signalling responses to insulin and AA treatment in 
muscle cells. However, it remains unclear whether intracellular impairments arise 
as a consequence of diminished substrate delivery to SM, particularly considering 
that the vasodilatory response to insulin is diminished in ageing (Meneilly et al., 
1995) and microvascular function becomes impaired in T2D and exacerbates 
muscle loss (Groen et al., 2014). The temporal regulation of these phenomena is 
also not completely understood, and given the important anabolic role of insulin 
in stimulating MPS (Bennet and Rennie, 1991; Biolo et al., 1995), it is important 
to establish whether anabolic resistance is partly mediated by the loss of insulin 
anabolism in insulin resistant conditions. The association between lipid-induced 
IR and anabolic resistance has been seen across different models. For example, 
in mice (Anderson et al., 2008) and rats (Masgrau et al., 2012), diet-induced 
obesity impairs activation of MPS in response to feeding, in a manner that is 
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associated with chronic intramuscular lipid infiltration (Masgrau et al., 2012). 
Furthermore, compared to lean individuals, obese women demonstrate impaired 
whole-body protein anabolic responses to hyperinsulinaemia and 
hyperaminoacidaemia (Chevalier et al., 2005), and MPS in response to these 
stimuli is negatively related to whole-body fat mass in humans (Guillet et al., 
2004). However, although associated, the contribution of lipid-induced IR to 
anabolic resistance remains unclear. Independently from overfeeding or lipid 
infusions, SM disuse also leads to loss of muscle mass, associated with 
increased body fat (Ferrando et al., 1996; Brooks et al., 2008), loss of strength 
(Rudrappa et al., 2016) and the development of IR (Mikines et al., 1991; Biensø 
et al., 2012). Therefore, experimental models of disuse can be used to investigate 
the development of insulin and anabolic resistance (which may be partly 
mediated by impaired lipid homeostasis) separately from lipid overflow.  
Muscle disuse, which can result from physical inactivity during critical illness, 
recovery from trauma or chronic inactive behaviour, has been extensively 
modelled experimentally by strategies including bed rest (systemic) and forearm 
or leg immobilisation (local) (Rudrappa et al., 2016). In otherwise healthy 
humans, long periods of disuse (10-42 days) lead to a rate of muscle loss of ~0.5-
0.6 % per day (reviewed in (Phillips et al., 2009; Wall and van Loon, 2013) and 
disuse-induced atrophy is accompanied by decreased functional capacity 
(Deitrick, 1948; Gibson et al., 1987), basal metabolic rate (Haruna et al., 1994), 
insulin sensitivity (Stuart et al., 1988; Mikines et al., 1991; Dirks et al., 2016) and 
glucose tolerance (Yanagibori et al., 1994; Dirks et al., 2016). In bed rest studies, 
reduced glucose tolerance and insulin sensitivity is seen after only 3 days 
(Lipman et al., 1972; Yanagibori et al., 1994; Dirks et al., 2016) and these become 
significantly impaired after 7-9 days, as seen during hyperinsulinaemic-
euglycaemic clamps in healthy humans (Lipman et al., 1972; Kenny et al., 2017). 
Bed rest represents a clinically relevant model, reflecting disuse in periods such 
as hospitalisation, but does not eliminate the systemic effects contributing to 
muscle atrophy, such as systemic inflammation (Drummond et al., 2013; Mutin-
Carnino et al., 2014), vascular dysfunction (Hamburg et al., 2007), impaired 
hormonal homeostasis (Choukèr et al., 2013; Guerra et al., 2014) and whole-
body insulin sensitivity (Bergouignan et al., 2011). 
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A model of local inactivity, such as leg or forearm immobilisation, makes it 
possible to better isolate the mechanisms regulating muscle function while 
individuals remain active and maintain habitual food intake (or consume 
controlled diets as experimental interventions). Leg immobilisation for 7 days 
leads to an approximate 15-25 % impairment in muscle glucose uptake (Richter 
et al., 1989) and after 14 days leads to a ~30 % impairment in protein synthetic 
response to protein ingestion (Wall, Snijders, et al., 2013). Changes to MPS 
during bed rest and limb immobilisation have been observed without apparent 
increases in MPB (Gibson et al., 1987; Phillips et al., 2009), suggesting that 
atrophy during disuse is primarily mediated by an impairment in MPS in response 
to anabolic stimuli (Ferrando et al., 1996; Symons et al., 2009). 
The mechanisms of disuse-induced insulin and anabolic resistance remain 
unclear but it is believed that alterations in lipid metabolism, particularly 
accumulation of intramyocellular lipid and lipotoxic metabolites may contribute to 
the development of these impairments. Indeed, prolonged periods of disuse (> 4 
weeks) are associated with IMCL accumulation (Manini et al., 2007; Cree et al., 
2010) and shorter periods of disuse have demonstrated changes to DAG 
metabolism and PKC signalling (Dirks et al., 2016, 2018), which are directly 
implicated in the development of IR (Bosma et al., 2012). Independently of 
disuse, increase in lipid availability by direct intravenous infusion of lipid not only 
directly impairs insulin sensitivity (Kruszynska et al., 2002) but also inhibits AA-
induced increase in MPS in healthy men (Stephens et al., 2015). It, therefore, 
remains to be understood whether disuse brings about impairments in insulin and 
anabolic resistance by altering lipid metabolism (in a manner known to induce IR) 
and whether lipid overflow per se (or IR) alters AA metabolism to drive loss of 
muscle mass.    
The study presented in this chapter addresses these questions by aiming to 
determine the effect of lipid availability on the development of inactivity-induced 
insulin and anabolic resistance. This was assessed by applying the arterialised 
venous-deep venous (AV-V) forearm balance method prior to and following 2 and 
7 days of forearm immobilisation in young healthy males.  
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Dietary intake was controlled during immobilisation and participants consumed a 
eucaloric control diet or hypercaloric high-fat diet (providing an additional 50 % 
energy from fat) to better understand the role of lipid overflow per se on the 
development of insulin and anabolic resistance during disuse. A local model of 
inactivity (forearm immobilisation) was used as it induces muscle disuse in an 
isolated limb whilst only moderately impacting daily living (less invasive than leg 
immobilisation) and experimental test days were conducted after 2 and 7 days of 
immobilisation to establish whether the substantial IR seen following 7 days of 
disuse (Dirks et al., 2016) is already present after 2 days. It was hypothesised 
that the 2.5 fold increase in dietary fat (during HFD) would exacerbate the early 
development of insulin resistance by diminishing insulin-stimulated glucose 
uptake following mixed meal drink consumption and immobilisation would impair 
AA balance across the forearm in a manner that was also accelerated by high-fat 
overfeeding.  
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 Results 
Thirteen healthy young males (age 25 ± 2 years) were subjected to 7 days of 
forearm immobilisation under one of two dietary interventions, controlled 
eucaloric diet (CON) or hypercaloric diet providing 50 % excess energy from fat 
(HFD). Eligible participants underwent a baseline visit where the AV-V sampling 
method was employed alongside measures of blood flow to access substrate 
utilisation prior to intervention. Subjects returned to the lab for a casting visit 
where forearm immobilisation and dietary intervention were initiated. After 2 and 
7 days of immobilisation, participants returned to the lab for experimental days. 
Detailed study schematics, test day schematics and participant characteristics 
before the start of the study can be found under Methods (2.3). 
4.1 Dietary intervention 
The two experimental groups did not differ in any of the participant characteristics 
prior to the start of the study. Habitual dietary intake was not different between 
participants in eucaloric diet (CON; n=8) or high-fat diet (HFD; n=5) groups 
(Figure 4.1A; P>0.5 for all parameters). Compared to habitual diet, controlled 
diets during immobilisation both showed lower protein and higher CHO content 
(in percentage energy, % en, for both, P<0.01 and g·d-1 CHO for HFD P≤0.01). 
Caloric intake in HFD was 1.5 fold higher than in CON (P<0.001), which was 
primarily attributed to a 2.5 fold increase in fat content (g·d-1; P<0.001), 
particularly saturated fat (3.6 fold higher in HFD compared to CON; P<0.001). 
During immobilisation dietary protein content was matched between groups (1.2 
± 0.0 g·KgBW·d-1; P>0.05) so that protein intake did not differ between diets. To 
maintain the target macronutrient composition of the diets, the volume of the 
mixed meal drink (Ensure Plus, Abbott Nutrition) taken at t= 0 on baseline, day 2 
and day 7 was adjusted so that 0.2 g fat, 0.3 g protein and 1.1 g CHO (g·KgBW·d-
1) were ingested in both groups. Participants in the CON diet maintained body 
mass throughout the immobilisation period, whereas this significantly increased 
in the HFD group (1.1 Kg ± 0.45 for day 7 against baseline; P<0.05; Figure 4.1B) 
suggesting that individuals in CON groups maintained energy balance whereas 
individuals in the HFD groups were on positive energy balance, as expected. 
 









Figure 4.1 Dietary intake and body weight prior to and during 7 day 
immobilisation 
A) Dietary intake prior to and during 7 day immobilisation period for young 
healthy male volunteers (n=13) allocated to eucaloric controlled diet (CON; n=8) 
or high-fat diet providing 50 % excess energy from fat (HFD; n=5).  Parameters 
of habitual food intake were taken from self-reported 3-day food diaries prior to 
the start of the study and controlled diet during immobilisation was calculated 
and provided by the research team. **P<0.05 for habitual diet relative to 
controlled diet; #P<0.05 for CON against HFD during immobilisation (unpaired 
t-test). B) Body weight (Kg) prior to and after 2 and 7 days of immobilisation. No 
change in CON groups after 7 days (n=5; P>0.05) but significant increase in 
HFD group after 7 days (n=5; P<0.05) assessed using unpaired t-tests between 
day 7 and baseline.  
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4.2 Forearm muscle function is impaired following 7 days of immobilisation 
Forearm muscle strength was assessed using a hand-held dynamometer prior to 
and after 7 days of immobilisation and represented as percentage change in 
strength (Kg) from pre-immobilised period. Muscle strength was comparable at 
baseline between CON and HFD groups and no changes were observed in the 
non-immobilised arm after immobilisation. In the casted arm, immobilisation 
decreased strength by 17.4 ± 3.4 % and 17.5 ± 2.1 % in CON and HFD groups, 
respectively, demonstrating an effect of disuse on function which was not 
exacerbated by HFD (P(day)<0.001, P(intervention)>0.05; Figure 4.2). 
4.3 Glucose balance across the forearm is altered by immobilisation but not 
exacerbated by HFD 
Arterialised plasma glucose levels were measured prior to and after consumption 
of a mixed meal drink (at t=0) before and after 2 and 7 days of immobilisation 
(Figure 4.3A,B). No differences were observed in fasting glucose levels across 
immobilisation for either CON or HFD groups (P>0.05) where fasting arterialised 
venous glucose in CON was 4.4 ± 0.06 mmol/L at baseline, 4.2 ± 0.16 mmol/L on 
day 2 and 4.38 ± 0.1 mmol/L on day 7 and in HFD was 4.4 ± 0.15 mmol/L at 
baseline, 4.6 ± 0.19 mmol/L on day 2 and 4.5 ± 0.19 mmol/L on day 7. Mixed 
meal drink consumption significantly increased arterialised venous plasma 
glucose in both CON (n=8; Figure 4.3A) and HFD (n=5; Figure 4.3B) 
(P(time)<0.001 for both) at all days. In CON group significant changes from fasting 
glucose levels were seen in the first 120 minutes at baseline (peaked at 40 
minutes 6.6 ± 0.2 mmol/L), between 20-60 minutes at day 2 (peak at 40 minutes 
6.6 ± 0.2 mmol/L) and between 40-140 minutes at day 7 (peak at 40 minutes 6.1 
± 0.2 mmol/L), with levels returning to fasting concentrations at baseline and day 
2 but remaining elevated at day 7 (P<0.05 for 180 against 0 on day 7; Figure 
4.3A). In HFD group no significant changes from fasting concentrations were 
observed at baseline (peaked between 40-60 minutes 5.9 ± 0.4 mmol/L) and day 
2 (peaked between 40-60 minutes at 5.4 ± 0.3 mmol/L) (P>0.05) with the time 
effect being attributed to a significant increase in glucose after 20 minutes at day 
7 (peak at 20 minutes 5.8 ± 0.3 mmol/L) (P<0.05; Figure 4.3B). No changes were 
observed in total area under the curve indicating that the same total amount of 
glucose was available across all days (insets Figure 4.3A-B).   
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The difference between arterialised venous and venous blood glucose was 
assessed to infer on glucose balance across the forearm during immobilisation. 
Combined analysis of CON and HFD groups at baseline and day 7 demonstrated 
that mixed meal drink consumption increased AV-V glucose balance 
(P(time)<0.001), whereas this effect was attenuated by immobilisation (P(day)<0.01) 
demonstrating a time*day interaction (P(interaction)<0.001). Fasting AV-V difference 
was not altered by immobilisation or diet (average fasting AV-V in CON across 
all days = 0.09 ± 0.03 compared to HFD = 0.17 ± 0.03). Postprandial AV-V 
difference decreased during immobilisation (P(day)<0.05) but no effect of diet was 
observed. In the CON group, postprandial AV-V difference peaked at 40 minutes 
in baseline (0.88 ± 0.2 for 40 minutes compared to fasting 0.15 ± 0.07 mmolL-1; 
P>0.05 baseline) and day 2 (0.5 ± 0.08 for 40 minutes compared to fasting 0.04 
± 0.01 mmol-1 ; P<0.01) but this increase was not observed after 7 days (0.3 ± 
0.2 mmolL-1 at 40 minutes compared to 0.1 ± 0.04 mmolL-1 at fasting; P>0.05; 
Figure 4.3C). This is also reflected when taking into account total postprandial 
AV-V glucose balance calculated as the area under the curve for the 180 minute 
postprandial period, which demonstrated a 67.28 % decrease after 2 days 
(P<0.01) and additional 12 % decrease after 7 days of immobilisation (P<0.05 for 
day 2 and 7 vs baseline; P>0.05 day 7 vs day 2; Figure 4.3E). In the HFD group 
there was a significant increase in AV-V balance after 60 minutes at baseline (1.1 
± 0.1 at 60 minutes compared to 0.2 ±0.06 mmolL-1 at fasting; P≤0.01) and after 
40 minutes on day 2 (0.5 ± 0.04 at 40 minutes compared to 0.13 ± 0.05 at fasting; 
P<0.05) but no differences were seen at day 7 (P>0.05) (Figure 4.3D). Across 
the postprandial period, total AV-V glucose balance decreased by 56.6 % after 2 
days (P<0.05 against baseline) and further 12% between days 2 and 7 (P>0.05 
compared to day 2; Figure 4.3E). These data suggest that the balance of glucose 
across the forearm was impaired after 2 days of immobilisation irrespective of 
consumption of a eucaloric or HFD, and this was not significantly aggravated by 




















Figure 4.2 Functional impairment following immobilisation is not 
exacerbated by HFD 
Mean (± SEM) percentage loss in grip strength following 7 days of forearm 
immobilisation in healthy, young males in either eucaloric controlled diet 
(CON; n=8) or high fat diet (HFD; n=5) groups. Data analysed as percentage 
change from pre-immobilisation for both immobilised and non-immobilised 
forearms with two-way ANOVA (time x intervention) showing significant 
immobilisation effect (***P<0.001) but no difference between interventions 
(P>0.05). 










Figure 4.3 Arterialised-venous deep-venous forearm glucose balance is 
impaired following immobilisation but not exacerbated by HFD 
Arterialised venous glucose concentration at baseline and following 2 and 7 days of 
immobilisation in healthy young males fed a controlled eucaloric diet (CON; n=8) (A) 
or a high fat diet providing 50 % excess energy from fat (HFD; n=5) (B) assessed 
during 180 minutes after consumption of a mixed meal drink (t=0). Significant time 
effect in CON and HFD (P(time)<0.001) with no change caused by immobilisation 
(P(day)>0.05), two-way repeated measures ANOVA with Bonferroni’s multiple 
comparisons. Insets in A and B represent total area under the curve (AUC) for the 
180 minute postprandial period. Arterialised-venous deep-venous (AV-V) forearm 
glucose balance at baseline and following 2 and 7 days of immobilisation for subjects 
in CON (C) or HFD (D) groups and representative AUC for the 180 minute 
postprandial in E. Significant effect of drink consumption and immobilisation in CON 
(P(time)<0.01, P(day)<0.05) and HFD (P(time)<0.01, P(day)<0.05) with two way ANOVA 
with repeated measures. E) AUC was significantly lower at day 2 and day 7 
compared to baseline in CON (**P<0.01) and day 2 and day 7 compared to baseline 
in HFD (#P<0.05); two-way ANOVA with Bonferroni’s multiple comparisons. 
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4.4 Forearm immobilisation for 7 days does not alter brachial artery blood 
flow under eucaloric or HFD.  
To achieve a true measure of net glucose balance, the Fick’s Principle was 
applied (Methods 2.4.7.1). Brachial artery assessments were made prior to and 
during 180 minute postprandial period following mixed meal drink consumption 
before and after 2 and 7 days of forearm immobilisation (Figure 4.4). 
Immobilisation did not alter brachial artery area (Figure 4.4A,B), velocity (Figure 
4.4C,D) or blood flow (Figure 4.4E,F), calculated as the product between area 
and velocity, in CON (A,C,E) or HFD (B,C,D) groups (P(day)>0.05 for all 
parameters). In CON group, a time effect was observed in area (A), velocity (C) 
and blood flow (E) (P(time)<0.05) but no differences from fasting levels were 
detected with multiple comparisons. The same was the case for velocity (D) and 
blood flow (F) in HFD group but no time effect was observed on arterial area (B) 
(P(time)>0.05). There was a trend towards higher blood flow in the HFD group 
across immobilisation (P(day)=0.08; Figure 4.4F).  
4.5 Forearm glucose uptake is impaired following immobilisation but not 
exacerbated by HFD  
Forearm glucose uptake (FGU) was calculated as the product of the AV-V 
glucose balance (Figure 4.3C,D) and brachial blood flow (Figure 4.4E,F). In CON 
group, as blood flow was unchanged during immobilisation, FGU closely 
resembles AV-V balance (Figure 4.5A). Significant time (P(time)<0.01) and 
immobilisation (P(day)<0.05) effects were observed in CON (Figure 4.5A). Across 
the 180 minute postprandial period, total glucose uptake calculated as total area 
under the curve was reduced by 57.5 % after 2 days and by a further 43 % by 
day 7 in CON (P<0.05 and P<0.01 for day 2 and 7 vs baseline, respectively; 
Figure 4.5C). In the HFD group, a significant time effect was seen (P(time)<0.05) 
but the effect of immobilisation was not significant (P(day)>0.05; Figure 4.5B). Total 
postprandial glucose uptake decreased by 38.5% after 2 days and an additional 
15 % by day 7 in the HFD group (Figure 4.5C) but these effects did not reach 
statistical significance. No difference was observed between diets (P>0.05 HFD 
compared to CON; Figure 4.5C).  











Figure 4.4 Brachial arterial area, velocity and blood flow are not altered 
by immobilisation, irrespective of energy balance.  
Brachial artery area (A, B), blood velocity (C,D) and blood flow (E,F) following 
mixed meal drink consumption (at t=0) prior to and following 2 and 7 days of 
forearm immobilisation in young healthy males (n=13), measured using 
Doppler Ultrasound. During immobilisation participants were subjected to 
eucaloric controlled diet (CON; n=8) (A,C,E) or high-fat diet providing 50 % 
excess energy from fat (HFD; n=5) (B,D,F). All parameters except HFD 
arterial area (B) showed a time effect (P(time)<0.05) but no interaction with 
intervention by two-way ANOVA with repeated measures.   
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4.6 Serum insulin concentrations and calculated whole body insulin 
sensitivity are not altered by forearm immobilisation under eucaloric or 
HFD 
Insulin was measured in serum from arterialised blood samples prior to and post 
immobilisation. Mixed meal drink consumption significantly increased insulin 
concentrations in both CON (P(time)<0.001; Figure 4.6A) and HFD (P(time)<0.001; 
Figure 4.6B) groups but no effect of immobilisation or diet were observed 
(P(day)>0.05 and P(intervention)>0.05 for both; Figure 4.6A,B). Total serum insulin 
across the postprandial period was not altered by immobilisation or diet (P>0.05 
for day and intervention; Figure 4.6C). Matsuda index was calculated to infer 
whole-body insulin sensitivity, reflecting rate of glucose disposal into insulin 
sensitive tissues, primarily SM (Defronzo, 1999) and the homeostatic model 
assessment of insulin resistance (HOMA-IR) was used as a proxy for IR (primarily 
hepatic) and β-cell function (Matthews et al., 1985). Matsuda (Figure 4.6D) and 
HOMA-IR (Figure 4.6E) indices did not reveal a significant effect of immobilisation 



















Figure 4.5 Forearm glucose uptake is impaired following immobilisation 
but not exacerbated by HFD 
Forearm glucose uptake (FGU) at baseline and following 2 and 7 days of 
forearm immobilisation from young healthy males fed an eucaloric controlled 
diet (CON; n=8) (A,C) or high fat diet providing 50 % excess energy from fat 
(HFD; n=5) (B,C). FGU was calculated as the product of the AV-V difference 
in glucose and brachial arterial blood flow. C) Total forearm glucose uptake 
calculated as area under the curve from A and B over the 180 minute 
postprandial period. Significant effect of immobilisation (P(day)<0.05) but diet 
(P(intervention)>0.05 for total FGU. *P<0.05 against baseline in CON.  
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Figure 4.6 Insulin levels and insulin sensitivity are not altered by forearm 
immobilisation under eucaloric or HFD 
Arterialised-venous (AV) serum insulin concentrations at baseline and 
following 2 and 7 days of forearm immobilisation in healthy young males fed 
a eucaloric control diet (CON; n=8; A) or a high-fat diet providing 50% excess 
energy from fat (HFD; n=5; B). C) Total area under the curve (AUC) for the 
180 minute postprandial period following ingestion of a mixed meal drink in 
CON and HFD groups. No effect of immobilisation or diet on insulin 
concentrations (P(day)>0.05, P(intervention)>0.05) with two-way ANOVA with 
Bonferroni’s multiple comparisons. D) Matsuda index E) Homeostatic Model 
Assessment of Insulin Resistance (HOMA-IR). No differences in insulin 
sensitivity indices. 
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4.7 Immobilisation did not alter leucine and phenylalanine availability under 
eucaloric or HFD 
Leucine and phenylalanine concentrations were measured in arterialised-venous 
and venous plasma samples before and after immobilisation in CON and HFD 
groups. Mixed meal drink consumption significantly altered the levels of 
arterialised plasma leucine in CON (P(time)<0.001; n=8; Figure 4.7A) and HFD 
(P(time)<0.05; n=5; Figure 4.7B) and phenylalanine in CON (P(time)<0.001; n=8; 
Figure 4.7C) and HFD (P(time)<0.001; n=5; Figure 4.7D). Neither immobilisation 
nor dietary intervention significantly altered arterialised leucine (P(day)>0.05, 
P(intervention)>0.05; Figure 4.7E) or phenylalanine (P(day)>0.05, P(intervention)>0.05; 
Figure 4.7E) concentrations. As blood flow was not altered by immobilisation or 
diet (Figure 4.4) these data indicate that AA delivery into the forearm was not 
impaired by immobilisation.  
4.8 Net amino acid balance is altered by immobilisation and HFD 
Impairments in AA uptake may be a driving mechanism for anabolic resistance. 
The net balance of leucine and phenylalanine were therefore measured to assess 
the impact of immobilisation and high-fat overfeeding on AA uptake. Leucine 
balance across the forearm was calculated by normalising the AV-V difference in 
AA concentration to blood flow in the fasting period and in the first 60 minutes 
following mixed meal ingestion. An effect of immobilisation and diet was seen in 
fasting net leucine balance (P(day)<0.05, P(intervention)<0.05) which was attributed to 
a significantly lower net balance in HFD compared to CON after immobilisation 
(P<0.05 for day 7 between HFD and CON; Figure 4.8A). The negative fasting net 
leucine balance seen before immobilisation (Figure 4.8A) was acutely reversed 
by mixed meal drink consumption in both CON and HFD (Figure 4.8B). Mixed 
meal drink consumption did not revert negative fasting balance after 
immobilisation in CON or HFD groups. Positive net balance seen at baseline in 
the postprandial period was significantly altered by immobilisation (P(day)≤0.01). 
This was attributed to a significant difference in leucine balance after 
immobilisation in CON group (P<0.05 for day 7 vs baseline in CON; n=8; Figure 
4.8B). 
 










Figure 4.7 Immobilisation did not alter leucine and phenylalanine 
availability under eucaloric or HFD 
Arterialised-venous (AV) plasma leucine concentrations at baseline and 
following 2 and 7 days of forearm immobilisation in healthy young males fed 
a eucaloric control diet (CON; n=8; A) or a high-fat diet providing 50% excess 
energy from fat (HFD; n=4; B) and phenylalanine in CON (C) and HFD (D). 
Total area under the curve (AUC) in the 180 minute postprandial period 
following ingestion of a mixed meal drink in CON and HFD groups before and 
after immobilisation for leucine (E) and phenylalanine (F). No effect of 
immobilisation or diet on amino acid concentrations (P(day)>0.05, 














Figure 4.8 Net amino acid balance is altered by immobilisation and HFD 
Net balance of leucine (Leu) calculated as the product of AV-V difference in plasma 
leucine concentration and blood flow in the fasting period (A) and calculated as 
total area under the curve for the first 60 minutes following ingestion of mixed meal 
drink (B)  prior to (baseline) and after 7 days of forearm immobilisation in young 
healthy males fed a eucaloric controlled diet (CON; n=8) or a high fat diet providing 
50 % excess energy from fat (HFD; n=4). C) Fasting net balance in plasma 
phenylalanine (Phe) levels before and after immobilisation in CON and HFD 
groups. D) Net balance of phenylalanine calculated as area under the curve for the 
first 60 minutes following mixed meal drink ingestion before and after 
immobilisation in CON and HFD group. Significantly immobilisation and diet effect 
in fasting leucine balance (P(day)<0.05, P(intervention)<0.05), diet effect in fasting Phe 
(P(intervention)<0.05), and immobilisation in postprandial net balance of Leu and Phe 
(P(day)<0.05) with two-way ANOVA with Bonferroni’s multiple comparisons. *P<0.05 
for HFD against CON, $P<0.05 for day 7 against baseline.  
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Discussion 
It is well-established that excessive lipid availability brings about IR in SM cells 
(in vitro), acting via mechanisms described in the main introduction to this thesis 
and discussed in Chapter 3. In Chapter 3, treatment of skeletal muscle cells with 
high concentrations of palmitate led to loss of anabolic sensitivity, demonstrated 
as blunted activation of intracellular signalling proteins in the insulin/PKB and 
mTOR/S6K1 intracellular signalling pathways in response to acute treatment with 
insulin and mixed EAAs. These data suggest that lipid overflow induces insulin 
and anabolic resistance by impairing intracellular signalling. However, it is not 
known whether these lipid-induced intracellular impairments arise as a 
consequence of reduced substrate (glucose, AAs) delivery in vivo nor whether 
loss of the anabolic effect of insulin (in IR conditions) drives anabolic resistance.  
To study insulin and anabolic resistance in humans, a model of SM disuse was 
used here, as physical inactivity (modelled by bed rest and limb immobilisation 
disuse models) induces insulin (Bergouignan et al., 2011) and anabolic 
resistance (Symons et al., 2009; Breen et al., 2013; Tanner et al., 2015) and 
causes muscle atrophy. Furthermore, it has been shown in experimental models 
of disuse that prolonged (> 4 weeks) bed rest or limb suspension causes 
substantial IMCL accumulation, ranging from 15 % to 75 % increase in 
intramyocellular lipid content (Manini et al., 2007; Cree et al., 2010). As lipid 
infusion in humans directly induces insulin resistance (Kelley et al., 1993; 
Stephens et al., 2015), and muscle lipid accumulation is negatively correlated 
with insulin sensitivity, this has in the past been hypothesised to be a likely driver 
of disuse-induced IR. However, such overt accumulation of lipid is not apparent 
after 5-7 days of disuse (Wall et al., 2015; Dirks et al., 2016), suggesting that 
IMCL accumulation per se does not participate in the rapid development of IR. 
Independently of triglyceride accumulation, changes in DAG metabolism (Dirks 
et al., 2016) and PKCθ gene expression have been observed in the first week of 
disuse (Dirks et al., 2018), and DAG-PKC signalling directly contributes to the 
development of IR (Bosma et al., 2012). It remains unknown, however, whether 
these changes drive insulin and anabolic resistance and whether a positive 
energy balance driven by fat overfeeding would exacerbate the effects seen by 
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disuse. By investigating the development of these disuse-induced metabolic 
impairments in energy balance and lipid overflow (by high fat overfeeding), the 
role of lipid per se can be investigated. As such, participants in this study were 
subjected to 7 days of forearm immobilisation and fed a controlled eucaloric diet 
or high-fat diet providing excess 50 % energy from fat during immobilisation.  
Data in this chapter demonstrated that forearm immobilisation caused both 
functional and metabolic impairments to forearm muscle tissue. Grip strength, 
used as a functional output, decreased ~17 % after 7 days of immobilisation, 
irrespective of energy balance. The magnitude of this change is equivalent to that 
seen after 21 days of forearm immobilisation (17-20 %) (Kitahara et al., 2003; 
Miles et al., 2005; Matsumura et al., 2008), suggesting that functional decline is 
already present at 7 days and is not exacerbated by a longer period of 
immobilisation. To study in vivo muscle metabolism, the forearm AV-V balance 
technique was applied, which is a well-established method to measure glucose 
uptake across the forearm (Lipman et al., 1970, 1972; Jackson et al., 1987; 
Richter et al., 1989) and other metabolites (Forster et al., 1972; Abumrad et al., 
1981; Sonnenberg and Keller, 1982) and enables simultaneous sampling of 
arterialised venous and deep venous blood draining directly from the forearm 
muscle tissue (Jackson et al., 1987).  
In this study, it was demonstrated for the first time that disuse-induced muscle IR 
is evident after only two days of immobilisation, manifested by > 50 % decrease 
in insulin-stimulated glucose uptake to the forearm muscle bed, which was not 
aggravated by an additional 5 days of immobilisation. Contrary to the hypothesis, 
these effects were not altered by lipid overflow from HFD. In addition, it was 
demonstrated for the first time that immobilisation did not impair postprandial-
mediated increase in blood flow. The effect of 7 days of immobilisation on glucose 
uptake seen here is in agreement with others demonstrating 30-40 % decrease 
in insulin sensitivity following one week of disuse (Mikines et al., 1991; Alibegovic 
et al., 2009; Dirks et al., 2016; Dirks et al., 2019). Work by Dirks and colleagues 
suggests that disuse-induced IR occurs between day 1 and 3 of muscle disuse, 
and plateaus thereafter. One day of bed rest is not sufficient to significantly affect 
whole-body insulin sensitivity, irrespective of energy balance (Dirks et al., 2018), 
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which is likely a protective mechanism to resist the deleterious metabolic effects 
of short periods of physical inactivity, such as during sleep. However, by day 3 of 
bed rest, insulin sensitivity diminishes (Yanagibori et al., 1994) and after 5-7 days 
glucose disposal declines by ~ 30 %, assessed during hyperinsulinaemic-
euglycaemic clamps (Dirks et al., 2016). Here, the systemic effects of bed rest 
models are eliminated as forearm immobilisation induces muscle disuse in an 
isolated limb. As this was used in combination with the AV-V balance technique 
(sampling blood draining directly from the forearm muscle bed) these data 
suggest that removal of muscle contraction leads to a more rapid decline in 
muscle glucose uptake (compared to bed rest) likely due to an immediate loss of 
substrate requirement. This also expands on current knowledge by confirming 
earlier suggestions that bed-rest induced whole-body IR occurs primarily in SM 
(Stuart et al., 1988) and supports the use of the forearm immobilisation model to 
quantify glucose uptake as a direct measure of muscle insulin sensitivity. It is 
intriguing that the additional 5 days of disuse here did not cause more substantial 
impairments, particularly as muscle loss with immobilisation is substantially 
decreased at the earlier stages but continues at a reduced rate for an extended 
period of time (Wall and van Loon, 2013). It is plausible that motor unit recruitment 
is diminished early on due to reconditioning and that this precedes atrophy 
(Kawakami et al., 2001; Deschenes et al., 2002; de Boer et al., 2007; Farthing et 
al., 2009) or that changes to intracellular delivery/signalling occur early on and 
become rate-limiting so that no further aggravation is seen. Understanding the 
time course of development of these impairments is critical, however, as the first 
few days bring about the greatest loss of muscle mass and strength (primarily 
driven by anabolic resistance) (White, Davies and Brooksby, 1984; LeBlanc et 
al., 1992; Ferrando et al., 1995; de Boer et al., 2007). 
Blood flow and arterialised glucose concentration measured here were not 
altered by immobilisation, suggesting that the haemodynamic effect of insulin in 
the postprandial period to increase blood flow (ie. substrate delivery) to insulin 
sensitive tissues was not altered (Laakso et al., 1990). However, insulin also 
controls microvascular perfusion and recruitment so it is possible that muscle 
perfusion is altered despite the unaltered arterial blood flow and glucose 
availability.  
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For example, insulin elicits its effects on muscle protein synthesis partly via 
endothelial-dependent vasodilation which enhances nutritive flow and mTORC1 
signalling (Timmerman et al., 2010) so it is possible that IR is seen at the 
endothelial level to impair glucose delivery. It is also plausible that impaired 
glucose uptake arises from blunted glucose transport into muscle, as others have 
demonstrated that 7 days of bed rest, which resulted in a 22 % decline in insulin 
sensitivity, reduced muscle GLUT4, HK and PKB expression and blunted insulin-
induced PKB and glycogen synthase activation (Biensø et al., 2012). It would be 
important to establish whether these changes are already present after 2 days of 
immobilisation by applying the forearm cast model combined with muscle 
biopsies.  
Despite the significant increase in dietary fat intake in the high-fat overfed group 
(~260 g fat per day compared to 100 g per day in CON), disuse-induced decline 
in glucose uptake was comparable between diets. This was corroborated by 
comparable HOMA-IR values between dietary interventions and no effect of HFD 
on Matsuda index, as a proxy for peripheral insulin sensitivity. These data 
suggest that, contrary to the hypothesis, high-fat overfeeding did not impact 
insulin sensitivity of the immobilised muscle tissue or systemically. This effect is 
unlikely to originate from lack of adherence to the diet from participants as the ~1 
Kg body mass gain during HFD is in line with previous observations (Parry et al., 
2017). Although most reports indicate that high-fat overfeeding induces IR after 
3-7 days (Wulan et al., 2014; Hulston et al., 2015; Lundsgaard et al., 2017), 
others have demonstrated no effect of HFD on insulin sensitivity (Adochio et al., 
2009; Brøns et al., 2009). The contribution of dietary fat to total energy intake in 
the hypercaloric diet given here (55 % en fat) is fractionally lower than fat contents 
of diets used previously (average ~ 65 %) (Bachmann et al., 2001; Hulston et al., 
2015; Lundsgaard et al., 2017; Parry et al., 2017), which may contribute to the 
lack of HFD-induced IR seen here. In addition, protein and CHO total dietary 
content were matched between HFD and CON groups here to prevent metabolic 
impairments arising from other macronutrient changes during disuse. This may 
contribute to the discrepancy with other studies, for example, demonstrating 
decreased whole-body and leg glucose disposal following 3 days of increased fat 
(75 % en fat) but not CHO availability (Lundsgaard et al., 2017) and increased 
Discussion  Chapter 4 
153 
markers of IR such as reduced CHO oxidation and increased FFAs after HFD (75 
% fat) compared to isocaloric diet (Constantin-Teodosiu et al., 2012). 
In addition to impaired glucose homeostasis, short-term disuse (5-7 days) leads 
to rapid development of muscle atrophy and loss of functional strength in both 
young (Wall et al., 2014) and old individuals (Dirks et al., 2014). For example, 
one-legged knee immobilisation for 5 days caused a ~1.4 % decline in muscle 
mass concomitant with ~9% decline in muscle strength (M. L. Dirks et al., 2014). 
Atrophy developed over longer periods of disuse (> 10 days) is also associated 
with reduced functional capacity (Deitrick, 1948; Gibson et al., 1987) and basal 
metabolic rate (Haruna et al., 1994). Muscle mass is maintained by a balance 
between MPS and MPB and evidence suggests that disuse-induced atrophy 
primarily derives from impaired postprandial response to anabolic stimuli to 
promote MPS (anabolic resistance), as opposed to increased MPB rates (Gibson 
et al., 1987; Phillips et al., 2009). The mechanisms regulating the development 
of anabolic resistance remain poorly understood but contributing factors may 
include systemically impaired protein digestion (Ferrando et al., 1996; Pennings, 
Koopman, et al., 2011), AA absorption (Pennings, Boirie, et al., 2011; Pennings, 
Koopman, et al., 2011), and microvascular perfusion (Rasmussen et al., 2006; 
Hamburg et al., 2007; Timmerman et al., 2010), and/or local impairments in AA 
uptake (Drummond et al., 2010) or intracellular signalling (Cuthbertson et al., 
2005; Fry et al., 2011). In addition, disuse impairs metabolic flexibility (Kelley and 
Mandarino, 2000) and leads to IMCL accumulation (Cree et al., 2010; 
Bergouignan et al., 2011) and given that anabolic resistance features in 
conditions marked by IR, such as T2D, ageing and disuse, it is possible that lipid-
induced IR may contribute to the development of anabolic resistance. As such, 
AA metabolism was also investigated in this study to assess whether 
immobilisation would alter AA balance and the effect of high-fat overfeeding on 
this response.  
Data in this chapter demonstrated that 7 days of forearm immobilisation did not 
alter arterialised concentration of the EAAs leucine and phenylalanine in the 
fasting or postprandial period. Mixed meal ingestion transiently increased the 
concentrations of these AAs, as expected, which along with increased circulating 
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insulin postprandially is sufficient for maximal protein anabolism (Greenhaff et al., 
2008; Moore et al., 2009; Witard et al., 2014). In addition, as blood flow was 
maintained throughout immobilisation, these data demonstrate for the first time 
that the delivery of leucine and phenylalanine to the forearm muscle bed was not 
impaired by immobilisation, regardless of energy balance. This is consistent with 
data demonstrating that the postprandial increase in plasma AA concentrations 
following 20 g bolus of dietary protein (meal like quantity) is not altered following 
14 days of leg immobilisation (Wall, Snijders, et al., 2013); and suggests that 
systemic digestion, absorption and AA availability in the muscle vicinity are 
unlikely to be the main mediator behind disuse-induced anabolic resistance.  
As muscle tissue was not collected, it was not possible to measure intracellular 
signalling/processes/energy stores to gain a better insight into the mechanisms 
regulating AA metabolism during disuse. However, net balance of leucine and 
phenylalanine were measured before and after immobilisation in the 
postabsorptive and postprandial periods. The net balance approach has been 
developed to assess simultaneous rates (combined with tracers) of protein 
synthesis and breakdown across tissues and has made important contributions 
to the study of protein metabolism (Cheng et al., 1985; Barrett et al., 1987). In 
addition, the AV-V method has been validated as primarily reflecting SM 
metabolism across leg/forearm, with minor contribution from tissues such as fat 
and skin (Macdonald, 1999; van Hall et al., 1999). Using deep-venous cannulae 
also minimises the contribution from non-muscle compartments to AV-V 
differences in AA concentrations (Macdonald, 1999; van Hall et al., 1999). 
Leucine and phenylalanine are EAAs, i.e., they cannot be synthesised de novo 
so these AAs are only available from dietary AA intake (intestinal absorption of 
dietary AA) or endogenous protein breakdown. Therefore, measuring the balance 
of an AA that is minimally metabolised (transaminated or oxidised) in SM, such 
as phenylalanine (Van Hall et al., 1999), provides a direct measure of the balance 
of synthesis and breakdown occurring across the forearm (in this study). In 
addition to phenylalanine, leucine net balance was assessed. The rate of leucine 
uptake corresponds to synthesis as well as oxidation (as leucine is transaminated 
in muscle) so net balance of leucine alone cannot be used to estimate rates of 
MPS.  
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However, leucine is a potent anabolic AA, as it alone can act to stimulate MPS 
(Atherton et al., 2010) and increasing concentrations of leucine regulate the 
amplitude of the anabolic response to protein ingestion (Breen and Phillips, 
2011). Therefore, a change in leucine net balance would have important 
functional implications for SM during disuse.  
In this study, fasting (postabsorptive) leucine and phenylalanine balance were 
reduced after immobilisation during HFD but not controlled diet. During fasting, 
the rates of protein breakdown supersede those of synthesis to result in net 
muscle protein loss whereas in the postprandial response to food intake, 
increased AA availability (Tipton et al., 1999), mainly leucine (Wall, Hamer, et al., 
2013), stimulates MPS (and inhibit breakdown) resulting in a positive net balance. 
The more negative fasting AA balance seen here after high-fat overfeeding may, 
therefore, be the result of reduced postabsorptive MPS or enhanced MPB. It is 
also possible that the moderate increase in blood flow seen during immobilisation 
in the HFD exacerbated this effect, as net balance takes into account the AV-V 
difference and blood flow. Immobilisation did not alter postabsorptive balance 
during controlled eucaloric diet. Some evidence suggests that postabsorptive 
MPS is impaired by immobilisation, manifested by ~40 % decrease (5 days 
single-leg immobilisation) (Wall et al., 2016) and 27 % decrease (14 days single-
leg immobilisation) in myofibrillar protein synthesis rate (Glover et al., 2008) and 
by others in different experimental disuse models (Gibson et al., 1987; Ferrando 
et al., 1996; Paddon-Jones et al., 2006; de Boer et al., 2007). The decline in basal 
MPS appears to occur during the initial stages of disuse (de Boer et al., 2007; 
Wall and van Loon, 2013). MPB is experimentally difficult to measure and 
therefore seldom reported (Symons et al., 2009), so measurements of 
components of the proteolytic pathways are used as markers of breakdown. Such 
markers appear to also increase transiently in the early stages of disuse (Tesch 
et al., 2008) and not change after 1-2 weeks (Abadi et al., 2009). Although some 
changes to postabsorptive MPS/MPB have been documented, others have failed 
to see changes to postabsorptive MPS with disuse (bed rest) (Drummond et al., 
2012) so a better understanding is still required of the effect of disuse and lipid 
overflow on postabsorptive AA metabolism.  
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Leucine balance increased in response to mixed meal drink consumption before 
immobilisation, as expected, but it was demonstrated here for the first time that 
immobilisation impaired this postprandial response to protein/AA ingestion (from 
mixed meal drink consumption). It was also demonstrated for the first time that 
postprandial net leucine balance diminishes in the absence of atrophy (likely 
preceding and therefore driving atrophy) and is not substantially altered by HFD. 
Although this is not a direct measure of the rate of MPS or MPB, net balance 
provides a direct measure of the net change in synthesis (and oxidation) relative 
to breakdown, as a postprandial increase in leucine concentration (as seen here) 
drives MPS (Leenders and van Loon, 2011; van Loon, 2012), offsetting negative 
balance. Disuse-induced anabolic resistance has been demonstrated by others. 
For example, hyperaminoacidaemia-induced whole-body MPS rates are impaired 
following 14 days of bed rest (Biolo et al., 2002, 2004); AA-induced MPS is 
delayed and attenuated after 14 days of single-leg immobilisation (in young 
males) (Glover et al., 2008); and 5 days of single-leg immobilisation reduces 
postprandial MPS rates by 50 % (in response to 25 g protein) (Wall et al., 2016). 
However, an effect of immobilisation on postprandial net leucine balance has not 
been reported, particularly in a forearm immobilisation model. Data in this 
chapter, therefore, provide important evidence to support the concept that the 
removal of contraction appears to represent a very potent stimulus that rapidly 
attenuates intracellular demand for glucose and highly anabolic AAs, to an extent 
that it is not altered by diet. The follow-up data from this study (e-publication 
ahead of print Dirks et al., 2019), demonstrates that non-esterified fatty acid 
(NEFA) balance increases with disuse (likely driven by increased fatty acid 
uptake into muscle) irrespective of lipid overfeeding. It is therefore plausible that 
disuse maximises insulin and anabolic resistance (relatively rapidly following loss 
of contraction) via impaired lipid metabolism, independently of diet. Cell data from 
Chapter 3 (and by others discussed in Chapter 3) suggests that lipid overflow 
induces these metabolic impairments in muscle and, independently from disuse, 
lipid overflow has demonstrated detrimental effects on anabolic sensitivity. For 
example, increased lipid availability by acute intralipid infusion, not only 
decreases glucose disposal by 20 % but also prevents the 2.2-fold increase in 
mixed MPS rate in response to AA (21 g) ingestion (Stephens et al., 2015).  
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Without a HFD non-immobilised control group in the present study, it is not 
possible to clarify whether HFD alone would alter insulin and anabolic resistance 
to the same extent, but in this study, the effect of disuse appears to supersede 
that of diet by causing substantial impairment to glucose and AA metabolism.  
The systemic and cellular mechanisms that drive disuse-induced insulin and 
anabolic resistance or mediate lipid-induced anabolic resistance remain unclear. 
Given that, here, immobilisation did not alter arterialised concentrations of 
glucose and EAAs, nor blood flow, but balance of both glucose and leucine were 
significantly impaired by immobilisation, local mechanisms such as delivery to 
intracellular pools and intracellular signalling are most likely governing these 
impairments. For instance, AA uptake is partly regulated by expression of AA 
transporters such as LAT1, SNAT2, CD98 and PAT1, all of which become 
upregulated in response to EAA ingestion (Drummond et al., 2010, 2011). The 
postprandial increase in expression of SNAT2 and LAT1 is blunted following 7 
days of bed rest (Drummond et al., 2012) but no change in mRNA expression is 
observed following 5 days of leg immobilisation (Wall et al., 2016) leading to 
inconclusive evidence for an impairment in AA uptake following disuse. Protein 
and AA ingestion also upregulate mTOR pathway signalling (Glover et al., 2010; 
Drummond et al., 2012; Wall et al., 2016) and immobilisation (5 days single-leg) 
significantly impairs postprandial activation of mTOR and 4E-BP1 (Wall et al., 
2016). Independently of disuse, lipid-induced anabolic resistance is associated 
with impaired postprandial 4E-BP1 activation and increased muscle LCFA-CoA 
and acylcarnitine content (Stephens et al., 2015), which are markers of 
incomplete lipid oxidation known to be associated with the development of IR 
(Figure 1.6). It is also clear from data presented in Chapter 3 that lipid overflow 
impairs intracellular responses to insulin and AA treatment. It remains to be 
established, however, whether increased expression of lipotoxic intermediates 
and blunted activation of these intracellular signalling pathways is already seen 
after two days of forearm immobilisation. It would also be interesting to assess 
changes to AA balance in the first two days of disuse to assess the temporal 
differences between insulin resistance (in terms of loss of insulin-stimulated 
glucose uptake) and anabolic resistance.  
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If postprandial net balance of a potent anabolic AA such as leucine is not altered 
after two days, it is possible that insulin resistance precedes anabolic resistance 
and contributes to the loss of response to AAs. IR is a plausible driver of anabolic 
resistance as insulin directly enhances protein synthesis by activation of 
mTORC1 (Proud, 2002) and stimulates endothelial vasodilation by increasing 
capillary recruitment and microvascular volume, which increases nutritive flow to 
SM (Rasmussen et al., 2006).  
Summary and future work 
Taking advantage of a minimally invasive methodology to study in vivo human 
muscle metabolism, this study demonstrated that short-term forearm 
immobilisation leads to rapid and severe muscle IR, leading to substantial 
impairment in insulin-stimulated glucose uptake after only two-days. As this was 
not exacerbated by further immobilisation or HFD, it is likely that removal of 
muscle contraction per se is the main contributor to disuse-induced IR. 
Furthermore, this study also demonstrated for the first time that postprandial 
balance of a potent anabolic AA such as leucine was decreased following 7 days 
of immobilisation, suggesting that AA uptake or synthesis (and oxidation) are 
altered by disuse. It is not possible to conclude at this time that intracellular 
signalling responses to mixed meal drink consumption were impaired by 
immobilisation, as muscle tissue was not collected, nor is it possible to conclude 
whether IR preceded anabolic resistance, as data for AA balance after two days 
are not available. However, it is possible to speculate that removal of muscle 
contraction leads to a rapid decline in energy substrate demand by skeletal 
muscle (possibly due to intracellular negative feedback loops resulting in 
diminished substrate uptake) and that this is, at least in part, driven by increased 
expression of lipotoxic metabolites in muscle (likely derived from increased NEFA 
uptake). Elucidating such mechanisms can be challenging in vivo but similarly to 
the translation seen between Chapter 3 and this chapter it is possible to use in 
vitro data to better understand the mechanisms driving the changes seen in vivo.  
A better understanding of disuse-induced anabolic resistance can be gained by 
assessing the rates of postabsorptive and postprandial MPS and MPB during 
immobilisation.  
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This can be achieved by the use of stable isotope tracers of AAs such as 
phenylalanine (L-phenylalanine, RING-D5, 99 %) and leucine (L-leucine, 1-13C, 
99 %). This technique was applied to this study during the baseline days and after 
7 days of immobilisation, however, due to the small sample size presented here, 
the data were too underpowered to be able to draw conclusions from it. It would 
be interesting, in future experiments, to apply this technology prior to and 
following two days of forearm immobilisation in order to assess alterations in 
synthesis and breakdown rates of AAs. Furthermore, as it appears that NEFA 
uptake by muscle is increased during disuse, it would be interesting to adopt 
stable isotope FA tracers to better understand the dynamic changes in lipid 
metabolism occurring during disuse and HFD.  
In conclusion, given the rapid and substantial impairments seen after a short 
period of disuse, which appears to occur regardless of energy balance, strategies 
to maintain metabolic and functional health should aim to incorporate a level of 
muscle contraction (Wall and van Loon, 2013; Dirks, Wall and van Loon, 2018) 
during periods of inactivity and improve lipid handling to diminish accumulation of 
intramyocellular lipotoxic moieties.
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Regulation of blood glucose by pharmacological 
activation of AMPK in Sprague-Dawley rats 
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Introduction 
In healthy individuals, glucose metabolism is regulated by neuroendocrine 
processes in an interplay between the pancreas, SM, liver, AT and the brain; 
acting to maintain glycaemia within a physiological range (DeFronzo, 1988). 
Impaired glucose homeostasis is a predominant feature of diabetes and 
maintaining blood glucose is a daily challenge for individuals with diabetes. This 
is especially true in T1D and advanced/insulin-treated T2D, given the increased 
risk of iatrogenic hypoglycaemia (Cryer, 2008). 
The physiological defence against hypoglycaemia termed the counterregulatory 
response (CRR), acts to prevent further decreases in blood glucose levels. 
Firstly, insulin secretion is suppressed in response to a drop within the 
physiological range. As blood glucose levels drop further, α-cell glucagon 
secretion is increased followed by adrenaline release from the adrenal medulla 
(Dagogo-Jack et al., 1993). In diabetes, severe hypoglycaemia and recurrent 
exposure to hypoglycaemic events lead to impairment of the CRR (Hedrington et 
al., 2010) as well as loss of awareness of hypoglycaemia (IHA) and may cause 
severe brain damage and death (McCrimmon and Sherwin, 2010). Impaired 
counterregulation occurs as a result of previous exposure to hypoglycaemia 
(Cryer and Heller, 1991) decreased suppression of insulin secretion 
(exogenously administered), impaired glucagon secretion and attenuated 
sympathoadrenal response, causing delayed adrenaline release and symptom 
awareness (Taborsky, Ahrén and Havel, 1998; Mundinger et al., 2015). Blunted 
glucagon release in response to hypoglycaemia is a major contributor to 
increased frequency of hypoglycaemia in T1D (Garber et al., 1976; Rizza et al., 
1979; Dagogo-Jack et al., 1993; Segel et al., 2002) and, therefore, an important 
therapeutic target to explore.  
AMPK has emerged as an important component of cellular and whole-body 
energy sensing over the past 20 years. The enzyme is allosterically activated by 
AMP (and ADP) during energy stress (such as hypoglycaemia) due to increased 
[AMP]/[ATP] ratios (Xiao et al., 2007; Oakhill, Scott and Kemp, 2012). Activation 
by AMP further stimulates AMPK activation by enhancing its phosphorylation by 
upstream kinases, such as liver kinase B1 (LKB1) (Hawley et al., 2003; Gowans 
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et al., 2013) and calcium (Ca2+)-calmodulin dependent protein kinase kinase-β 
(CAMKKβ) (Woods et al., 2005) at threonine 172 residue, a site required for full 
kinase activation (Hawley et al., 1996; Xiao et al., 2007). Binding of ADP and 
AMP to AMPK also protects the enzyme from dephosphorylation by 
phosphatases such as PP2A and PP2C (in vitro) (Davies et al., 1995; Hawley et 
al., 1995; Gowans et al., 2013). Once activated, AMPK acts to suppress anabolic 
and promote catalytic processes to increase energy availability (Hardie, 2007). 
Activated AMPK targets signalling proteins involved in pathways regulating 
protein synthesis (Inoki et al., 2003), glycolysis (Marsin et al., 2000; Bando et al., 
2005; Sakamoto and Holman, 2008), lipid metabolism (Carling, Zammit and 
Hardie, 1987) and mitochondrial homeostasis (Herzig and Shaw, 2018) (functions 
summarised in Figure 1.4). AMPK activation is also important in whole-body 
hormone and nutrient sensing (Hardie et al., 2016; Carling, 2017).  
 
Control of whole-body metabolism by AMPK is, at least in part, mediated by its 
actions in the brain (Minokoshi et al., 2004). Brain plasma glucose levels are 
lower than peripheral levels and maintained at a narrower range (0.5-2.5 mmol/L) 
(Gruetter et al., 1992). Deviations from this range are sensed by populations of 
glucose-sensing neurones such as GE and GI neurones (Song et al., 2001) in 
various neuroendocrine brain regions, such as the hypothalamus and hindbrain 
(Levin et al., 2004). Other glucose sensors are present in the hepatoportal vein, 
gut, carotid body and oral cavity and these constitute important entry points 
relaying neuroendocrine information to the brain (Adachi et al., 1984; Watts and 
Donovan, 2010). Neuronal firing rate increases in GE and GI neurones as 
glucose levels increase and decrease, respectively. In GE neurones, an increase 
in glucose availability generates more intracellular ATP, leading to closure of KATP 
channels, cellular depolarisation, calcium influx and initiation of action potential 
firing, akin GSIS in β-cells (Anand et al., 1964; Mountjoy and Rutter, 2007; 
McTaggart et al., 2010). During hypoglycaemia, however, reduced ATP 
production leads to KATP channel opening, silencing these neurones. This 
response is believed to be an important transducing signal to trigger the CRR, as 
inhibition of VMH KATP with sulfonylureas attenuates counterregulation (Evans et 
al., 2004); whereas opening of the channel using diazoxide can amplify the CRR 
in healthy and counterregulatory-impaired rats (Evans et al., 2004; McCrimmon 
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et al., 2006). In vitro evidence from glucose-sensing hypothalamic neuronal cells 
further suggests that this response is AMPK-dependent, as genetically knocking 
down AMPK-α2 blunts the cells’ response to low glucose (Beall et al., 2012).  
Direct pharmacological activation of AMPK in the VMH using an AMP mimetic, 
AICAR, increases the response to hypoglycaemia due to increased HGP, 
observed during hyperinsulinaemic-hypoglycaemic clamps in rats (McCrimmon 
et al., 2004). This was also observed in a rodent model of T1D, the BB rat, in 
acute and recurrent hypoglycaemia (Fan et al., 2009). In the latter, the glucagon 
response to hypoglycaemia was also amplified following AMPK activation. 
Furthermore, knockdown of VMH AMPK-α2 in rats caused a 60% and 40% 
reduction in glucagon and adrenaline, respectively, during hyperinsulinaemic-
hypoglycaemic clamp studies, leading to impaired HGP and whole-body glucose 
uptake (McCrimmon et al., 2008). Importantly, although AMPK is activated in 
response to acute hypoglycaemia, shown in vitro in a model of GE neuron (Beall 
et al., 2012) and primary GI neurones (Murphy et al., 2009), recurrent 
glucoprivation via injection of 2-DG into rats diminishes AMPK activation in 
response to subsequent insulin-induced hypoglycaemia (Alquier et al., 2007). 
Together, these data suggest that central AMPK activation in response to 
hypoglycaemia is an important signal whose suppression may lead to defective 
counterregulation following recurrent hypoglycaemia.  
Activation of AMPK in neuroendocrine sensory brain regions is also important for 
appetite regulation. Anorexigenic stimuli, which reduce food intake, such as 
insulin, leptin, exercise, hyperglycaemia and a shift from fasted to fed state all 
decrease AMPK activity. (Andersson et al., 2004; Minokoshi et al., 2004). 
Contrastingly, orexigenic, or appetite-promoting hormones, such as ghrelin or 
adiponectin, increase AMPK activity in the hypothalamus (Andersson et al., 2004; 
Kola et al., 2005). Pharmacologically or genetically enhancing AMPK and its 
activity in the hypothalamus stimulates food intake (Andersson et al., 2004; 
Minokoshi et al., 2004), whereas expressing dominant-negative AMPK mutants 
in this region attenuates glucoprivation-induced (with 2-DG) food intake in rats 
(Kim et al., 2004). Furthermore, knockdown of AMPK-α2 in POMC and NYP-
AgRP neurones of mice leads to altered neuronal glucose sensing and whole-
body metabolism (Claret et al., 2007).  
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In SM, AMPK activation promotes glucose disposal and enhances insulin 
sensitivity to lower hyperglycaemia (Musi and Goodyear, 2003), whereas direct 
activation of α-cell AMPK stimulates glucagon secretion (Leclerc et al., 2011; Sun 
et al., 2015). It is therefore important to differentiate the effect of central versus 
peripheral activation of AMPK at differing blood glucose levels. Pharmacological 
targeting of brain AMPK has often relied on compounds with low specificity (such 
as AICAR) or weak brain permeability (such as metformin) and these have, thus 
far, been directly injected into the brain. Novel AMPK activators have since been 
developed by companies such as Rigel Pharmaceuticals (CA, USA), who have 
collaborated in this project by providing two such compounds, R481 and R419. 
R481 is an indirect, metformin-like AMPK activator, which exhibits a positive 
brain:plasma distribution within 30 minutes of oral administration to mice 
(unpublished).   
In this chapter, R481 was used to test the hypothesis that increased AMPK 
activation via peripheral administration of a brain permeable activator would 
amplify the CRR to hypoglycaemia, in healthy rats. AMPK activity in response to 
R481 was assessed in vitro, in GT1-7 glucose-sensing hypothalamic neurones, 
and the compound was subsequently used in vivo, in healthy Sprague-Dawley 
rats, where it was hypothesised that it would promote food intake and enhance 
the defence against hypoglycaemia.  
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 Results 
5.1 R481 activates AMPK in GT1-7 hypothalamic neurones  
To test the effect of R481 on AMPK activation and activity, in vitro, GT1-7 
glucose-sensing hypothalamic neurones were treated with R481 (0-50 nM) for 30 
minutes and changes to the AMPK signalling pathway assessed using Western 
blotting. R481 treatment significantly increased the levels of phosphorylated 
AMPK at threonine 172, in a concentration-dependent manner (Fig. 5.1.1A,B). 
R481 at 10 nM increased AMPK phosphorylation 2.63 ± 0.33 fold relative to 
control and reached a 10.17 ±1.99 fold increase at 50 nM (n=6; P<0.01 for both; 
Figure. 5.1.1B).  
To determine whether changes to AMPK phosphorylation were accompanied by 
changes to AMPK activity, phosphorylation of a downstream substrate, ACC, was 
assessed. R481 treatment concentration-dependently increased phosphorylation 
of ACC (serine 79) from a 2.27 ±0.34 fold increase with 10 nM to 4.71±0.73 fold 
with 50 nM (n=8; P<0.01 for both; Figure. 5.1.1A,C).  
AMPK is activated by an increase in the [AMP]/[ATP] ratio but despite activating 
AMPK, R481 did not alter the intracellular levels of ATP (measured using 
luminescence based plate assay), even at concentrations 10-fold higher than 
those required to activate AMPK in these cells (n=6; Figure. 5.1.2).  
5.2 R481 did not alter feeding ad libitum or in response to fasting or 
hyperinsulinaemia 
The effect of R481 on feeding behaviour was assessed in ab libitum, fasting-
induced and hyperinsulinaemia-induced feeding studies. Healthy male Sprague-
Dawley rats (250-300 g) were treated with R481 (20 mg/Kg; i.p.) or vehicle 
(HPMC) at the start of the dark-phase and food intake measured at 1, 2 and 4 
hours post-injection. R481 had no effect on feeding at any time point (P>0.05, 
Vehicle n=4; R481 n=4; Figure 5.2A). Following a 16 hour (dark-phase) fast, 
healthy male Sprague-Dawley rats (300-350 g) were treated with R481 (5 mg/Kg; 
orally) or vehicle (HPMC) followed by insulin (0.75 U/Kg) one hour later. Food 
was re-introduced one hour after insulin injection and intake measured at 1 and 
4 hours. R481 had no effect of insulin-induced feeding (P>0.05, Vehicle n=5; 
R481 n=5; Figure 5.2B). A third cohort of rats (250-300 g) was fasted for 16 hours  














Figure 5.1.1 R481 increases AMPK phosphorylation and activity in GT1-
7 neurones 
GT1-7 mouse hypothalamic neurones treated with increasing concentrations 
of R481 for 30 minutes. A) Representative immunoblots for AMPK (pT172), 
AMPK, ACC (pS79), ACC and Actin. Densitometric analysis of the mean 
pooled data for phospho-AMPK normalised to total AMPK shown in B (n=6) 
and phospho-ACC normalised to total ACC in C (n=8) (**P<0.01; ***P<0.001; 
One-sample t-test in comparison to control).  



















Figure 5.1.2 R481 treatment does not alter intracellular ATP levels in 
GT1-7 neurones 
Intracellular ATP levels of GT1-7 mouse hypothalamic neurones treated for 
30 minutes with increasing concentrations of R481 (0-200 nM), measured 
using a luminescence based assay (ATPLite) (n=6). 















Figure 5.2. R481 did not alter feeding ad libitum or in response to fasting 
or hyperinsulinaemia 
A) R481 (20 mg/Kg; i.p.) was administered at the start of the dark-phase and 
food intake measured 1, 2, 4 and 24 hours following injection (Vehicle n=4; 
R481 n=4). B) R481 (5 mg/Kg; orally) was administered one hour prior to insulin 
injection (0.75 U/Kg; i.p.), food re-introduced after 60 minutes and intake 
measured 1, 4 and 24 hours later (Vehicle n=5; R481 n=5). C) Rats were 
administered R481 (20 mg/Kg; i.p.) following 16 hour fast and food introduced 
immediately following injection and measured 1, 4 and 24 hours later (Vehicle 
n=9; R481 n=9);  Two-way ANOVA with repeated measures, no significant drug 
effect.  
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and treated with R481 (20 mg/Kg; i.p.) or vehicle (HPMC), food introduced 
immediately after and food intake measured after 1 and 4 hours to assess the 
effect of the drug on fasting-induced feeding. R481 moderately, but not 
significantly, decreased food intake after 1 hour, which normalised after 4 hours 
(Vehicle n=9; R481 n=9; Figure. 5.2C).  
5.3 R481 attenuates the insulin-induced drop in blood glucose  
To assess the effect of R481 treatment on insulin-induced hypoglycaemia, rats 
(300-350 g) were fasted (16 hours) and treated with R481 (5 mg/Kg; orally), 
followed by insulin (0.75 U/Kg; i.p.) one hour later and blood glucose measured 
after 30 minutes. Basal blood glucose levels were not different between R481 
and vehicle-treated rats (Figure. 5.3A), but the drug caused a modest yet 
significant attenuation of the drop in blood glucose following insulin treatment, 
compared to vehicle controls (Vehicle n=9; R481 n=9; P<0.05, unpaired two-
tailed t-test; Figure 5.3B). 
5.4 R481-induced increase in peak glycaemia is attenuated by AMPK 
inhibitor SBI-0206965 and ANS blocker hexamethonium 
Glucose tolerance tests (2 g/Kg glucose; i.p.) were undertaken to assess the 
effect of R481 on glucose tolerance and clearance. SBI-0206965, an AMPK 
inhibitor, was used to test the dependency of the R481 effect on AMPK activation. 
Healthy, male Sprague-Dawley rats (200-300 g) were fasted (16 hours) and 
treated with SBI-0206965 (3 mg/Kg; i.p.) or vehicle (DMSO; 0.5 % DMSO v/v) for 
30 minutes before being administered R481 (5 mg/Kg; i.p.) or vehicle (HPMC) 
and glucose (2 g/Kg; i.p.). Blood glucose was measured from the tail vein prior to 
(t=0) and after 15, 30, 60 and 120 minutes of R481/glucose injection. R481 
significantly increased peak glucose excursion compared to SBI-0206965 treated 
controls (SBI-0206965 n=6; R481 n=10; R481+SBI-0206965 n=8; *P<0.05(drug), 
***P<0.001(time), ***P<0.001(interaction), with Bonferroni’s multiple comparisons 
analysis, **P<0.01, ***P<0.001 for R481 against vehicle at 15 and 30 minutes 
respectively), and this was attenuated by AMPK inhibitor SBI-0206965 ($P<0.05 
for R481 versus R481+SBI-0206965; Figure. 5.4.1A). R481 enhanced peak 
glycaemia without altering glucose clearance, denoted by comparable total area 
under the curve measured between groups (P>0.05; One-way ANOVA; Figure. 
5.4.1B). 














Figure 5.3. R481 attenuates insulin-induced decrease in blood glucose 
Effect of R481 treatment on acute insulin-induced hypoglycaemia A) Male 
Sprague-Dawley rats were treated with R481 (5 mg/Kg; orally) following a 16 hour 
fast and 60 minutes later injected with a single dose of insulin (0.75 U/Kg; i.p.), 30 
minutes after which blood glucose was measured. Basal glucose did not differ 
between groups but R481 attenuated the insulin-mediated drop in blood glucose 
after 30 minutes, shown in B (Vehicle n=9; R481 n=9; *P<0.05, Two-way ANOVA 
with Bonferroni’s multiple comparisons).  
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To test whether R481 elicited the effects on peak glycaemia via activation of the 
autonomic nervous system (ANS), glucose tolerance tests were performed using 
a non-brain permeable homologue of R481, R419, and R481 ± ANS blocker 
hexamethonium. Healthy male Sprague-Dawley rats (200-300 g) were randomly 
assigned into five groups: vehicle (HPMC) (n=6), vehicle with hexamethonium 
(50 mg/Kg) (n=3), R419 (20 mg/Kg) (n=6), R481 (20 mg/Kg) (n=6) or R481 with 
hexamethonium (n=4). Hexamethonium was administered to fasted rats (16 
hours; i.p.) 30 minutes before designated drug and glucose (2 g/Kg; i.p.) and 
blood glucose measured from the tail vein before (t =0) and 15, 30, 60 and 120 
minutes post-injection (Figure. 5.4.2A,B). R481 significantly increased peak 
glucose response to glucose administration compared to vehicle controls 
(P<0.01, P<0.001 at 15 and 30 minutes, respectively for R481 against vehicle; 
Figure 5.4.2B) with no significant effect on glucose clearance, as blood glucose 
normalised to levels akin those of vehicle-treated animals after 120 minutes 
(P>0.05 for R481 against vehicle at 120 minutes). The increase in peak 
glycaemia by R481 was completely prevented by treatment with hexamethonium 
(P<0.01, P<0.001 at 15 and 30 minutes, respectively for R481 against R481 with 
hexamethonium). R419 did not significantly alter glucose levels compared to 
vehicle-treated rats (P>0.05; Figure 5.4.2A,B).   
5.5 R481 raises fasting glycaemia independently of changes to insulin 
secretion and does not alter glucose infusion rate during 
hyperinsulinaemic-euglycaemic clamp 
Subsequent experiments aimed to assess the effect of R481 on insulin sensitivity 
and endogenous insulin secretion. This was assessed during hyperinsulinaemic-
euglycaemic clamps, performed in healthy male Sprague-Dawley rats (250-300 
g) ~14 days after surgical implantation of carotid artery and jugular vein catheters 
(surgeries at Charles River, Margate, UK). Arterial and venous catheters were 
exteriorised by vascular access buttons, which enabled continuous infusion and 
pain-free blood sampling from conscious, freely moving rats. Fasted (16 hours) 
rats (200-350 g) were treated with R481 (20 mg/Kg; i.p.) or vehicle (HMPC) and 
60 minutes later infused with insulin (20 mU/Kg/min) and glucose (50 % dextrose; 
w/v), marking the start of the clamp (t=0). Blood glucose target at steady state 
was 5.5 mmol/L (Study design in Figure 5.5A). 














Figure 5.4.1 Increase in peak glycaemia with R481 is attenuated by AMPK 
inhibitor SBI-0206965 
Glucose tolerance tests assessing the effect of R481 on glycaemia ± AMPK 
inhibition SBI-0206965 in Sprague-Dawley rats. A) After 16 hour fast, rats were 
administered SBI-0206965  (SBI; 3 mg/Kg; i.p.) or vehicle for 30 minutes, followed 
by R481 (5 mg/Kg; i.p.) or vehicle (HPMC) and glucose (2 g/Kg; i.p.) 
simultaneously (at t= 0). Blood glucose was measured prior to R481 treatment (t= 
0) and after 15, 30, 60 and 120 minutes from tail vein samples using a glucometer 
(SBI-0206965 n=6; R481 n=10; R481+SBI0206965 n=8); Two-way ANOVA with 
repeated measures *P(drug)<0.05, ***P(time)<0.001, ***P(interaction)<0.001, and 
Bonferroni’s multiple comparisons analysis, **P<0.01, ***P<0.001 for R481 
against vehicle, $P<0.05 for R481 versus R481+SBI-0206965. B) Total area 
under the curve (AUC) for data shown in A; P>0.05, One-Way ANOVA.  











Figure 5.4.2 R481 activates the autonomic nervous system to raise 
glycaemia 
Glucose tolerance test assessing the effect of ANS blockade on R481-induced 
glycaemia. A) Healthy male Sprague-Dawley rats were assigned to: vehicle 
(HPMC) (n=6), vehicle with hexamethonium (Veh + Hex, 50 mg/Kg; n=3), R419 
(20 mg/Kg; n=6), R481 (20 mg/Kg; n=6) or R481 with hexamethonium (R481 
+ Hex; n=4). Hex or vehicle (saline) (i.p.) was administered to fasted (16 hours) 
animals 30 minutes before R481/R419 or vehicle (HPMC) + glucose (2 g/Kg; 
i.p.) and blood glucose measured before R481/R419 injection and 15, 30, 60 
ad 120 minutes later. R481 significantly increased peak glucose response 
compared to control, which was prevented by hexamethonium. Two-way 
ANOVA with repeated measures, **P(drug)<0.01, ***P(time)<0.001, 
***P(interaction)<0.001, with Bonferroni’s analysis **P<0.01, ***P<0.001 for R481 
against vehicle; $$P<0.01, $$$P<0.001 for R481 against R481+Hex. B) Hex 
significantly prevents ($P<0.05 R481+Hex Vs R481) R481-induced increase in 
peak glycaemia (*P<0.05 for R481 VS vehicle). 
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Blood glucose levels at baseline were slightly elevated in R481 treated animals 
(7.1 ± 0.6 mmol/L at t= -60 to 7.5 ± 0.2 mmol/L at t= 0), but decreased slightly in 
vehicle treated animals (7.2 ± 0.2 mmol/L at t= -60 to 6.3 ± 0.2 mmol/L at t= 0). 
This generated a significant relative increase in blood glucose at the start of the 
clamp in R481 treated rats (P<0.05; n=8; Figure 5.5B). Despite this difference, 
blood glucose profiles were well-matched between R481 and vehicle treated rats 
during the clamp (P(drug)>0.05; Figure 5.5B). There was no difference in GIR 
between treatments (Figure 5.5C). To assess changes to insulin secretion, C-
peptide levels were measured throughout the clamp. C-peptide levels decreased 
over the course of the clamp, but did not differ between vehicle and R481 treated 
animals at any time point (Vehicle n=7; R481 n=6; *P(time)<0.001, P(drug)>0.05; 
Figure 5.5D).  
5.6 R481 delays exogenous glucose requirements during 
hyperinsulinaemic-hypoglycaemic clamps 
To determine for the first time whether peripheral administration of a brain 
permeable AMPK activator, R481, could amplify the CRR to hypoglycaemia, 
hyperinsulinaemic-hypoglycaemic clamps were performed. Healthy male 
Sprague-Dawley rats (200-300 g) were purchased with pre-implanted catheters 
and vascular access buttons, as above, from Charles River (Margate, UK). 
Clamps were performed ~ 14 days following surgery and target blood glucose at 
nadir was 3.0 mmol/L (study design Figure. 5.6A). Fasted rats (16 hours) were 
treated with R481 (20 mg/Kg; i.p.) or vehicle (HMPC) and 60 minutes later clamp 
started. A bolus dose of insulin (80 mU/Kg/min) was administered for 10 minutes 
immediately followed by a continuous infusion at 20 mU/Kg/min concomitantly 
with variable 20% dextrose (w/v) for a total of 90 minutes. Target blood glucose 
was achieved during the last 30 minutes of the clamp (Vehicle= 2.98 ± 0.06 
mmol/L; R491= 3.042 ± 0.12 mmol/L), and glucose profiles were well matched 
between R481 and vehicle treated animals (Figure 5.6B). R481 significantly 
delayed exogenous glucose requirements, denoted by decreased GIR (Vehicle 
n=9; R481 n=9) ***P(time)<0.001, *P(drug)<0.05, *P(interaction)<0.05; Figure 5.6C). 
R481 significantly increased peak glucagon levels, seen at t= 30 (P<0.05; Vehicle 
n=9; R481 n=9; Figure 5.6D-E).  
Results  Chapter 5 
175 
Plasma adrenaline levels increased over the course of the clamp, in response to 































Figure 5.5 R481 does not alter glucose infusion rate during 
hyperinsulinaemic-euglycaemic clamp or alter endogenous insulin secretion 
Hyperinsulinaemic-euglycaemic clamps in healthy male Sprague-Dawley rats ~14 
days following surgical implantation of carotid artery and jugular vein catheters. A) 
Study design. B) Blood glucose profiles during clamp measured from tail vein 
samples with glucometer (Vehicle n=8, R481 n=8). No overall drug effects 
P(drug)>0.05; mixed-effects analysis of repeated measures, but *P<0.05 for R481 
against vehicle at t= 0 using Bonferroni’s post-hoc test. C) Glucose infusion rate 
(GIR; mg/Kg/min) during the clamp using a 50% dextrose solution (Vehicle n=8; 
R481 n=8). D) Plasma C-peptide measured by ELISA (Vehicle n=8; R481 n=7). 




Figure 5.6 R481 delays exogenous glucose requirements during 
hyperinsulinaemic-hypoglycaemic clamp by augmenting glucagon levels during 
hypoglycaemia 
Hyperinsulinaemic-euglycaemic clamps in healthy male Sprague-Dawley rats ~14 
days following surgical implantation of carotid artery and jugular vein catheters. A) 
Study design. B) Blood glucose profiles during clamp measured from tail vein samples 
with glucometer (Vehicle n=10, R481 n=8). No overall drug effects P>0.05(drug).C) 
Glucose infusion rates (GIR; mg/Kg/min) during the clamp using a 20% dextrose 
solution. *P(drug)<0.05, ***P(time)<0.05, *P(interaction)<0.05; two-way ANOVA with repeated 
measures. D) Plasma glucagon profile with peak (t= 30) shown in E, measured by 
ELISA (Vehicle n=9; R491 n=9; *P<0.05, unpaired t-test). F) Plasma adrenaline profile 
with peak shown in G, measured by ELISA (Vehicle n=8; R481 n=8; ns, not significant). 
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Discussion 
Therapeutic approaches to manage glycaemia in diabetes primarily aim to reduce 
hyperglycaemia and risk of developing associated co-morbidities (American 
Diabetes Association, 2019b). Such strategies, namely long-term insulin 
treatment in T1D and advanced T2D, however, often lead to increased risk of 
hypoglycaemia (Fanelli et al., 1994). One or recurrent hypoglycaemic episodes 
leads to defective CRR (Ma et al., 2018), which further increases risk for 
hypoglycaemia eventually leading to impaired hypoglycaemia awareness (Gold 
et al., 1994; Davis et al., 1997; Geddes et al., 2008). Strategies to manage 
hypoglycaemia and recover the CRR are scarce and a better understanding of 
the mechanisms regulating these processes is necessary to devise novel 
therapeutic approaches. 
In this chapter, AMPK activator R481 was used to assess whether peripheral 
administration of a brain permeable AMPK activator could amplify the CRR to 
hypoglycaemia. Data from the collaborators that provided the compounds, at 
Rigel Pharmaceuticals (California, USA), not presented here, demonstrated that 
R481 penetrates the CNS, exhibiting a positive brain:plasma ratio and activates 
AMPK centrally for up to 4 hours following oral dosing in mice. Furthermore, their 
evidence suggests that R481 acts as an indirect metformin-like AMPK activator, 
increasing kinase activity by mild mitochondrial inhibition (ie. mitochondrial 
hormesis (Hawley et al., 2010). The data presented here, performed in Exeter, 
demonstrated that R481 treatment activated the ANS to raise glycaemia, a 
response that was attenuated by pharmacological AMPK inhibition, without 
altering insulin secretion or peripheral insulin sensitivity; and amplified the CRR 
to hypoglycaemia by enhancing peak glucagon levels, in healthy rats.   
The GT1-7 murine cell line was used as an in vitro model of GE neurone. These 
cells demonstrate AMPK-dependent glucose sensing capacity and are useful for 
examining responses in a single neuronal population (Beall et al., 2012). In these 
cells, R481 significantly increased AMPK phosphorylation and activity 
(demonstrated by increase p-ACC) at low nanomolar concentrations and within 
30 minutes of drug administration.  
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Treatment with R481, despite activating AMPK, did not compromise intracellular 
levels of ATP, even at concentrations 10 fold higher than that required to 
significantly increase AMPK phosphorylation. This suggests that mild energetic 
stress caused by the drug may increase AMP levels to activate AMPK, but the 
catalytic effect of the kinase and rapid nucleotide turnover maintain the total levels 
of ATP in the cell. The potent ability to activate AMPK as well as CNS-
permeability demonstrated by R481 made this compound a useful tool to test the 
overarching hypothesis of this study. 
The contribution of AMPK activation to the central regulation of feeding (Hardie 
et al., 2012) generated the hypothesis that R481 would promote food intake in 
vivo. Contrary to the hypothesis, R481 treatment did not alter ad libitum feeding 
or feeding responses to hyperinsulinaemia or fasting. AMPK is essential for 
glucose/hypoglycaemia sensing by POMC and NPY/AgRP appetite regulatory 
neurones, and its activation is enhanced and reduced by orexigenic and 
anorexigenic stimuli, respectively (Kola, 2008). Hypothalamic AMPK activity is 
suppressed by peripheral leptin administration and enhanced by ghrelin 
administration, leading to decreased and increased food intake, respectively 
(Andersson et al., 2004). Pharmacological activation of AMPK by injection of 
AICAR into the third ventricle or directly into the hypothalamic PVN promotes food 
intake (Andersson et al., 2004). Conversely, direct leptin injections into the MBH 
decrease ARC and PVN AMPK activity, and adenoviral induction of dominant-
negative AMPK into the MBH decreases food intake and body weight in rodents 
(Minokoshi et al., 2004). Direct injection of R481 into an appetite regulatory brain 
region would, therefore, provide more concrete evidence of a role for the 
compound in food intake and until better tissue distribution of the drug is 
assessed, it is not possible to determine whether hypothalamic or hindbrain 
AMPK activity is enhanced by R481. It is possible that R481 treatment 
(particularly oral dosing) may not be sufficient to amplify hypothalamic AMPK 
activation induced by prolonged fasting (López et al., 2008). Furthermore, R481 
may activate AMPK without altering food intake, which would concur with findings 
demonstrating altered glucose metabolism downstream of hypothalamic AMPK 
activation without changes to food intake or body weight (Kinote et al., 2012). 
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Pharmacological (and naturally occurring) AMPK activators have been developed 
as anti-hyperglycaemic agents for use in T2D, promoting glucose disposal 
primarily in SM (Merrill et al., 1997; Kurth-Kraczek et al., 1999). The non-
permeable homologue of R481, R419, activates SM AMPK and enhances insulin 
sensitivity in DIO mice (Marcinko et al., 2015). The effect of both R481 and R419 
on glucose tolerance was assessed here by IPGTTs and data demonstrated that 
R419 did not alter peak glycaemia or glucose clearance, whereas, R481 
significantly increased glucose excursion in response to glucose administration 
without altering glucose clearance. Pre-treatment with AMPK/Uncoordinated 
(Unc)-51-like kinase (ULK-1) inhibitor SBI-0206965 (Egan et al., 2015) 
attenuated the transient increase in glycaemia and ANS blocker hexamethonium 
completely abolished R481-mediated peak glucose excursion, suggesting that 
R481 acts centrally to enhance glycaemia in a manner that is attenuated by 
AMPK inhibition. Kume and colleagues demonstrated that pharmacological 
activation of hypothalamic AMPK by intracerebroventricular (icv) AICAR injection 
suppresses first-phase GSIS via autonomic innervation of α-adrenergic 
pancreatic nerves, which is hypothesised to be a protective mechanism to 
promote glucose delivery to the brain during fasting (Kume et al., 2016). The 
inhibition of R481-mediated peak glycaemic response by hexamethonium seen 
here suggests the involvement of the parasympathetic or sympathetic nervous 
systems in this response, which is in line with those observations. However, an 
acknowledged small caveat in this experiment is the lack of data on insulin levels 
during the GTT, which would help determine whether R481 alters insulin 
secretion. Furthermore, direct activation or suppression of hypothalamic AMPK 
activity differentially regulates HGP (Yang et al., 2010; Lam et al., 2011; Kinote 
et al., 2012). Fructose-stimulated hypothalamic AMPK activation up-regulates 
HGP (Kinote et al., 2012), whereas molecular and pharmacological inhibition of 
hypothalamic AMPK suppresses HGP (Yang et al., 2010; Lam et al., 2011). 
Future work with R481 would aim to assess blood glycaemia following pyruvate 
load, as a measure of glucose synthesis from pyruvate (gluconeogenesis) and 
assess levels of hepatic gluconeogenic enzymes, such as PEPCK, to determine 
whether R481 acts centrally to decrease glucose-induced inhibition of HGP 
(Kowalski et al., 2017). This is supported by observations that pharmacological 
AMPK activation in the hypothalamus using AICAR or A-769662 increases 
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hepatic PEPCK expression and glucose synthesis during pyruvate tolerance test 
(Kinote et al., 2012). 
Pre-treatment with AMPK/ULK1 inhibitor SBI-0206965 attenuated the R481-
mediated increase in peak glucose response during GTTs. SBI-0206965 was first 
reported, in vitro and in vivo, to act as a highly selective inhibitor of ULK1, a critical 
serine/threonine kinase for the initiation of autophagy (Egan et al., 2015), whose 
activity is regulated by mTOR and AMPK (He and Klionsky, 2009). The 
compound has since been found to directly inhibit AMPK with 40 fold greater 
potency compared to conventionally used AMPK inhibitor Compound C (Dite et 
al., 2018). During energetic stress, such as in hypoglycaemia, central activation 
of AMPK stimulates glucose production, raising plasma glycaemia (McCrimmon 
et al., 2008), whereas during hyperglycaemia, peripheral AMPK activation is 
primarily glucose-lowering (Long and Zierath, 2006). Interestingly, during AA and 
growth factor deprivation, independently from autophagic events, ULK1 activation 
(whole-body) sustains glucose metabolic fluxes by directly phosphorylating 
glycolytic enzymes to enhance HK activity and promote glucose uptake, while 
suppressing gluconeogenic machinery (Li et al., 2016). It would, therefore, be 
interesting to establish whether central activation of ULK1 plays a paradoxical 
action to its peripheral effect and further establish whether R481 activates ULK1 
(dependently or independently of AMPK). SBI-0206965 (5 days treatment) has 
also demonstrated glucose clearing effects in mice fed a HFD (Yamamoto et al., 
2018), so a glucose-clearing effects of the compound cannot be ruled out as a 
possible explanation for the attenuated R481-mediated glucose response seen 
here. As R481 was administered peripherally, it is plausible that the drug 
activated AMPK in glucose-responsive tissues such as SM, to promote glucose 
disposal (Cokorinos et al., 2017). Data from GTTs, however, suggests that, if 
R481 alters glycaemia by activating AMPK, its central effect supersedes its 
peripheral actions. 
Hyperinsulinaemic-euglycaemic clamps were performed to assess the effect of 
R481 on insulin secretion and sensitivity, following the hypothesis that peripheral 
AMPK activation by the compound would enhance glucose disposal into SM. 
R481 did not alter GIR or the levels of C-peptide (used as a proxy for endogenous 
insulin secretion) before or during the euglycaemic clamp, suggesting that the 
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drug does not alter insulin secretion or sensitivity. Importantly, R481 was 
administered 60 minutes prior to the start of the clamp, so it is possible that R481 
suppressed first-phase IS immediately after administration (supporting GTT 
data), but its effects begin waning by 60-90 minutes, when blood glucose returns 
to baseline levels during GTT and animals reach steady-state during clamp. It 
would be interesting to determine whether simultaneous administration of R481 
and infusions at the start of the clamps would generate a different result. 
Nonetheless, AMPK has demonstrated both positive and negative regulatory 
effects on insulin secretion (Fu et al., 2013). Treatment of pancreatic β-cells and 
islets with increasing concentrations of AICAR increases insulin secretion (Akkan 
and Malaisse, 1994; Salt et al., 1998; Salt et al., 1998) with mild potentiation of 
insulin secretion seen during hyperglycaemia (Salt et al., 1998; Wang et al., 2005; 
Gleason et al., 2007). Paradoxically, activation of AMPK and ACC with AICAR 
has demonstrated suppressive effects on GSIS (Zhang and Kim, 1995) and 
treatment with thiazolidinediones seen to activate AMPK while reducing insulin 
secretion (Wang et al., 2007; Lamontagne et al., 2009). This is supported by 
others demonstrating an inverse relationship between acute pharmacological 
AMPK activation and insulin secretion (Salt et al., 1998; Leclerc and Rutter, 
2004). Studies using longer-term pharmacological (Targonsky et al., 2006; Cai et 
al., 2007) and molecular (Salt et al., 1998; Salt et al., 1998; Da Silva Xavier et al., 
2000) AMPK activation have more consistently shown an inhibitory effect on 
insulin secretion. Importantly, decreased glucose availability (in β-cell model) 
leads to AMPK-dependent inhibition of insulin secretion (Lim et al., 2009), which 
supports the notion that AMPK may suppress GSIS to prevent inappropriate 
hypoglycaemia. It is possible that this is not seen at euglycaemia, supporting the 
R481 effect seen here. Moreover, a single dose of the compound in lean rats, 
rather than chronic dosing in DIO mice, may explain the discrepancy between 
this study and evidence by Marcinko and colleagues using R419 (Marcinko et al., 
2015). Future studies would use glucose tracers prior to and during the clamp to 
determine rates of glucose appearance and disappearance from plasma to 
assess basal (fasting) HGP and glucose disposal into insulin-sensitive tissues 
(Zhang et al., 2018). The glucose-raising effect of R481 may also be dose-
dependent so it would be important to optimise the dose to prevent raised fasting 
glycaemia.  
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AMPK activation is important in hypothalamic glucose sensing, particularly during 
hypoglycaemia. The ability of R481 to amplify the CRR to hypoglycaemia was 
assessed here during hyperinsulinaemic-hypoglycaemic clamps, where the 
compound generated significantly lower GIRs, amplifying the CRR to 
hypoglycaemia by enhancing peak glucagon levels. R481-mediated 
hypothalamic AMPK activation was not assessed here, but these data are 
consistent with studies demonstrating amplified CRR by enhanced central AMPK 
activation. Direct AICAR-mediated activation of AMPK in the VMH has been 
shown to amplify the hormonal CRR to hypoglycaemia and increase HGP in 
healthy rats (McCrimmon et al., 2006) and enhance the glucagon and adrenaline 
responses to hypoglycaemia in type 1 diabetic rats (Fan et al., 2009). Conversely, 
downregulation of VMH AMPK suppresses glucagon (~60 %) and adrenaline 
(~40 %) responses to acute hypoglycaemia in healthy rats (McCrimmon et al., 
2008). VMH AMPK activation has also been shown to stimulate HGP in response 
to hypoglycaemia without altering counterregulatory hormone levels (McCrimmon 
et al., 2004).  
Here, R481 significantly increased glucagon without altering adrenaline levels, in 
response to hypoglycaemia. Release of glucagon and adrenaline are 
differentially regulated in response to decreasing plasma glucose (Sprague et al., 
2011). The mechanisms of glucagon release by α-cells remain poorly understood 
but studies in isolated α-cells, islets, rodents and humans suggest the 
involvement of paracrine mechanisms, such as inhibition of glucagon release by 
insulin (Cooperberg and Cryer, 2010) and somatostatin (Strowski et al., 2000) as 
well as gut incretin-derived (Holst et al., 2011) and neuronal mechanisms 
(Sprague et al., 2011; Thorens, 2011). Sympathetic innervation of β2-adrenergic 
receptors also stimulates glucagon release (Gerich et al., 1976; Fagerholm, 
Haaparanta and Scheinin, 2011) so it is possible that the ANS-dependent role of 
R481 alters glucagon release by α-cells. Peripheral glucose sensors, such as 
those in the hepatoportal vein may also regulate the ANS-mediated effects on 
glucagon secretion (Fujita et al., 2007). Adrenaline release from the adrenal 
medulla is mediated by sympathoadrenal responses to a decrease in blood 
glucose and adrenaline acts in the liver to stimulate HGP (Exton, 1987) and on 
α-cells to further enhance glucagon release (Gustavson et al., 2003).  
Discussion  Chapter 5 
184 
It is plausible, given the wide variety of mechanisms regulating glucagon release, 
that R481 acts directly on α-cell or adjacent mechanisms to enhance glucagon 
secretion independently of significant changes to adrenaline. Indeed, direct 
pharmacological (metformin, A-769662) and molecular (adenoviral transduction) 
activation of AMPK in α-cells in vitro and ex-vivo mouse islets is sufficient to 
stimulate glucagon release at both high and low glucose concentrations, whereas 
inactivation of AMPK suppresses low glucose-induced glucagon secretion 
(Leclerc et al., 2011). Furthermore, mice with α-cell specific AMPKα1 and LKB1 
knockouts demonstrate enhanced glucose disposal during hyperinsulinaemic-
hypoglycaemia clamps due to impaired glucagon release, suggesting the 
involvement of an LKB1-dependent signalling pathway involving, but not 
restricted to, AMPKα1 in glucagon secretion (Sun et al., 2015). However, an 
R481-dependent effect on glucagon secretion is unlikely to mediate the transient 
glucose intolerance seen during GTTs, as glucagon levels were not elevated at 
the start of the hypoglycaemic clamps (60 minutes post-injection). R481 may 
activate an AMPK-ANS-HGP axis while concomitantly activating an ANS-α-cell 
axis or directly enhancing α-cell glucagon release. Further work is necessary to 
establish the effect of R481 treatment on markers of HGP, as the compound may 
attenuate the suppression of HGP during GTT (Alquier et al., 2007), as well as 
direct effect of the compound on α-cell AMPK activation and glucagon release.  
Importantly, the work presented here was conducted in healthy rodents with 
effective CRR and hypoglycaemia awareness. Acute glucoprivation by injection 
of 2-DG (icv) enhances activity of VMH and dorsomedial hypothalamus (DMH) 
AMPKα1 and α2 and leads to elevated glucagon and corticosterone levels, 
amplifying the CRR (Chun et al., 1998; Marin-Spiotta et al., 2004; Alquier et al., 
2007). However, recurrent glucoprivation with 2-DG (icv) impairs hormonal CRR, 
in a manner that is associated with blunted and delayed hypothalamic AMPK 
activation (Alquier et al., 2007). Given that hyperglycaemia (Kim et al., 2004; 
Minokoshi et al., 2004) and recurrent hypoglycaemia/glucoprivation (Alquier et 
al., 2007) attenuate hypothalamic AMPK activity and suppression of expression 
and activity of AMPK in the VMH suppresses the hormonal CRR to 
hypoglycaemia (McCrimmon et al., 2008), it is plausible that AMPK activity is 
blunted in diabetes and that this may contribute to blunted CRR and awareness 
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of hypoglycaemia. AMPK activation may, therefore, be an important tool to 
recover impaired CRR. Future experiments using R481 would assess the effect 
of acute and chronic administration of the compound on glycaemia and CRR in 
diabetic models with impaired CRR and hypoglycaemia awareness. 
Summary and future work  
The data presented in this chapter demonstrate that peripheral administration of 
a brain permeable AMPK activator raises glycaemia in an ANS-mediated manner 
and amplifies the CRR to hypoglycaemia by enhancing glucagon levels. The 
glucose-raising effect of R481 was attenuated by AMPK inhibition and ANS 
blockade, suggesting that R481 acts centrally and providing proof-of-concept that 
pharmacological activation of central AMPK may represent an import therapeutic 
target for amplifying the defence against hypoglycaemia. It also highlighted that 
central AMPK activation likely supersedes peripheral activation to generate a 
whole-body net glucose-raising effect to protect the brain from glucoprivation 
(Kume et al., 2016). 
Data from Rigel Pharmaceuticals demonstrated whole-brain AMPK activation 
following oral administration of R481 in mice. However, no evidence exists of the 
regional specificity of the drug or difference in bioavailability between mice and 
rats, so a critical next step is to assess whether R481 is actively transported into 
specific brain regions or undergoes pan brain transport, and which ganglia it 
regulates. Furthermore, a better understanding of the tissue-specific effects of 
R481 on AMPK activation, particularly central versus peripheral effects, is 
required to establish whether the compound amplifies CRR by hypothalamic-
hindbrain-to-periphery axis or by direct action on α-cells. Using R419 during 
glucose clamps would also aid in distinguishing the central from peripheral effects 
as the compounds exhibit structural homology but different brain:plasma ratios. 
Notably, in vivo regulation of AMPK activity is also complex as studies assessing 
the effect of central activation or inhibition of AMPK must consider distinct kinase 
isoforms, time-courses, doses and target regions (such as different hypothalamic 
nuclei) (Alquier et al., 2007). Nonetheless, these data show promising effects to 
support the use of indirect peripherally administered (translatable approach) 
AMPK activators to treat diabetes. 
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Main findings and future considerations 
Energy balance is achieved by a well-tuned interplay between multiple organs 
that regulate energy intake and energy expenditure to maintain homeostasis. 
Energy imbalance represents a fundamental aetiological factor for the 
development of obesity, diabetes and a number of increasingly prevalent 
conditions aggravated by increasingly common human behaviours such as 
overeating and inactivity. Impaired glucose homeostasis is a predominant feature 
of diabetes and maintaining blood glucose is still a daily challenge for individuals 
with both T1D and T2D. More and better strategies are continually being 
developed to counteract these metabolic impairments from “nutraceuticals” to 
“exercise-pills” to better and more sensitive monitoring and diagnostic 
technologies. However, a better understanding of the mechanisms regulating 
these impairments is still required to devise better-targeted and effective 
therapeutic strategies. As such, the primary aim of the work presented in this 
thesis was to better understand and target the pathophysiology of impaired 
glucose homeostasis.  
Impaired glucose clearance by skeletal muscle is the main driver of impaired 
glucose disposal in diabetes (primarily T2D). Appropriate nutrient balance in 
skeletal muscle is also critical for muscle function and for maintaining mass and 
strength. In Chapter 3, mechanistically focused in vitro experiments aimed to 
elucidate the mechanisms by which excessive lipid availability alters insulin and 
amino acid sensitivity in muscle cells. It was hypothesised that the purinergic 
signalling system, particularly extracellular ATP which has well-documented pro-
inflammatory effects as a signalling molecule, would participate in the metabolic 
impairments and inflammatory response following treatment with high 
concentrations of fatty acids. Data in the chapter suggests that extracellular ATP 
derived from palmitate treatment does not mediate the loss of anabolic response, 
mitochondrial dysfunction or release of inflammatory cytokines brought about by 
treatment with the fatty acid. Instead, novel roles of extracellular ATP in the 
regulation of glucose metabolism were elucidated, showing that the nucleotide 
may have important insulin and exercise mimetic properties that may be 
therapeutically targetable. Findings summarised in Figure 6.1. 




Figure 6.1 Schematic summary of findings in Chapter 3 
Extracellular ATP-P2R-mediated regulation of glucose metabolism in skeletal muscle 
cells. Work by Ito et al., (2018) (dark blue) demonstrated extracellular ATP-mediated 
phosphorylation of S6K1 (to stimulate hypertrophy) via activation of a 
P2Y2R/PI3K/PLC/IP3R pathway, through class III PI3K (Vps34) and not class I 
(PI3K/PKB) which primarily regulates insulin signalling. Work by Osorio-Fuentealba 
et al., (2013) (orange) demonstrated that ATP released from electrical stimulation of 
myotubes enhanced glucose uptake by increased mobilisation of GLUT4 transporters 
via a PI3Kγ-PKB-AS160. Work in this thesis (red circles) demonstrated that treatment 
with ATPγS enhanced the phosphorylation of ERK1/2 (positive control), S6K1 and 
PKB in a P2YR (but not P2X4R or P2X7R)-dependent manner and stimulated 
glucose uptake into C2C12 myotubes in an insulin-independent manner. In addition, 
treatment with ATPγS stimulated glycolysis in a P2YR-dependent manner. 
Furthermore, treatment with ATPγS resulted in increased release of IL-6 and 
suppression of MIF release. As expected, ATP treatment increased intracellular 
calcium, which was also observed following treatment with mixed essential amino 
acids (AA). AA treatment also enhanced extracellular ATP levels (dashed light blue 
lines; unknown mechanism) and enhanced S6K1 suggesting that the purinergic 
signalling system may, in part, modulate AA-dependent hypertrophy (feeding into a 
similar mechanisms to that demonstrated by Ito et al., 2018). The P2R via which ATP 
exerts its glucose regulatory effects remains to be elucidated, as does the ability of 
ATP to stimulate glucose uptake in insulin resistant states (eg. lipid-induced insulin 
resistance).  
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The effects of increased lipid availability on muscle insulin and anabolic 
resistance may reside at the level of systemic impairments such as delivery of 
nutrients to skeletal muscle, and may be temporally regulated. As in vitro models 
are limited to assess these changes, the work in Chapter 3 was translated to a 
human study investigating the effect of elevated lipid availability in a disuse model 
of insulin resistance, in Chapter 4. Data in this chapter demonstrated, for the first 
time, that skeletal muscle glucose uptake is substantially impaired after only two 
days of immobilisation and that increasing lipid availability by overfeeding with 
saturated fats did not aggravate this effect. Novel evidence also demonstrated 
that postabsorptive and postprandial blood blow is not altered by immobilisation 
or affected further by diet, suggesting that nutrient delivery is preserved and 
alterations to nutrient balance occur due to impaired responses in muscle tissue.  
Figure 6.2. Schematic summary of findings in Chapter 4 
Young healthy males were subjected to 7 days of forearm immobilisation under a controlled 
eucaloric diet (CON) or high-fat diet (HFD). Despite the increase in body mass (BW), the 
excess lipid availability in the HFD group did not exacerbate the effects of immobilisation on 
muscle substrate utilisation and function. Two days of immobilisation caused significant 
muscle insulin resistance (but not systemic) and this was not aggravated by an additional 5 
days of disuse, suggesting that removal of contraction leads to a rapid decline in energy 
substrate demand by skeletal muscle (possibly due to intracellular negative feedback loops 
resulting in diminished substrate uptake). After 7 days, postprandial amino acid (leucine) 
balance was impaired, suggesting muscle anabolic resistance. Importantly, blood flow was not 
altered by immobilisation or diet, suggesting that impairments in nutrient balance do not occur 
as a result of diminished arterial delivery (despite possible microvascular impairments). It 
remains unclear whether insulin resistance causes anabolic resistance and whether impaired 
lipid metabolism contributes to their development.    
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Skeletal muscle energy metabolism is critical in diabetes pathophysiology, but 
glucose regulation occurs by more than one tissue/organ. Central regulation of 
glucose homeostasis is particularly important in the control of hypoglycaemia. 
Data in Chapter 5 addresses the pharmacological regulation of blood glucose, 
using AMPK as a target. AMPK activators are used widely in the treatment of T2D 
to lower glycaemia, primarily by acting on skeletal muscle and liver. However, 
emerging data suggest that central AMPK activation may be important to amplify 
the counterregulatory response to hypoglycaemia, to protect the brain from 
glucose deprivation. Data in Chapter 5 demonstrated that peripheral 
administration of a brain permeable AMPK activator (R481) regulates glycaemia 
by activation of the autonomic nervous system and amplifies the 






Figure 6.3. Schematic summary of findings in Chapter 5 
Central AMPK activation in the regulation of whole body glucose homeostasis. In 
vitro, indirect AMPK activator R481 enhanced activation and activity of AMPK in 
glucose-sensing hypothalamic neurons. In vivo, peripheral administration of R481 
(brain-permeable) enhanced glucose excursion in response to glucose 
administration in a manner that was blunted by blockade of the autonomic nervous 
system (ANS) with hexamethonium and attenuated by inhibition of AMPK with 
direct inhibitor SBI-0206965. In response to insulin treatment, R481 attenuated the 
insulin-induced drop in blood glucose and during a hyperinsulinaemic-
hypoglycaemic clamp amplified the counterregulatory response to hypoglycaemia 
by enhancing glucagon release. Central AMPK activation may represent an 
important target for the recovery of impaired counterregulation in diabetes.  
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The different scientific approaches taken in these studies generated thought-
provoking ideas and elucidated important processes, biomarkers and 
mechanisms that may be interconnected from an integrated physiology point of 
view. In this chapter, I would like to give an overview of concepts that were not 
discussed above and would represent interesting avenues to pursue following the 
work carried out here.  
Combating skeletal muscle metabolic impairments and atrophy in 
metabolic disease: ATP as a therapeutic tool 
Physical inactivity is a strong predictor of major metabolic diseases such as T2D 
(Booth et al., 2002) and has been proposed as the 4th leading cause of death 
worldwide (Kohl et al., 2012). Some situations result in inadvertent periods of 
inactivity, such as recovery from illness or injury and these are strongly 
associated with loss of muscle mass and metabolic health. Data in Chapter 4 
demonstrated that two-days of immobilisation were sufficient to reduce muscle 
glucose uptake by 50 % in an insulin-stimulated state. After 7 days, muscle 
strength was 17 % decreased and glucose and amino acid balance were 
impaired. Although this local insulin and anabolic resistance develop more rapidly 
in experimental models of disuse compared to chronic physical inactivity (such 
as by sedentary lifestyles) these models enable mechanistic understanding and 
a platform to assess the effect of countermeasures to combat disuse-induced 
atrophy and metabolic impairments. Such countermeasures primarily focus on 
increasing/modifying physical activity and adjusting nutritional intake to match 
anabolic demand. Although effective, these are not always successful. Such 
measures have been studied extensively and have been expertly reviewed 
recently (Leenders and van Loon, 2011; Wall and van Loon, 2013; Dirks et al., 
2018; Hawley et al., 2019) so will not be discussed here. Of interest, based on 
the work presented here, is the potential usefulness of molecules such as ATP 
(or small molecular ATP receptor agonists) to attenuate the loss of muscle mass 
and strength in metabolic disease.  
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Recent evidence suggests that reintroduction of a level of muscle contraction by 
application of neuromuscular electrical stimulation (NMES) can enhance both 
postabsorptive and postprandial muscle protein synthesis rates and 
prevent/attenuate muscle loss during short periods of disuse (Dirks et al., 2014; 
Dirks et al., 2018). Interestingly, as discussed in Chapter 3, electrical stimulation 
of muscle fibres leads to increased ATP release (Buvinic et al., 2009; Osorio-
Fuentealba et al., 2013) as does exercise (González-Alonso et al., 2002; 
Mortensen et al., 2011). To date, no evidence exists to suggest that the benefits 
of NMES in delaying impairments brought about by disuse are mediated by ATP. 
Data presented in Chapter 3, supported by work from others (Osorio-Fuentealba 
et al., 2013; Ito et al., 2018) suggests that extracellular ATP also promotes 
glucose uptake into skeletal muscle and enhances mTOR signalling pathway 
activity. It would, therefore, be interesting to establish whether ATP (P2 receptor 
agonists or ATPase inhibitors) could be used to mimic the exercise and insulin 
sensitising effects of NMES, during disuse.  
ATP is readily available as an oral supplement and has already been shown to 
promote hypertrophy after resistance exercise (Wilson et al., 2013) and lower 
blood pressure in hypertensive women after exercise (de Freitas et al., 2018). As 
ATP is rapidly metabolised by the action of ecto-nucleotidases, it is challenging 
to assess whether ATP bioavailability increases in the muscle vicinity (after oral 
dosing) to elicit these effects. It would therefore be interesting to assess the effect 
of intravenous ATP infusion in a model of disuse such as forearm immobilisation 
to investigate alterations to strength and insulin/anabolic sensitivity. As ATP also 
acts as a potent vasodilator, this could have important implications in diabetes. 
In T1D, muscle blood flow, capillary density and mass are reduced (Rivard et al., 
1999), and in T2D microvascular function becomes impaired and exacerbates 
muscle loss (Groen et al., 2014). However, physical activity can prevent or 
reverse microvascular impairments in T2D, so it would be interesting to establish 
whether ATP supplementation could mimic these effects.  
ATP is an attractive candidate to modulate in these disease models. However, it 
is important to consider the caveats of such an intervention, particularly given the 
widespread expression of purinergic receptors across multiple tissues. An 
important first step would be to understand the time (length of treatment or 
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repeated supplementation) and concentration-dependent regulation of glucose 
metabolism across tissues other than muscle, such as adipose tissue (Burnstock, 
2014; Burnstock and Gentile, 2018), liver (Burnstock et al., 2014) or the gut 
(Burnstock, 2016). Elucidating a specific P2R-mediated effect would then enable 
more targeted therapeutic developments as P2R agonists/antagonists are 
already commercially available and continually being developed (Burnstock, 
2017; da Silva Ferreira et al., 2019).  
Furthermore, it is now possible to measure ATP (and other 
nucleotides/nucleosides) in whole blood in near real-time. Sarissa Biomedical 
(Coventry, UK) have developed enzyme-coated electrode biosensors 
(SMARTChip and SMARTCap (Dale et al., 2019) that detect the levels of these 
markers in a small drop of whole-blood within ~5 minutes. An ATP SMARTChip 
was developed for the first time to be piloted in the studies conducted in this 
thesis. Following observations of increased eATP in response to palmitate 
treatment in Chapter 3, it was hypothesised that eATP levels would be elevated 
after ingestions of a high-fat drink (pilot study) and 7 days of high-fat overfeeding, 
which would have been measurable in the study conducted in Chapter 4. 
Unfortunately, the turnover of generation of this novel tool was extremely low, 
meaning that only a small proportion of electrodes were trialled. The pilot data 
generated from the acute high-fat drink ingestion experiment is demonstrated in 
Appendix D. Importantly, optimisation of this technique led to measurable levels 
of ATP in whole blood so the technique could be used in future to test hypotheses 
where the primary outcome measure is a change in blood nucleotide/nucleoside 
levels. This could be applied to an immobilisation model to investigate changes 
to venous ATP output from immobilised muscle, as loss of the anabolic effect of 
eATP may also contribute to the metabolic impairments observed during disuse. 
Immunometabolic regulation of glucose homeostasis: role for autophagy? 
Under stresses such as inflammation or nutrient starvation, autophagy is 
stimulated to break down proteins and organelles (often damaged) and lipid 
droplets (Singh et al., 2009) to provide amino acids and precursors necessary for 
maintaining cellular and metabolic homeostasis (Singh and Cuervo, 2011).  
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Dysregulation of the physiological function of autophagy occurs in the 
pathophysiology of a number of conditions, including diabetes (Bhattacharya et 
al., 2018). Under sufficient nutrient supply, mTOR directly phosphorylates ULK1 
(S757) to inhibit its activation of autophagy whereas nutrient 
deprivation/starvation activates AMPK, which directly phosphorylates ULK1 
(S317 and S777) (Egan et al., 2011; Dunlop and Tee, 2013) (and inhibits mTOR 
(Kim et al., 2011) to promote autophagy. ULK1 initiates autophagy by activation 
of the Class III PI3K complex (PI3KC3-C1), of which Vps34 is a critical 
component (Stjepanovic et al., 2017). 
Autophagy is regulated by a number of stimuli, pathways and pathophysiological 
processes mentioned in this thesis, but elucidating these mechanisms is 
challenging as they appear to be altered by nutrient/hormonal status. For 
example, regulation of autophagy by excess lipid availability, as modelled in 
Chapters 3 and 4, appears to be bi-phasic. This was demonstrated in the liver of 
mice fed a high-fat diet for 2 weeks, which enhanced autophagy, compared to 
mice on a high-fat diet for 10 weeks or exposed to an acute bolus of high lipid 
concentration, where autophagy was suppressed (Papáčková et al., 2012). The 
latter may be a consequence of insulin resistance and hyperinsulinaemia, as this 
has been shown to blunt the expression of autophagy genes such as vps34 (Liu 
et al., 2009) or possible hyperactivation of mTOR, which is observed in hepatic 
tissue from HFD-fed mice (Korsheninnikova et al., 2006; Wang et al., 2010). In 
the brain, chronic HFD suppresses autophagy, and decreased hypothalamic 
autophagy appears to exacerbate diet-induced obesity (Meng and Cai, 2011). 
Data for the role of excess lipid availability on autophagy in skeletal muscle is 
less consistent (Campbell et al., 2015), but reports suggest that alterations in 
mitophagy may play a role in the development of insulin resistance (Kim et al., 
2013), particularly given the role of lipid-induced mitochondrial dysfunction in this 
process (as seen in Chapter 3).  
In Chapter 3, overnight treatment of muscle cells with palmitate also enhanced 
MIF release, whereas treatment with ATPγS decreased MIF release. MIF has 
been shown to induce autophagy in cardiomyocytes (Xu et al., 2013, 2014), 
endothelial cells (Chen et al., 2015) and in human hepatoma cell lines (Chuang 
et al., 2012), but its roles in muscle and brain are understudied. 
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MIF secretion is enhanced during amino acid and serum starvation and its 
autophagy-inducing effects appear to be partly mediated by increased ROS 
generation (Chuang et al., 2012). Although nutrient deficiency increases MIF, 
particularly under stresses such as inflammation and starvation, MIF plasma 
levels are elevated in humans with T2D (Toso et al., 2008), impaired glucose 
tolerance (Kleemann and Bucala, 2010) and T1D (Hanifi-Moghaddam et al., 
2003). It is plausible that a decrease in energy availability leads to increased MIF 
release (Chuang et al., 2012), as a signal of nutrient deficiency and that this is 
dysregulated in metabolic disease, where mitochondrial dysfunction leads to 
excessive ROS. It would be interesting to establish a relationship between amino 
acid availability, MIF and extracellular ATP and their roles in autophagy as, given 
the data presented here, it appears that amino acids regulate extracellular ATP 
and eATP regulates both mTOR signalling and MIF release. This could have 
important implication for skeletal muscle as although autophagy is critical for 
maintenance of muscle mass and strength (Masiero et al., 2009), excess 
autophagy induces muscle atrophy (Sandri, 2013). Importantly, this relationship 
could also be relevant in the context of caloric/amino acid restriction and the 
metabolic and longevity benefits associated with these interventions. Indeed, 
methionine-restriction in rodents (known, like caloric restriction, to increase 
lifespan) leads to decreased glucose and insulin levels (Masoro et al., 1992; Miller 
et al., 2005) and increased hepatic MIF mRNA levels (Miller et al., 2005). 
Furthermore, as discussed in Chapter 5, AMPK is an important inducer of 
autophagy and is differentially regulated by these nucleotides and cytokines.  
Although AMPK activation is well-characterised as a potent stimulus to initiate 
autophagy, this regulation appears to change in response to glucose availability, 
similarly to its metabolic roles discussed in Chapter 5. For instance, silencing of 
AMPK can induce autophagy to protect β-cells from hyperglycaemia (Han et al., 
2010). Autophagy also mediates a number of processes that are altered by AMPK 
activation dependently or independent of activation of AMPK. For example, in 
hypothalamic AgRP and POMC neurones, genetic suppression of autophagy 
dysregulates their control of energy balance. Suppression of autophagy in AgRP 
neurones causes leanness (Kaushik et al., 2011) and loss of autophagy in POMC 
neurones leads to increased adiposity, body weight and altered glucose 
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homeostasis (Coupé et al., 2012) in mice. Pharmacological AMPK 
activators/inhibitors can also alter autophagy independently of AMPK. In cancer 
cells, Compound C induces protective autophagy by suppressing PKB/mTORC1 
signalling (Vucicevic et al., 2011) and AICAR suppresses autophagy by 
interfering with formation of the PI3KC3-C1 complex in fibroblasts (Viana et al., 
2008). Given the observations in Chapter 5, it would be interesting to better 
elucidate the effect of indirect and direct AMPK activators on autophagy, 
particularly during low glucose availability.  
Adenosine signalling in the pathophysiology of Diabetes: strategy to treat 
hypoglycaemia? 
Extracellular ATP has been discussed throughout this thesis as a pleiotropic 
signalling moiety that may be used as a tool to mimic insulin or exercise effects 
in skeletal muscle. This is primarily driven by the roles played by transiently 
increased levels of eATP on glucose metabolism, supported by work presented 
here. However, chronically elevated eATP likely leads to its well-characterised 
inflammatory effects in numerous tissues. In addition, an increase in eATP 
availability will also generate elevated levels of adenosine extracellularly, which 
may directly contribute to metabolic disease progression. Indeed, accumulating 
evidence highlights a role for extracellular adenosine signalling in the regulation 
of glucose homeostasis (Koupenova and Ravid, 2013) and the pathophysiology 
of T1D and T2D (Johnston-Cox et al., 2012; Yip et al., 2013; Csóka et al., 2014).   
Adenosine regulates glucose metabolism in tissues such as skeletal muscle, liver 
and adipose tissue by acting via P1 receptors A1R, A2AR, A2BR and A3R and has 
demonstrated both glucose-raising and lowering actions. For example, 
pharmacological stimulation of hepatic A2BRs stimulates hepatic glucose 
production and glycogenolysis in primary rat hepatocytes (Harada et al., 2001; 
Yasuda et al., 2003) and in obese and diabetic mice (Figler et al., 2011). 
Furthermore, inhibition of adenosine transporter ENT1 in hepatocytes leads to 
enhanced hepatic glucose production and suppresses the effect of AMPK 
activator AICAR on glucose production (Logie et al., 2018). Adenosine (and 
analogues) also demonstrates glucose-raising effects by direct stimulation of 
glucagon secretion (in a concentration-dependent manner) from α-cells (Chapal 
et al., 1985) and suppression of insulin secretion (via A1R) in perfused rat 
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pancreas (Hillaire-Buys et al., 1987). Paradoxical evidence, however, suggests 
that adenosine can enhance insulin secretion by activating A2ARs, and that A2BR 
activity may suppress hepatic glucose production (Csóka et al., 2014). Within the 
context of T2D, activation of A2ARs in brown adipose tissue appears to stimulate 
thermogenesis, which protects mice against diet-induced obesity (Gnad et al., 
2014) whilst activation of A2BRs in skeletal muscle is associated with the 
development of insulin resistance (Figler et al., 2011). Furthermore, stimulation 
of A1Rs in adipose tissue increases lipogenesis and reduces lipolysis, whereas 
A2BR decrease adipogenesis and adipose tissue inflammation. In skeletal 
muscle, A1Rs can increase or decrease glucose uptake (Vergauwen, Hespel and 
Richter, 1994) whereas A2BR decreases glucose uptake (Antonioli et al., 2015). 
These discrepancies often arise from differing experimental approaches, using 
pharmacology or genetic manipulation to agonise/antagonise these pathways; 
which highlights the need for clearer evidence for the roles played by the 
adenosine signalling system on glucose homeostasis. Nonetheless, a growing 
body of evidence suggests that adenosine signalling does modulate glucose 
homeostasis and a number of these functions may be therapeutically targetable. 
Of interest, is the understudied use of adenosine to modulate the 
counterregulatory response to hypoglycaemia.  
Adenosine has a rapid half-life in plasma (< 10 s) as it is rapidly cleared and 
metabolised (Moser et al., 1989; Marlinge et al., 2017), meaning that adenosine 
raising compounds or P1R agonists may represent better therapeutic tools. Such 
compounds may already be used clinically but be repurposed for this use. For 
instance, rosuvastatin, a potent statin primarily used to lower plasma cholesterol, 
has been reported to increase HbA1c levels in individuals with and without 
diabetes (Ridker et al., 2008; Ooba et al., 2016). Interestingly, rosuvastatin has 
also demonstrated adenosine raising effects in humans (Meijer et al., 2009) by 
inhibiting ENT1. Given the roles of adenosine receptor activation in liver and α-
cells described above, it would be interesting to assess the effect of a drug such 
as rosuvastatin on hypoglycaemia counterregulation. Importantly, it would also 
be critical to establish whether this off-target effect is mediated via adenosine. To 
test such a hypothesis a series of in vivo experiments would be conducted in 
diabetic models using acute and chronic administration of the compound and 
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performing hyperinsulinaemic-hypoglycaemic clamps to assess changes to 
counterregulatory hormones and blood glucose.  
The benefit of using a clinically-tested widely available compound is the rapid 
translatability to individuals with diabetes. As mentioned above, technologies 
such as the SMARTChip (Dale et al., 2019) can be used to measure adenosine 
in near real-time in a clinical setting. It would be interesting to apply this to a study 
comparing daily glucose profiles (time in target blood glucose using CGMS) of 
individuals with T1D treated with rosuvastatin or placebo (chronically) to test a 
relationship between blood glucose and plasma adenosine levels.  
Conclusions 
This thesis highlights the complexity of the integrated physiology of glucose 
control. It is becoming increasingly apparent that activation of specific 
proteins/pathways may regulate glycaemia/metabolism differentially depending 
on energy status and target tissues. Here, extracellular ATP enhanced glucose 
uptake and utilisation in muscle cells suggesting that, in the whole-body, eATP 
may be blood glucose lowering. However, breakdown of ATP into adenosine 
leads to adenosine-mediated blood glucose-raising actions. Although these 
paradoxical mechanisms may occur synergistically and continuously, it remains 
important to identify the specific tissue impairments or metabolic status that 
dysregulates these processes to contribute to the pathophysiology of metabolic 
disease.  
The same applies to lipid-induced insulin and anabolic resistance. It is clear from 
data presented here that lipid overflow in muscle cells causes insulin and anabolic 
resistance by impairing intracellular machinery. Although this likely occurs in 
humans, it appears from human data presented here that lipid-induced changes 
may be negligible if metabolic function is already impaired, such as during disuse. 
However, it is plausible that disuse dysregulates anabolic sensitivity by impairing 
lipid metabolism in the first place. Therefore, it is important to understand the 
crosstalk between these metabolic states and how they bring about impaired 
glucose (and in this case amino acid) balance.  
 
General conclusions                             Chapter 6                                                                                                    
199 
 
During hypoglycaemia, central AMPK activation appears to protect the brain from 
glucose deprivation, but in peripheral tissues, AMPK activation is anti-
hyperglycaemic. This represents a challenge pharmacologically as inadequate 
activation of AMPK peripherally during hypoglycaemia could aggravate this. 
R481-like compounds have therapeutic potential as they protect against 
hypoglycaemia without lowering blood glucose, suggesting that central effects of 
AMPK activators may supersede peripheral roles in response to a change in 
glucose availability.  
Going forward, the understanding of disease pathophysiology or development of 
novel therapeutic strategies should re-enforce the importance of tissue-specific 
or metabolic status specific actions of the targets of interest.  
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Ana Cruz  
 
Information sheet for participants (Version 4: 13-04-2017) 
 
You are being invited to take part in this research study. Before you decide it is very 
important for you to understand why the research is being undertaken and what it will 
involve. Please take time to read the following information carefully and discuss it with 
friends, relatives and your GP if you wish. Ask us if there is anything which is not clear 
or if you would like more information. Take time to decide whether or not you wish to 
take part. If you decide not to take part, there will be no disadvantage to you of any kind 
and we thank you for considering our request. 
 
What is the purpose of this study?  
With ageing, we experience a progressive loss of muscle tissue, which affects strength 
and quality of life. Individuals with type-2 diabetes lose more muscle tissue with 
advancing age. The reason is likely linked to reduced physical activity and/or overeating, 
leading to an impaired ability of muscles to extract important nutrients from blood. This 
study aims to identify how physical inactivity and overeating affect the muscle’s response 
to nutrition. We will measure how arm muscles of young people obtain nutrients from 
their blood after they have been made physically inactive and fed a normal or excessive 
energy diet for 7 days. As such, this study will inform future research to attenuate/prevent 
muscle loss in older individuals with and without type-2 diabetes, thereby supporting 
metabolic health and quality of life. 
 
What types of participants are needed? 
We are inviting healthy, young men aged 18-40 years to take part in this study. We are 
looking to recruit recreationally active individuals, if you are currently involved in an 
intensive endurance or resistance training programme you will also not be allowed to 
participate. After the screening procedure a decision will be taken if you are suitable for 
the study i.e. you do not violate any of the exclusion criteria. The exclusion criteria 
include: 
 
 A body mass index (BMI) below 18 or above 30 kg/m2 
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 Regular smoker 
 Any diagnosed metabolic impairment (e.g. type 1 or 2 Diabetes).  
 Any diagnosed cardiovascular disease or hypertension. 
 Elevated blood pressure at the time of screening. 
 Chronic use of any prescribed or over the counter pharmaceuticals.  
 Regular use of nutritional supplements (e.g. creatine, protein supplementation) 
 Metallic implants (including heart pacemaker, cochlear implants, medication 
pumps, surgical clips, plates or screws).  
 A personal or family history of thrombosis, epilepsy, seizures or schizophrenia.  
 Any previous motor disorders. 
 
What will participants be asked to do?  
The study will involve 5 visits to the laboratory. A simple summary of the study is that we 
want to assess what happens to muscle when it is not being used (contracted); this is 
known as ‘muscle disuse’. To answer the question of what happens to a muscle when 
you do not use it we will make a variety of measurements before during and after the 7 
days of forearm casting. During that week, you will be randomly allocated to energy 
matched standardized food, or high-fat overfeeding (providing 50% more energy than 
the energy-matched diet, predominantly from fat). 
 
So firstly to immobilise the muscle we will use a cast (on one forearm) and a sling so you 
will not be able to use that arm for the entire 7 day period. You will always have to wear 
the cast, including when washing (a cover will be provided for the cast). 
 
We will assess forearm muscle size of both arms 3 times over the study period and this 
will be done via a magnetic resonance imaging (MRI) scan. Each MRI scan will last 
approximately 20 minutes and will take place at the Medical School on St. Luke’s 
campus. The scan will involve you lying on the bed of the MRI scanner facing upwards 
with your arms next to your body, and you will be rolled into the MRI scanner so both 
arms are inside the centre of the MRI scanner. The MRI scans will happen on the 
baseline visit (between 10 and 7 days before immobilization), on day 2 of immobilization 
and on day 7 (immediately following cast removal). 
 
To assess the impact of inactivity and dietary intake on the uptake of nutrients from the 
diet, you will undergo a metabolic test on the same days as the MRI scans. For this test, 
you will be laying on a bed in the laboratory for a 4.5 h period. During this period you can 
watch movies or series on the television which is present. Before the test, we will have 
three cannulas inserted in your arms: one in each elbow and one on a hand. During the 
entire 4.5 h period, we will have an infusion of stable isotope amino acids running to 
quantify the amount of amino acids (the building blocks of proteins) that are taken up by 
the muscle. The other two cannulas will be used to take a total of 12 small blood samples 
throughout the test. On three occasions during the first and last visit a finger prick will 
also be performed to get a small blood sample. Additionally, we will use an ultrasound 
device on the inside of your elbow to measure blood flow at the same times as we take 
a blood sample. After 90 min, you will receive a drink containing a mixture of 
carbohydrates, protein and fat to assess the effect of food intake on the uptake of 
nutrients by the arm muscles. After another 3 hours, the test day will be finished. 
 
Nowadays, inactivity is also accompanied by an increased energy intake, which could 
be contributing to the negative effects that are observed. In order to test this, we will 
provide you with a standardized diet during the 7 days of forearm immobilization. You 
will receive all your daily food, composed of three daily main meals and several daily 
snacks. You are requested to eat at certain set times, so the normal meal moments. 
During this week you are not allowed to consume other food/drink products than the 
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products you receive from us. Half of the participants will receive food products which 
are matched to their energy expenditure, and the other half of the participants will receive 
food products which are 50% higher in calories (predominantly from fat) than their normal 
diet. 
 
Having an adequate supply of a molecule called nitric oxide is very important for 
maintaining a healthy body. However, it is possible that the consumption of a high 
fat diet could lower its availability by reducing the amount of a particular type of 
oral bacteria that are responsible for producing it. To test if this is the case, we 
will also ask you to provide an oral swab sample, and a saliva sample, on the 
same days as the MRI visits. The oral swab samples simply involve the 
researcher brushing your tongue for 3-5 seconds with a small, soft brush. 
Lastly you will be asked to record your diet (both food and drink) intake to get an idea of 
your habitual dietary intake. To do this we need you to write down everything you eat 
and drink with a description of the items e.g. how much (weight or volume) and brand 
names. You will be given recording sheets to do this during the screening visit and will 
be asked to record your diet for a total of 3 days, to be completed prior to the baseline 
visit. 
 






Task completed during visit 
1 Screening  Informed consent gained (if not already previously 
gained). 
 Explanation of study by experimenter and shown 
equipment and tests. 
 Height and weight measurement. 
 Body composition measurement e.g. % body fat and 
muscle via BODPOD. 
 Shown how to fill out diet diary. You will do this for 3 
days prior to the baseline visit (visit 2). 
 Health screening form completed. 




-10 and -7) 
 Arrive at the lab at 8:15, while being fasted. 
 MRI scan of both arms arm to assess muscle size. 
 Take place on the bed, where you will be rested for 
4.5 h. You can watch movies during this time. 
 Insertion of three venous cannulas: two in the elbow 
veins and one on the hand. From these cannulas, a 
total of 12 blood samples will be taken during this day. 
Finger pricks will also be conducted alongside three of 
the samples. Together with every blood sample, blood 
flow measurements are performed using an 
ultrasound device. 
 Start infusion of the stable isotope infusion. 
 After 15-30 min, you will be asked to provide a saliva 
and oral swab sample. 
 After 90 min, you will be given a test drink. 
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 3 hours after consuming the drink, the test is finished. 




 Arrive at the lab at 7:30; you do not need to be fasted. 
 Forearm cast is applied. 
 You will be given a sling to put your arm in. 
 You will receive weighed and packaged food for the 




 Arrive at the lab at 8:15, while being fasted 
 MRI scan of the immobilised arm to assess muscle 
size 
 Take place on the bed, where you will be rested for 
4.5 h. You can watch movies during this time. 
 Insertion of two venous cannulas: one in the elbow 
vein and one on the contralateral hand. From these 
cannulas, a total of 12 blood samples will be taken 
during this day. Together with every blood sample, 
blood flow measurements are performed using an 
ultrasound device. 
 You will be asked to provide a saliva and oral swab 
sample.  
 After baseline measurements, you will be given a test 
drink. 
 3 hours after consuming the drink, the test is finished. 
 You will receive weighed and packaged food for the 
last 4 days (day 3, 4, 5, 6). 
5 Experimental 
(day 7) 
 Arrive at the lab at 8:00, while being fasted. 
 The cast will be removed. 
 MRI scan of the (previously immobilised) arm to 
assess muscle size. 
 Take place on the bed, where you will be rested for 
4.5 h. You can watch movies during this time. 
 Insertion of three venous cannulas: two in the elbow 
veins and one on the hand. From these cannulas, a 
total of 12 blood samples will be taken during this day. 
Finger pricks will also be conducted alongside three of 
the samples. Together with every blood sample, blood 
flow measurements are performed using an 
ultrasound device. 
 Start infusion of the stable isotope infusion. 
 After 15-30 min, you will be asked to provide a saliva 
and oral swab sample.  
 After 90 min, you will be given a test drink. 
 3 hours after consuming the drink, the test is finished. 
 Grip strength will be assessed. 
 
 
Are there any risks associated with taking part?  
The risks involved in this study are minimal. Insertion of the cannulas for blood sampling 
may cause some temporary discomfort. However, these techniques are regularly used 
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in physiology testing. The investigators are trained and experienced in all aspects of 
these procedures to ensure they are completed safely. Every effort will be made to 
minimise the above risks by thorough instruction and observation of symptoms during 
testing sessions.  
Please be aware that any concerns that you have about any of the procedures will be 
addressed in full by the researcher prior to you giving your consent to participate. 
 
Can I change my mind?  
You can stop being in the project at any time without giving a reason and without any 
disadvantage to yourself of any kind.  
 
What data or information will be collected, and how will it be used?  
The samples will be code labelled without showing the participant’s name and stored 
securely. Samples will be disposed of immediately once the analysis has been 
completed. Your anonymity will be protected in the case of publication of our findings. 
Any data collected will be used to establish response profiles across the group of 
subjects involved and these cumulative scores may be available for public inspection in 
research journals and/or seminars and conferences. In addition, individual response 
profiles indicative of the typical response may also be presented. However, in all cases, 
anonymity will be strictly preserved. Therefore, while results of this project may be 
available for public inspection; any data so displayed will in no way be linked to any 
specific individual. Upon completion, the data will be securely stored in such a way that 
only the researchers involved in this investigation will be able to gain access to it. At this 
point, you are most welcome to request a copy of the results of the project should you 
wish and we will be available to explain and interpret your specific data and how it 
compares to the results of the group as a whole. 
 
What if participants have any questions?  
If you have any questions about our project, either now or in the future, please feel free 
to contact Marlou Dirks or Mandy Dunlop: 
 
Marlou Dirks  01392 725496  m.dirks@exeter.ac.uk 
Mandy Dunlop  01392 724715  m.v.dunlop@exeter.ac.uk 
Ana Cruz     a.cruz@exeter.ac.uk 
 
 
This project has been approved by the Ethics Committee of Sport and Health Sciences, 















Appendix B  
 
Medical Questionnaire 
This questionnaire belongs to the study ‘The effect of physical inactivity and 
overfeeding on muscle amino acid uptake’. Please fill out this questionnaire as 
completely as possible. All information in this questionnaire is considered 
confidential.  
General questions 







Date of birth:  
Gender: 
  
☐  Male          ☐ Female  
Ethnicity  
Phone number: 








Weight:                   kg 
Height:                   m 
Are you currently in another study?   ☐  Yes ☐  No 
If yes, which study and with which researcher? 
 
Have you participated in studies in the past? ☐  Yes ☐  No 
If yes, with which researcher? 
 




Do you feel healthy at the moment? ☐ Yes ☐  No 
 If no, what are the complaints? 
Are you currently being treated by a doctor, dentist, paramedic 
or alternative healer? 
☐ Yes ☐  No 
 If yes, by whom? 
 For what reason? 
Have you been ill in the past 12 months? ☐ Yes ☐  No 
 If yes, how many days? 
 When?                       
 What were the complaints? 
Do you have a sensitivity or allergy? ☐ Yes ☐  No 
 
If yes, for what? 
                 Food  
                  Medicine 
                  Penicillin (antibiotics) 
                 Iodine or brown bandaids 
                  Other: 
 When did you first notice? 
Do you have complaints about your back, legs, knees or 
shoulders?   
☐ Yes ☐  No 
 
If yes, where? 
                 Back  
                  Legs 
                  Knees 
                 Shoulders 
                
 What is the nature of these complaints? 
Have you donated blood in the past 3 months? 
☐  
Yes 
☐  No 
 If yes, when 
Medical history  
Have you ever had problems with your kidneys or urinary tract?  
(for example inflammation, kidney stones, blood loss) 
☐Yes ☐  No 
 If yes, what kind of problem(s)?  
 When?                      
 How often?  
 How was/is it treated? 
Have you ever undergone surgery? 
☐ 
Yes 
☐  No 
 If yes, on what? 
 When?                     
 Why? 
Do you have diabetes?  ☐Yes ☐  No 
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 If yes, since when?  
 How is/was it treated? 
Have you or anyone in your family ever had thrombosis?  ☐Yes ☐  No 
 If yes, who and when? 
 What was the cause and how was/is it treated? 
Drugs 
Are you currently using any sleeping aids or drugs? 
(including aspirin or paracetamol) 
If yes, which? 
















Have you used any sleeping aids or drugs in the past year? 
(including aspirin or paracetamol) 
If yes, which? 















Has your body weight the past 3 months: 
 Increased with more than 3 kg?  ☐  Yes ☐  No 
 If yes, how many kg? kg 
 Reason:  
 Decreased with more than 3 kg?   ☐  Yes ☐  No 
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 If yes, how many kg? kg 
 Reason: 
 
Are you on a (medically prescribed) diet?  
(For example, cholesterol lowering diet, weight loss diet or 
macrobiotic diet.) 
☐  Yes ☐  No 
  If yes, what kind of diet? 
 Why are you on this diet? 
Are you a vegetarian? ☐  Yes ☐  No 
Do you normally eat breakfast? ☐  Yes ☐  No 
Are you using dietary supplements? ☐  Yes ☐  No 
 If yes, 
which? 
Which brand? How often? Why? 
☐ Vitamins    
 ☐ Mineral    
 ☐ Fiber    
 ☐ Other:    
On average, how many times do you eat the following foods (please circle) 
Meat, meat products and meat dishes 
Never or < 1x per 
month 
1-3x per month Once a week >2-4 x per 
week 
Fish and fish products 
Never or < 1x per 
month 
1-3x per month Once a week >2-4 x per 
week 
Eggs and dairy products (milk, yoghurt, cheese) 
Never or < 1x per 
month 
1-3x per month Once a week >2-4 x per 
week 
Beans, peas and lentils 
Never or < 1x per 
month 
1-3x per month Once a week >2-4 x per 
week 
Nuts and whole grains (e.g. bulgur, quinoa, amaranth, oats) 
Never or < 1x per 
month 
1-3x per month Once a week >2-4 x per 
week 
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Tofu, soya meat, TVP, soya products 
Never or < 1x per 
month 
1-3x per month Once a week >2-4 x per 
week 
Protein enriched foods (e.g. protein shakes/bars etc.) 
Never or < 1x per 
month 
1-3x per month Once a week >2-4 x per 
week 
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Recreational drugs / alcohol 
Do you drink alcoholic beverages?  ☐  
Yes 
☐  No 
 If yes, what kind?  
 How many?  
☐   1-7 glasses per week 
☐   8-14 glasses per week 
☐   15-21 glasses per week 
☐   more than 21 glasses per week 
Do you smoke tobacco?                                                        ☐  
Yes 
☐  No 
 If yes, how often?  
☐  less than once per day 
☐  1-5 times per day 
☐  6-10 times per day 
☐  more than 10 times per day 
 If no, have you smoked in the past? ☐  
Yes 
☐  No 
Do you use nicotine patches or nicotine gum?  ☐  
Yes 
☐  No 
 If yes, what kind? 
 How often? 
Do you use recreational drugs? ☐  
Yes 
☐  No 
 If yes, what kind? 
 How often? 
Physical activity 







Quite active Very active 
Approximately how long do you spend sitting per day? (please circle) 
 < 3 hours 3-6 hours 6-9 hours 9-12 hours >12 hours 
Do you exercise regularly? (fitness, sports) ☐  
Yes 
☐  No 
 If yes, what kind of sport(s)? 
 How many hours per week? 
 
 




Do you have anything else you want to report about your health? 
 
Completed as true and correct, 





















INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
We are interested in finding out about the kinds of physical activities that people do as 
part of their everyday lives. The questions will ask you about the time you spent being 
physically active in the last 7 days. Please answer each question even if you do not 
consider yourself to be an active person. Please think about the activities you do at work, 
as part of your house and yard work, to get from place to place, and in your spare time 
for recreation, exercise or sport. 
Think about all the vigorous and moderate activities that you did in the last 7 days. 
Vigorous physical activities refer to activities that take hard physical effort and make you 
breathe much harder than normal. Moderate activities refer to activities that take 
moderate physical effort and make you breathe somewhat harder than normal. 
PART 1: JOB-RELATED PHYSICAL ACTIVITY 
The first section is about your work. This includes paid jobs, farming, volunteer work, 
course work, and any other unpaid work that you did outside your home. Do not include 
unpaid work you might do around your home, like housework, yard work, general 
maintenance, and caring for your family. These are asked in Part 3. 
1. Do you currently have a job or do any unpaid work outside your home? 
 Yes 
 No Skip to PART 2: TRANSPORTATION 
The next questions are about all the physical activity you did in the last 7 days as part of 
your paid or unpaid work. This does not include traveling to and from work. 
2.  During the last 7 days, on how many days did you do vigorous physical activities 
like heavy lifting, digging, heavy construction, or climbing up stairs as part of your work? 
Think about only those physical activities that you did for at least 10 minutes at a time. 
_____ days per week 
No vigorous job-related physical activity Skip to question 4 
3. How much time did you usually spend on one of those days doing vigorous 
physical activities as part of your work? 
_____ hours per day 
_____ minutes per day 
4. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate 
physical activities like carrying light loads as part of your work? Please do not include 
walking. 
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_____ days per week 
No moderate job-related physical activity Skip to question 6 
5. How much time did you usually spend on one of those days doing 
moderate physical activities as part of your work? 
_____ hours per day 
_____ minutes per day 
6. During the last 7 days, on how many days did you walk for at least 10 minutes at 
a time as part of your work? Please do not count any walking you did to travel to or from 
work. 
_____ days per week 
No job-related walking Skip to PART 2: TRANSPORTATION 
7. How much time did you usually spend on one of those days walking as part of 
your work? 
_____ hours per day 
_____ minutes per day 
PART 2: TRANSPORTATION PHYSICAL ACTIVITY 
These questions are about how you travelled from place to place, including to places like 
work, stores, movies, and so on. 
8. During the last 7 days, on how many days did you travel in a motor vehicle like a 
train, bus, car, or tram? 
_____ days per week 
No traveling in a motor vehicle Skip to question 10 
9. How much time did you usually spend on one of those days traveling in a train, 
bus, car, tram, or other kind of motor vehicle? 
_____ hours per day 
_____ minutes per day 
Now think only about the bicycling and walking you might have done to travel to and from 
work, to do errands, or to go from place to place. 
10. During the last 7 days, on how many days did you bicycle for at least 10 minutes 
at a time to go from place to place? 
_____ days per week 
No bicycling from place to place Skip to question 12 
11. How much time did you usually spend on one of those days to bicycle 
from place to place? 
_____ hours per day 
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_____ minutes per day 
12. During the last 7 days, on how many days did you walk for at least 10 minutes at 
a time to go from place to place? 
_____ days per week 
No walking from place to place Skip to PART 3: HOUSEWORK, HOUSE 
MAINTENANCE, AND CARING FOR FAMILY 
13. How much time did you usually spend on one of those days walking from place 
to place? 
_____ hours per day 
_____ minutes per day 
PART 3: HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR FAMILY 
This section is about some of the physical activities you might have done in the last 7 
days in and around your home, like housework, gardening, yard work, general 
maintenance work, and caring for your family. 
14. Think about only those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do vigorous physical activities 
like heavy lifting, chopping wood, shovelling snow, or digging in the garden or yard? 
_____ days per week 
No vigorous activity in garden or yard Skip to question 16 
15. How much time did you usually spend on one of those days doing vigorous 
physical activities in the garden or yard? 
_____ hours per day 
_____ minutes per day 
16. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate 
activities like carrying light loads, sweeping, washing windows, and raking in the garden 
or yard? 
_____ days per week 
No moderate activity in garden or yard Skip to question 18 
17. How much time did you usually spend on one of those days doing 
moderate physical activities in the garden or yard? 
_____ hours per day 
_____ minutes per day 
18. Once again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate 
activities like carrying light loads, washing windows, scrubbing floors and sweeping 
inside your home? 
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_____ days per week 
No moderate activity inside home Skip to PART 4: RECREATION, SPORT 
AND LEISURE-TIME PHYSICAL ACTIVITY 
19. How much time did you usually spend on one of those days doing moderate 
physical activities inside your home? 
_____ hours per day 
_____ minutes per day 
PART 4: RECREATION, SPORT, AND LEISURE-TIME PHYSICAL ACTIVITY 
This section is about all the physical activities that you did in the last 7 days solely for 
recreation, sport, exercise or leisure. Please do not include any activities you have 
already mentioned. 
20. Not counting any walking you have already mentioned, during the last 7 days, on 
how many days did you walk for at least 10 minutes at a time in your leisure time? 
_____ days per week 
No walking in leisure time Skip to question 22 
21. How much time did you usually spend on one of those days walking in your 
leisure time? 
_____ hours per day 
_____ minutes per day 
22. Think about only those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do vigorous physical activities 
like aerobics, running, fast bicycling, or fast swimming in your leisure time? 
_____ days per week 
No vigorous activity in leisure time Skip to question 24 
23. How much time did you usually spend on one of those days doing vigorous 
physical activities in your leisure time? 
_____ hours per day 
_____ minutes per day 
24. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate 
physical activities like bicycling at a regular pace, swimming at a regular pace, and 
doubles tennis in your leisure time? 
_____ days per week 
No moderate activity in leisure time Skip to PART 5: TIME SPENT SITTING 
25. How much time did you usually spend on one of those days doing moderate 
physical activities in your leisure time? 
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_____ hours per day 
_____ minutes per day 
PART 5: TIME SPENT SITTING 
The last questions are about the time you spend sitting while at work, at home, while 
doing course work and during leisure time. This may include time spent sitting at a desk, 
visiting friends, reading or sitting or lying down to watch television. Do not include any 
time spent sitting in a motor vehicle that you have already told me about. 
26. During the last 7 days, how much time did you usually spend sitting on a 
weekday? 
_____ hours per day 
_____ minutes per day 
27. During the last 7 days, how much time did you usually spend sitting on a weekend 
day? 
_____ hours per day 
_____ minutes per day 
This is the end of the questionnaire, thank you for participating. 
 
             
         








Pilot experiment using ATP SMARTChips to assess changes to whole-blood ATP 
following high-fat drink 
A) Study schematic. Participants came into the lab fasted for ~8 hours and asked to lie in 
a semi-supine position. A venous cannula was introduced in an antecubital vein and saline 
infusion used to maintain it patent. Following an acclimatisation period (~30 minutes) a 
venous blood sample was taken to measure fasting blood ATP (SMARTChip)(-20 min) and 
glucose (using YSI system) immediately. As soon as ATP measurement were complete 
(after calibration and reading), a capillary blood sample was taken from the hand via a 
finger prick (with lancet). Blood ATP was immediately measured. 20 minutes after the first 
sample, participants were given a high-fat test drink (C) and sampling method repeated. 
Two more samples were taken 140-150 minutes following drink ingestion. B) Schematic 
representation of the ATP SMARTChip. Chips are calibrated in a potentiostat by polarising 
at +50mV. ATP calibrant (10 μM) is used and generates a certain net current. A sample is 
then measured and generates a second net current which is used to calculate a “calibration 
factor”. Calibration factor x sample current = concentration C) Baseline characteristics of 
participants (n=5). D) Drink composition. Target caloric composition was 75 % of total daily 
estimated energy (EE) intake (using BMR and PAL) comprised of fat, primarily saturated 
fat (double cream). E) Venous blood ATP concentration measured using SMARTChip. F) 
Blood glucose measured from venous samples following ATP measurement. G) Capillary 
blood ATP concentration measured using SMARTChip. 
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